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Abstract   
 
This thesis explored knowledge management effectiveness in the pharmaceutical sector 
and included an examination of the critical relationship between knowledge 
management (KM) and quality risk management (QRM) as the dual enablers of an 
effective pharmaceutical quality system.  The primary research objectives were to 
improve understanding and effectiveness of the interdependency between KM and 
QRM and to improve knowledge management across the pharmaceutical product 
lifecycle, starting with a focus on knowledge transfer during technology transfer.  The 
thesis explored how improved KM across the product lifecycle coupled with thoughtful 
and intentional connectivity between KM and QRM as defined by this study could lead 
to more informed risk-based decision making and ultimately help benefit patients.   
 
This research study employed a variety of methods, including literature review, expert 
interviews, philosophical dialogue, focus groups, and case studies as a means to include 
a large number of stakeholders across the pharmaceutical sector.  The study progress 
was disseminated through a variety of methods and channels including several peer-
reviewed papers and conference presentations as a means to solicit input and feedback.   
 
The research findings verify that while KM and QRM are considered highly 
interdependent in theory, in practice they are – at best – partially integrated.  This 
suggests the industry is not leveraging the best knowledge available to inform QRM, 
leading to sub-optimal risk-based decision making.  Furthermore, knowledge created 
during QRM activities may not be effectively managed.   
 
When considering technology transfer, the study found that while knowledge transfer 
is considered critically important, knowledge transfer is only marginally effective for 
explicit knowledge and somewhat ineffective for tacit knowledge.  This lack of effective 
knowledge transfer poses a risk to successful technology transfer and the goals of ICH 
Q10.   
 
In response to these findings, the research generated a variety of outputs, many of 
which have already demonstrated outcomes and impacts on the sector and have the 
potential for seminal importance.  These outputs include a Knowledge Management 
Process Model to define the process of knowledge management, the Risk-Knowledge 
Infinity Cycle (RKI Cycle) as a framework to unite KM and QRM, a framework for 
knowledge transfer enhancement (KTE Framework) during technology transfer, and a 
variety of case studies to demonstrate the impact of these outputs and their 
applicability across the product lifecycle.   
 
These outputs can be immediately applied to the benefit of the pharmaceutical sector.  
Areas of future study include additional assets such as training and application materials 
to accelerate application of these outputs.  Additional opportunity also exists to better 
define knowledge transfer toolkits, create knowledge management frameworks for 
other phases of the product lifecycle, and to better define the relationship between 
data analytics, knowledge management and risk management.   
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HPRA Health Products Regulatory Authority (Ireland regulatory agency) 
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Term Definition 
ICH International Conference for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
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ICH Q14 ICH Guideline on Analytical Procedure Development  
(guideline in development) 
IEC International Electrotechnical Commission (an international standards 
organisation that prepares and publishes international standards for all 
electrical, electronic, and related technologies) 
ISO International Organisation for Standardisation 
ISPE International Society for Pharmaceutical Engineering 
KM Knowledge Management 
These terms will be used interchangeably throughout this thesis based on 
context 
KPI Key Performance Indicator 
KT Knowledge Transfer 
KTE Knowledge Transfer Enhancement 
MHRA U.K. Medicines and Healthcare products Regulatory Agency 
MSD Merck Sharp & Dohme 
NASA National Aeronautics and Space Administration (US Space Agency) 
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PDA Parenteral Drug Association 
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PMTC Pharmaceutical Manufacturing Technology Centre 
PPKL Pharmaceutical Product Knowledge Lifecycle 
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Term Definition 
PPQ Process Performance Qualification 
PQR Product Quality Review 
PQS Pharmaceutical Quality System 
PRST Pharmaceutical Regulatory Science Team (a research body at Technological 
University Dublin) 
Q&A Questions & Answers 
QbD Quality by Design 
QRM Quality Risk Management 
These terms will be used interchangeably throughout this thesis based on 
context 
RAQAB Regulatory Affairs and Quality Advisory Board of PDA 
RM Risk Management 
SIPOC Supplier-Input-Process-Output-Customer 
SME Subject Matter Expert 
TT Technology Transfer 
TU Dublin Technological University Dublin 
WHO World Health Association 
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Thesis Overview 
 
This thesis has been organised into four parts across 12 chapters as a means to 
summarise the important contributions of the associated research study as outlined 
below.  Significant findings from the research were disseminated through a series of 
peer-reviewed papers in a variety of journals which enabled socialisation and feedback 
on research progress during the study.  These papers are referenced appropriately 
throughout this thesis.   
 
Part One lays the foundation for this research study, including relevant background and 
context. A literature review examines expectations for managing knowledge and risk, 
the interdependency of Knowledge Management (KM) and Quality Risk Management 
(QRM), and reviews recent developments in KM.  It further explores relevant regulatory 
and industry guidance on technology transfer and knowledge management and profiles 
related research by the Pharmaceutical Regulatory Science Team (PRST) at the 
Technological University Dublin (TU Dublin). 
 
Part Two examines the relationship between knowledge and risk.  It explores the 
opportunity to better integrate KM and QRM.  In response to the findings of this 
examination, potential solutions are provided through a proposed Knowledge 
Management Process Model, the Risk-Knowledge Infinity Cycle (RKI Cycle) Framework 
to integrate KM and QRM, and the KTE Framework as a means to enhance knowledge 
transfer during technology transfer. 
 
Part Three demonstrates how the RKI Cycle can be applied across the product 
lifecycle, including three examples with a focus on each KM across the product lifecycle, 
change management during commercial manufacturing, and the link between QRM, KM 
and data analytics.  This part also explores the concept of knowledge culture, including 
a review of current cultural issues which are barriers to knowledge management in the 
pharmaceutical industry, existing definitions of knowledge culture outside of the 
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pharmaceutical industry, and benchmarking the corollary of quality culture.  This section 
concludes with proposing a preliminary ‘ideal knowledge culture.’ 
 
Part Four brings the research study to a close with a review of the outputs, outcomes, 
and impact of this research study, followed by conclusions and opportunities for future 
research.   
 
The following table (Thesis Overview) provides a chapter-level summary of the four 




Part One:  Research Study 
Foundations 
 
• Chapter 1:  Study Introduction and Context 
• Chapter 2:  Literature Review 
• Chapter 3:  Research Design, Methodology, and 
Methods 
Part Two:  Advancing KM 
and Developing QRM-KM 
Connectivity 
• Chapter 4:  A Process Model for Knowledge 
Management 
• Chapter 5:  Re-Imagining the QRM-KM Interdependency 
• Chapter 6:  The Opportunity to Improve Knowledge 
Transfer During Technology Transfer 
• Chapter 7:  A Proposed Framework and Toolkit to 
Enhance Knowledge Transfer During Technology 
Transfer 
Part Three:  The RKI Cycle 
Across the Product Lifecycle 
and Knowledge Culture as a 
Catalyst 
• Chapter 8:  Demonstrating How the RKI Cycle can be 
Applied Across the Product Lifecycle   
• Chapter 9:  Knowledge Culture as a Catalyst to 
Accelerate RKI Cycle Adoption and Impact 
Part Four:  Outcomes and 
Impact, Conclusions and 
Opportunities for Future 
Research 
• Chapter 10:  Outputs, Outcomes, and Impacts of this 
Research Study 
• Chapter 11:  Conclusions to this Research Study 
• Chapter 12:  Opportunities for Future Research 
 
  
  3 
Part One:  Research Study Foundations 
 
Part One lays the foundation for this research study, including: 
• Study introduction and context (Chapter 1) 
• A literature review of a variety of relevant topics (Chapter 2), setting the stage 
for the managing of knowledge and risk to inform risk-based decision making 
and ultimately benefit patients  
• An overview of the research methodology (Chapter 3) 
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Chapter 1:  Study Introduction and Context 
 
This thesis outlines a research study into Knowledge Management (KM) and Quality Risk 
Management (QRM) in the pharmaceutical sector1,2.  This study explored the current 
state of KM and QRM as dual enablers of an effective Pharmaceutical Quality System 
(PQS) and presented a framework for integrating them.  It further examined the state 
of knowledge management across the product lifecycle3, with specific focus on 
technology transfer and the challenges associated with the identification and transfer 
of tacit knowledge.   
 
The purpose of this opening chapter is to outline the intent and scope of the overall 
research study, define KM and its relevance within the pharmaceutical sector, preview 
the anticipated impact of this study, and introduce the researcher. 
 
1.1 Purpose of the research and the problem addressed 
The overarching goal at the commencement of this research study was to advance the 
understanding of KM within the pharmaceutical sector and encourage ways for it to be 
adopted more widely.  There are many benefits associated with KM including 
operational effectiveness and employee engagement (Yegneswaran, Thien and Lipa, 
2017), and the outputs of this thesis will further advance these impacts.    
 
However, the ultimate goal of this research was to provide tangible benefit to the 
patient by improving PQS effectiveness through meaningful advancement of KM as a 
PQS enabler.  As will be discussed later in this chapter and reinforced throughout this 
thesis, KM effectiveness in the pharmaceutical industry is lacking and the inter-
relationship between KM and QRM is not well established.  Yet, when organisations can 
apply their best knowledge, know-how, expertise, and experience – across boundaries 
 
1 The term “pharmaceutical sector” for the purpose of this thesis refers to the collective organisations 
involved in the product life cycle of a medicinal product (both chemical and biological entities) from 
discovery to patient, including industry, regulators, academia and related associations.     
2 For the purposes of this thesis, ‘biopharmaceutical’ and ‘pharmaceutical’ are considered synonymous, 
both terms are used interchangeably based on the source. 
3 The product lifecycle is defined in ICH Q10, section 1.2 and includes the stages of pharmaceutical 
development, technology transfer, commercial manufacturing, and product discontinuation (ICH, 2008). 
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including organisational structures, geographies, and time – to support risk-based 
decision making, acceleration of product development through the use of prior 
knowledge, more robust processes, solving problems at root cause, and right-first time 
and on-time technology transfers – the patient stands to benefit.  These patient benefits 
will include increased product quality (e.g., through reduced variability), accelerated 
availability of new therapies, the potential to reduce drug shortages, and more.  Figure 
1-1 illustrates this connection between the patient, the pharmaceutical regulations, the 
PQS as defined by ICH Q10 (ICH, 2008), and KM as an enabler to an effective PQS.   
 
 
Figure 1-1 – The link between the patient, the regulations, the PQS, and KM as a PQS enabler 
 
The researcher, as a member of the TU Dublin Pharmaceutical Regulatory Science Team 
(PRST), sought to improve KM competency and utilisation across the industry as a 
means to advance KM as an equally indispensable enabler to an effective PQS as QRM 
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1.2 Background on Knowledge Management and Quality Risk Management 
In 2008, the International Council for Harmonisation (ICH)4 published the guideline 
Pharmaceutical Quality System ICH Q10 (ICH, 2008), which described a model for an 
effective quality management system for the pharmaceutical industry, referred to as 
the Pharmaceutical Quality System, or PQS. In ICH Q10, knowledge management as a 
concept was cast into the mainstream of the pharmaceutical sector as it was positioned 
as a key enabler of an effective PQS, as depicted in Figure 1-2. 
 
 
Figure 1-2 – The pharmaceutical quality system per ICH Q10 (ICH, 2008) 
ICH Q10 defined KM as a ‘Systematic approach to acquiring, analysing, storing, and 
disseminating information related to products, manufacturing processes and 
components’ (ICH, 2008).  Additional definitions of KM are explored in Chapter 2 
(section 2.1).  
 
With KM and QRM positioned as key enablers for an effective PQS, the research study 
began with a literature review, evaluating the relationship between risk and knowledge. 
A key insight emerged from this review: risk varies inversely with knowledge applied.  
 
4 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry 
to discuss scientific and technical aspects of drug registration. ICH's mission is to achieve greater 
harmonisation worldwide to ensure that safe, effective, and high-quality medicines are developed and 
registered in the most resource-efficient manner. 
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Therefore, a seemingly logical goal would be to maximise knowledge in order to 
minimise risk.  Figure 1-3 created by the researcher attempts to convey the relationship 
between knowledge and risk, and the corresponding disciplines of knowledge 
management and risk management, in a simple manner.   
 
 
Figure 1-3 – Relating knowledge, knowledge management, risk & risk management 
It is acknowledged by the researcher that there are limitations to this ideal state, such 
as: 
• Risk cannot be completely eliminated in most situations, even with a high degree 
of knowledge.  
• There are economic and other considerations for how much time and expense 
is invested to maximise knowledge (i.e., at some point, risk will become 
acceptable even if it could be further reduced). 
• There are scientific limitations to an organisation’s knowledge and 
understanding.    
 
Arguably one factor within the control of organisations is their ability to effectively apply 
what is known (i.e., the ‘known-knowns’).  This knowledge should be inclusive of 
knowledge internal and external to the company and should include both explicit5 and 
 
5 Explicit knowledge refers to documents, pictures, videos, and other codified knowledge.   
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tacit6 knowledge.  An organisation applying the best of their knowledge should be a 
fundamental tenant of how risk management (RM) can leverage knowledge 
management to maximise understanding and minimise risk.   
 
However, as detailed in Chapter 2 of this thesis (Literature Review), there is strong 
evidence that the pharmaceutical industry’s adoption of KM and competency in KM has 
significantly lagged relative to the adjacent enabler of QRM as shown in the ICH Q10 
PQS diagram (Figure 1-2).  In fact, KM has been labelled an ‘orphan enabler’ (Calnan, 
Greene and Kane, 2018).  One must ponder why is it that QRM has progressed in the 
industry and KM has been left behind?   
 
The most common explanation is that QRM has benefited from having its own 
regulatory guidance, namely Quality Risk Management, ICH Q9 (ICH, 2005), while KM 
has no equivalent. Yet this leaves one wondering why did that happen?  Why was no 
guidance provided for KM?  While this may itself warrant its own research study, the 
researcher offers the following insights to address these questions based on his 
experiences, observations, and review of the literature. 
 
• Quality risk management is embedded in a PQS based on Good Manufacturing 
Practices (GMPs), while knowledge management is not.   
QRM and KM are both acknowledged in a PQS based on ICH Q10 and on ISO 
9001.  But KM is not an identified requirement in a PQS based on GMPs. (ISPE, 
2012) 
 
• Risk management has a head start:  risk management has been studied for 
about 70 years, while knowledge management only for about 30 years.   
 
6 Tacit knowledge refers to knowledge that resides in the minds of individuals and is surfaced in 
response to a situation or action (APQC, 2019).  Common examples of tacit knowledge include decision 
rationale, knowledge gained through experience, and mental models.  Tacit knowledge is often referred 
to as ‘know-how’, ‘know-why’, or ‘know-who’. 
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RM as an area of study is associated with the insurance industry dating back to 
about 1950 (Dionne, 2013).  KM has only been recognised as a discipline since 
1991. (Nonaka, 2007). 
 
• There is an existing body of literature, including many standards, on risk 
management and related topics.   
One need only look at the references section of ICH Q9 (ICH, 2005) to see there 
are 17 references, including ten (10) cited ISO and/or IEC standards and three 
(3) cited books on FMEA, in addition to two (2) other regulatory guidance 
documents and two (2) other references.  Many other standards exist, including 
from the Project Management Institute (Project Management Institute, 2019), 
the National Institute of Standards and Technology (NIST, 2016), and elsewhere. 
Considering KM, given there is no equivalent to ICH Q9, KM is introduced in ICH 
Q10 (ICH, 2008).  There are no references to explain KM, and the definition of 
KM in ICH Q10 was derived specific to ICH Q10. An ISO standard was not 
published on KM until 2018 (ISO, 2018) and ISPE industry guidance in 2021 (ISPE, 
2021b). 
 
• Quality risk management is ‘on the radar’ of regulatory authorities and 
industry groups alike. 
A recent presentation by O’Donnell (O’Donnell, 2020) asked a similar question: 
Why had QRM progressed relative to KM?  In reviewing QRM guidance in the 
GMPs and other official guidance, O’Donnell identified at least 18 sources of 
QRM guidance since 2008.  When asking the same question of KM, only four 
instances were noted, and typically these were a single passing reference to KM 
in the respective document.  Similarly, a review of the PDA Technical Report 
Bookstore (PDA, 2021) includes a series of six Technical Reports focused on 
QRM, while there are none on KM.   
 
• Quality risk management is more discrete and better understood than 
knowledge management. 
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QRM implementation in the pharmaceutical industry has been the subject of 
many studies by academia, industry, and regulators.  While there still remain 
many challenges7 with QRM implementation, the core concepts of what QRM is 
in practice are generally well established.  Figure 1 in ICH Q9 (ICH, 2005), 
included as Figure 1-4 below, conveys the essence of the RM process and several 
potential tools in the appendix to Q9 support the ‘how.’  Conversely, there is no 
equivalent figure to convey a generic KM process nor potential tools.   
 
 
Figure 1-4 – Overview of a typical quality risk management process (Figure 1, ICH Q9) (ICH, 
2005) 
KM is further complicated as it can overlap with many different disciplines, 
including Information Technology, Learning & Development, Operational 
Excellence, Human Resources, and others, thus bringing much diversity of 
opinion to what KM is and how to do it.  A recent survey from Knoco highlights 
the diversity of organisational alignment for KM functions in companies (Knoco, 
2017, 2020).  Furthermore, there is a broad diversity of issues for KM to address, 
which typically require very different approaches to manage both explicit and 
tacit knowledge.  According to Birkinshaw (Birkinshaw, 2001), KM is difficult 
 
7 QRM continues to evolve as witnessed by ongoing revision to ICH Q9, continued research and industry 
focus 
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because the range of possible approaches and tools to manage knowledge are 
more highly diverse and subjective and tend to be specific to organisational 
challenges or business models. 
 
Research presented by Kane in 2018 started to shine a light on this issue of lagging KM 
adoption in the pharmaceutical industry.  Kane emphasised the importance and benefit 
of managing knowledge as an asset in the pharmaceutical industry, providing a vision 
for end-to-end product knowledge accessibility and availability, as well as a blueprint 
for knowledge management (Kane, 2018).  The findings and relevance of Kane’s 
research on this study will be explored further in Chapter 2.  
 
Further to lagging KM adoption, another finding of concern to the researcher was the 
discovery that while QRM and KM are considered highly interdependent, they are not 
well integrated in practice today.  This suggested to the researcher a potential critical 
gap in the realisation of ICH Q10:  that the industry is not ensuring it is applying the best 
of what it knows to make optimal risk-based decisions. This influenced the direction of 
the research study, through an effort to develop a mechanism to address this gap. The 
next sections in this chapter further introduce this research journey. 
 
1.3 Researcher introduction and research positionality 
While this research study commenced formally in 2018, in reality it began a decade 
earlier when the researcher was first introduced to the concept of KM as a member of 
the MSD8 delegation to a US Food and Drug Administration (FDA) Cooperative Research 
and Development Agreement (CRADA9) workshop series.  This CRADA chartered a 
cohort of pharmaceutical and biotech companies to explore the industry’s adoption of 
the FDA’s new quality initiative for the 21st Century (US FDA, 2002; FDA, 2007; Shanley, 
2007).  A series of workshops, held in September 2007 and February 2008, explored the 
 
8 MSD, or Merck Sharp & Dohme, an American-based pharmaceutical company known as Merck & Co., 
Inc., Kenilworth, NJ USA in the USA and Canada, and MSD outside of the USA and Canada.  Any and all 
references to ‘Merck’ throughout this confirmation and associated works are solely in reference to 
“Merck & Co., Inc., Kenilworth, NJ USA” unless otherwise stated.   
9 The CRADA is a research agreement between FDA and non-Federal parties to collaborate in 
developing and moving new technologies to market (FDA, 2018) 
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practical implementation of the FDA’s new quality paradigm which had been formalised 
through a series of new guidance documents and included preliminary exploration of 
the concept of knowledge management, which was very much in its infancy at the time.  
This was the researcher’s first in-depth exposure to these regulatory guidelines, and 
more specifically to the role of KM in enabling an effective PQS, which launched a 
learning journey spanning nearly 15 years.  Steps taken and perspectives gained in this 
journey are explored throughout this thesis. Embarking upon this research study 
presented the researcher with a unique and exciting opportunity to drive meaningful 
improvement for the pharmaceutical industry and the patients it serves beyond the 
organisational boundaries of his employer.   
 
In addition to the CRADA workshop series, the researcher had been a student of KM, 
business strategy, organisational change management, lean six sigma and related 
methodologies for over half of his 27+ year professional career.  The researcher had 
been conducting informal research in KM through personal learning, benchmarking, 
publishing, and speaking as a KM thought leader and subject matter expert within the 
pharmaceutical industry and across industries since 2008.   
 
A specific example of a significant KM project dating back to 2008 is the researcher 
initiating a Lean Six Sigma Black Belt certification project to devise a KM strategy for the 
small molecule commercialisation function at a major multinational pharmaceutical 
company (MSD).  The strategy recommended that a proper KM organisational unit 
should be created, and the researcher was selected to lead that function. Since then, 
the KM organisational unit has led a successful KM program for MSD.  These activities 
established a strong foundation for the researcher in theory and practice and have 
uniquely positioned the researcher for this research study.  A timeline summary of key 
activities in the researcher’s KM learning and thought leadership prior to this research 
study is included in Appendix 1.   
 
Through this professional experience, the researcher has demonstrated a diverse, 
lengthy, and persistent presence in KM with a variety of global audiences for over a 
decade.  These audiences included regulatory authorities, industry groups, academia, 
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and organisations outside of the pharmaceutical industry. The researcher has also been 
active in KM through a variety of channels, including as a speaker, author, panellist, 
industry SME, guest lecturer at Columbia University and conference planning 
committee member.  These events and more presented opportunities for the 
researcher to demonstrate thought leadership and influence on a broad scale while at 
the same time embarking on a rewarding learning journey.  These collective experiences 
inherently formed the researcher’s thinking in undertaking this research study.  
 
1.4 Focus of this research study 
Initially, the researcher set out to explore two hypotheses focused primarily on 
improving KM and in particular, KM involving tacit knowledge.  These two hypotheses 
are discussed in detail in Chapter 3 and the essence of which are presented here as 
follows: 
 
1. The pharmaceutical sector does not currently have a holistic end-to-end view 
of what it knows about its products across the product lifecycle, nor how to 
best enable knowledge ‘flow’ to ensure the best possible quality- and 
operational-related outcomes.  
2. Tacit knowledge is critical but is not effectively managed during key activities 
across the pharmaceutical product lifecycle, such as technology transfer.  
 
During the course of the study on end-to-end KM, the researcher was struck by the 
pervasive gap in adoption between QRM and KM as highlighted in section 1.1 of this 
Chapter.  This motivated the researcher to accelerate examination of and reflection on 
the dual ICH Q10 enablers of QRM and KM in an attempt to challenge the siloed thinking 
evident in the pharmaceutical industry regarding these topics.  This led to a third 
hypothesis as follows: 
 
3. Quality risk management and knowledge management are not adequately 
integrated to ensure the best possible risk-based decisions.  Strengthening the 
relationship between QRM and KM has the opportunity to improve patient-
focused outcomes across the product lifecycle through reduced risk to product 
quality and availability.   
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The research study explored each of these three hypotheses; and the journey taken is 
described in the next chapters of the thesis, beginning with a literature review in 
Chapter 2.  Notably, the research activities for this study were in parallel and iterative, 
and not necessarily in the order presented.  While setting the context, the researcher 
believed it to be useful to introduce some of the primary outputs of the study at this 
stage. 
 
1.5 Overall timeline and progression of the research 
As noted previously, the research as described in the thesis was iterative in nature and 
while the study initially embarked with a focus on improving knowledge management 
for technology transfer (hypotheses 1 and 2), the emergence of the importance of the 
QRM-KM interdependency (hypothesis 3) changed the course of the research.  This is 
reflected by the order in which this research is presented in this thesis.  However, it is 
useful to introduce an overall timeline and progression of the research.  This timeline, 
consisting of four phases, is shown in Figure 1-5.  The numbered activities highlight 
many of the outward-facing research activities (e.g., conference presentations, papers 
published) and four primary outputs which are discussed in the next section.    
 
Complete details of the key research activities as depicted in Figure 1-5 are provided in 
Appendix 2.   
  15 
 
 















Phase 1:  Problem Definition Phase 2:  KM Framework (KTE) & KTE Toolkit
Phase 3:  QRM-KM Framework



























X Conference / 
Presentation











  16 
 
1.6 Primary outputs of this study as relevant to the PQS  
This research study resulted in many outputs, outcomes, and impacts as discussed in 
detail in Chapter 10.  Several of these outputs are expected in time to have a potentially 
significant impact on at least four areas of the PQS.  These four areas of the PQS are 
identified in Figure 1-6. 
 
 
Figure 1-6 – Anticipated impact of this study on the PQS 
 
The following primary outputs which impact each of these PQS areas are as follows (the 
output is noted in bold and the PQS area is underlined, and maps to Figure 1-6): 
 
1. Development of a Knowledge Management Process Model to define a process 
for KM as an enabler of the PQS. 
2. Development of the Risk-Knowledge Infinity Cycle (RKI Cycle) framework to 
define the relationship between QRM and KM as the dual enablers to the PQS. 
3. Development of a Knowledge Transfer Enhancement Framework (KTE 
Framework) to define a plan and toolkit for KM during the PQS lifecycle stage 
of technology transfer. 
4. Demonstration of RKI Cycle application and impact across the pharmaceutical 
product lifecycle to illustrate the PQS dependency on effective KM and to 
rapidly scale these new frameworks across the product lifecycle by maximising 
knowledge to minimise risk.  
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The following is an introductory explanation of each of these outputs.    
 
1.6.1 Knowledge Management Process Model 
A Knowledge Management Process Model (Figure 1-7), was strategically crafted similar 
to the familiar (and perhaps iconic) QRM Process Model found in ICH Q9 (ICH, 2005). 
The researcher believes that this model has the potential to enhance the understanding 
of knowledge management as an equal party to QRM in enabling an effective PQS.  This 
model is fully introduced and discussed in Chapter 4 of this thesis. 
 
 
Figure 1-7 – KM Process Model (preview) 
 
1.6.2 Risk-Knowledge Infinity Cycle Framework 
The development of the Risk-Knowledge Infinity Cycle (RKI Cycle) Framework (Figure 
1-8) may well be the most exciting output of this research study.  Based on its broad 
appeal and the interest since its publication in October 2020 (Lipa, O’Donnell and 
Greene, 2020a) and a subsequent survey assessing the utility of the RKI Cycle, the 
framework is already attracting significant attention, even before this thesis was 
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Figure 1-8 – The Risk-Knowledge Infinity Cycle (as applied to ICH Q10, preview) 
 
1.6.3 Knowledge Transfer Enhancement (KTE) Framework 
The development of a framework for Knowledge Transfer Enhancement (KTE 
Framework) offers a pragmatic ‘how’ to guide KM and knowledge transfer (KT) during 
the critical lifecycle stage of technology transfer.  In addition, an accompanying KTE 
Toolkit is proposed, along with case studies and demonstrated impact of tacit 
knowledge transfer approaches. This framework and toolkit are fully introduced and 
discussed in Chapter 7 of this thesis. 
 
Figure 1-9 – KTE Framework (preview) 
 
1.6.4 Demonstrating how the RKI Cycle can be applied across the product lifecycle 
Finally, building on all of these outputs, a mapping of KM focus and associated KM 
methods and tools was carried to demonstrate how the RKI Cycle can be applied across 
the end-to-end product lifecycle.  This mapping, along with two additional examples 
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which illustrate application of the RKI Cycle to change management during commercial 
manufacturing and to data analytics, illustrates the potential broad impact of the RKI 
Cycle. These examples illustrating the RKI Cycle across the product lifecycle are fully 
introduced and discussed in Chapter 8 of this thesis. 
 
 
Figure 1-10 – The RKI Cycle applied across the product lifecycle – examples (preview) 
 
In addition to each of these models and frameworks, the research study has fostered a 
dialogue of learning and education in the exchange of ideas and socialisation of 
concepts, touching several hundreds of people during the course of this study.  
Furthermore, it is in the translation of theory to practice through these models, 
frameworks, and maps that the researcher finds the greatest motivation and energy, 
with the ambition of influencing a large industry and ultimately having a tangible impact 
on the lives of patients served by this important industry.   
 
This chapter has introduced the research study background and context.  The next 
chapter provides a review of the main literature sources considered as part of this 
research study.  
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Chapter 2:  Literature Review 
 
The purpose of this chapter is to provide a summary of the relevant literature 
considered for this research study.  The literature review focused on a variety of topics, 
including the primary topics of knowledge management, risk management and 
technology transfer, and did so both within and beyond the pharmaceutical sector.  
Importantly, the literature review also examined a variety of intersections between 
topics to better discern relationships and adjacencies.  Figure 2-1 was designed to 
convey the scope of the literature review and also how the various topics relate.  The 
three large circles represent the main areas of focus, while the smaller (purple) circles 
represent related topics reviewed.  Figure 2-1 also provides a mapping of where the 
various topics are covered in this thesis.   
 
Figure 2-1 – Scope of literature review 
 
The review of each topic within this chapter will typically follow a progression from 
more general (e.g., managing knowledge across the product lifecycle) to more specific 
(e.g., managing knowledge specifically for technology transfer as a stage in the product 
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guidance, followed by industry guidance, and finally other academic or research-related 
literature. 
 
It is useful to provide a brief explanation of pharmaceutical sector context as there a 
variety of different organisations cited during the course of this study, with different 
and sometimes overlapping missions.  This research study will reference a sector 
comprised of three primary cohorts:  industry (for-profit organisations which provide a 
pharmaceutical product or associated service); regulatory agencies (authorities which 
have legal authority to regulate the pharmaceutical industry in their respective 
countries); and academia. In addition, there are a variety of associations which 
comprise of a mix of these cohorts.   
 
• Most notably referenced in this study ICH, the International Council for 
Harmonisation.  For the context of this study, ICH has authored a variety of 
guidelines which are widely adopted by worldwide regulatory authorities.  
Successful implementation of ICH guidelines forms a core focus of this research 
study, given their importance, relevance, and global reach.   
 
• Also of significance to this study are the professional associations of ISPE 
(International Society for Pharmaceutical Engineering) and PDA (Parenteral Drug 
Association), which each provide a venue for cross-stakeholder dialogue and 
exchange of ideas to advance the industry.  One feature of these associations is 
the creation of ‘best practices’, authored by industry subject matter experts, to 
support the industry in technical and regulatory success.    
 
• Another industry association referenced within this research study is 
BioPhorum, although this association is primarily comprised of industry and 
focused on connecting leaders and experts across industry members to share 
best practices and align on industry positions.   
 
These stakeholders and associations will be referenced regularly through this research 
study.  The following diagram (Figure 2-2) is intended to help the reader understand 
these various entities and serve as a helpful ‘quick reference guide’ throughout this 
document.   
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Figure 2-2 – Pharmaceutical Sector Landscape10 
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2.1 Managing knowledge across the product lifecycle 
Several definitions of knowledge management are presented in Table 2-1 to formally 
define the concept.  In the opinion of the researcher, the diversity seen across these 
definitions is the first clue of the variability and lack of common understanding of what 
KM is.   
 
Table 2-1 – Definitions of Knowledge Management 




The way in which knowledge is organised and used within a 
company, or the study of how to effectively organise and use it. 
ICH Q10 (ICH, 2008) Systematic approach to acquiring, analysing, storing, and 
disseminating information related to products, manufacturing 
processes and components 
ISO Standard 30401 
(ISO, 2018) 
Management with regard to knowledge.  
note 1: It uses a systemic and holistic approach to improve 
results and learning.  
note 2: It includes optimising the identification, creation, 
analysis, representation, distribution, and application of 
knowledge to create organisational value.) 
APQC11 (APQC, 2018) Systematic approaches to enable knowledge and information to 
grow, flow and create value; connecting people to people and 
people to content. 
 
2.1.1 Regulatory guidance 
This section includes a review of Regulatory Guidance literature and includes discussion 
specifically related to explicitly stated knowledge management expectations as well as 
references to expectations for managing knowledge during the product lifecycle.  The 
scope of literature surveyed represented diverse sources of guidance which are 
common inputs to shape an organisation’s PQS as follows:  
 
• International Conference on Harmonisation (ICH) Quality Guidelines, including  
o ICH Q8(R2): Pharmaceutical Development (ICH, 2009) 
o ICH Q9: Quality Risk Management (ICH, 2005) 
o ICH Q10: Pharmaceutical Quality System (ICH, 2008)  
o ICH Q8/Q9/Q10 Questions & Answers (ICH, 2010) 
o ICH Q11: Development and Manufacture of Drug Substances (Chemical 
Entities and Biotechnological/Biological Entities) (ICH, 2012) 
 
11 APQC, or American Productivity & Quality Center, is a global authority in KM.  www.apqc.org.  
  24 
o ICH Q12: Technical and Regulatory Considerations for Pharmaceutical 
Product Lifecycle Management (ICH, 2019) 
• World Health Organisation (WHO) Guidelines, including: 
o WHO Good Manufacturing Practices for Pharmaceutical Products:  Main 
Principles (WHO, 2014) 
• EudraLex Volume 4 – Good Manufacturing Practice (GMP) Guidelines (Part I) 
(European Commission, 2012) 
• Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good 
Manufacturing Practice for Medical Products (Part 1, Chapter 1) (PIC/S, 2018) 
 
Perhaps of note, no specific US FDA guidance is listed above.  FDA has participated in 
the development of ICH Quality Guidelines listed above and has subsequently adopted 
these guidelines.  Therefore, FDA guidance is included through the ICH documents.   
 
2.1.1.1 ICH Quality Guidelines 
Examining the ICH Quality guidelines sequentially starting with ICH Q8, Pharmaceutical 
Development (ICH, 2009), ICH Q8 establishes a risk-based approach to product 
development commonly referred to as Quality by Design (QbD).  While there is only a 
singular reference to KM in ICH Q8 (which directly references ICH Q10 (ICH, 2008)), ICH 
Q8 aptly sets the stage for the expectations of applying knowledge to increase product 
and process knowledge and make scientific- and risk-based decisions.  Furthermore, ICH 
Q8 acknowledges that new knowledge will be gained over the product lifecycle, for 
example as follows (note the specific acknowledgement for knowledge gained from 
‘failed’ experiments): 
 
Changes in formulation and manufacturing processes during development and 
lifecycle management should be looked upon as opportunities to gain additional 
knowledge and further support establishment of the design space. Similarly, 
inclusion of relevant knowledge gained from experiments giving unexpected 
results can also be useful (ICH, 2009). 
 
ICH Q8 also introduces the concept of prior knowledge.  This concept is not directly 
defined – its meaning can only be inferred as appropriately vetted and managed 
knowledge already existing in the organisation or other reputable source (e.g., from 
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prior products, scientific literature), and industry has continued to debate this at 
conferences (CASSS, 2018).   
 
ICH Q9, Quality Risk Management (ICH, 2005) is specifically dedicated to quality risk 
management as a ‘systematic process for the assessment, control, communication and 
review of risks to the quality of the drug (medicinal) product across the lifecycle.’  QRM 
is identified in ICH Q10 as an enabler adjacent to KM (ICH, 2008) yet there is no 
acknowledgement of KM as a dual enabler, nor corresponding guidance for KM.   
 
A comprehensive literature review of pharmaceutical regulatory guidance as it pertains 
to KM was conducted recently by Kane (Kane, 2018), which covered in particular detail 
ICH Q10, Pharmaceutical Quality System (ICH, 2008) and its approval.  This included a 
review of the positioning of KM as an enabler to the PQS, the definition of KM prescribed 
by ICH Q10 and the KM-specific questions and answers in the supplemental Q8/Q9/Q10 
Questions & Answers document (ICH, 2010).  Therefore, the researcher will not repeat 
this review but will summarise relevant key points.   
 
1. The term knowledge management is defined in ICH Q10 as ‘[a] 
systematic approach to acquiring, analysing, storing, and disseminating 
information related to products, manufacturing processes and 
components.’  While a valid definition, in the opinion of the researcher 
and as evidenced by subsequent literature invoking the need for ‘know-
how’ and other forms of tacit knowledge (ISPE, 2018), this definition is 
arguably narrow and focused primarily on explicit knowledge (i.e., 
documented knowledge).   
 
2. The scope of KM spans the entire product lifecycle as is identified in ICH 
Q10 section 1.6.1, ‘Product and process knowledge should be managed 
from development through the commercial life of the product up to and 
including product discontinuation.’  In addition, section 1.6.1 provides 
examples of sources of knowledge, which include but are not limited to 
‘prior knowledge (public domain or internally documented); 
pharmaceutical development studies; technology transfer activities; 
process validation studies over the product lifecycle; manufacturing 
experience; innovation; continual improvement; and change 
management activities.’  As one might discern, these are very broad 
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buckets of knowledge collectively covering many different processes 
(e.g., development studies) and activities (e.g., innovation) across the 
lifecycle. 
 
3. The supplemental Q8/Q9/Q10 Q&As (R4) document (ICH, 2010) provides 
useful clarification to a variety of questions across this trio of guidelines, 
including for KM within ICH Q10.  Key themes from these answers include 
that there is no prescribed ‘how’ to implement KM, that there are no 
specific dedicated computerised information management system 
requirements and there are no regulatory requirements for a formal KM 
system, although ‘it is expected that knowledge from different processes 
and systems will be appropriately utilised.’ 
 
The key representation of the pharmaceutical product lifecycle, the PQS and its two 
enablers from ICH Q10 shown in Figure 1-2 is of foundational importance and is 
referenced throughout this thesis. 
 
The importance of managing knowledge through acquisition, application and sharing is 
further reinforced in ICH Q11, Development and Manufacture of Drug Substances 
(Chemical Entities and Biotechnological/Biological Entities) (ICH, 2012) as it introduces 
the concept of proactive knowledge transfer across an organisation, specifically: 
 
Knowledge gained from commercial manufacturing can be used to further 
improve process understanding and process performance and to adjust the 
control strategy to ensure drug substance quality…the knowledge and process 
understanding should be shared as needed to perform the manufacturing 
process and implement the control strategy across sites involved in 
manufacturing the drug substance.  
 
ICH Q11 further reinforces the expectation for a ‘systematic approach to managing 
knowledge related to both drug substance and its manufacturing process through the 
[product] lifecycle’, inclusive of technology transfer activities.   
 
The final version of ICH Q12 Technical and Regulatory Considerations for 
Pharmaceutical Product Lifecycle Management, (ICH, 2019) adopted in late 2019, 
positions KM in a central role with respect to the change management process relating 
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to post-approval changes.  ICH Q12 builds upon the KM foundation established by ICH 
Q10 in order to ensure the latest, most comprehensive, and most accurate knowledge 
is applied to maintain the state of control and enable continual improvement.  
Furthermore, an effective KM capability acting as a PQS enabler, helps to ensure that 
knowledge is available to support other critical activities including RM and CAPA as well 
as post-approval changes.  A representation of the positioning of knowledge and 
knowledge management in conjunction with change management in ICH Q12 is 
depicted in Figure 2-3.  
 
 
Figure 2-3 – Knowledge management and change management processes (ICH, 2019)  
This interaction is further explained in appendix 2 of ICH Q12 as follows (emphasis in 
bold added by the researcher):   
 
An effective change management system includes active knowledge 
management, in which information from multiple sources is integrated to 
identify stimuli for changes needed to improve product and/or process 
robustness. The connection between knowledge management and change 
management is illustrated in [Figure 2-3]. These sources can include, but are not 
limited to, developmental studies, process understanding documents, product or 
process trending, and product-specific CAPA outcomes. Provisions should be 
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made for sharing knowledge (e.g., in quality agreements and/or contracts) that 
relates to product and process robustness or otherwise informs changes between 
the MAH and relevant manufacturing stakeholders (research and development 
organisations, manufacturers, CMOs, suppliers, etc.)… As described in ICH 
Quality Implementation Working Group on Q8, Q9, and Q10 Questions & 
Answers, there is no added regulatory requirement for a formal knowledge 
management system.   
 
Key concepts which may be extracted from this guidance include that: 
• Knowledge management is an intentional and proactive activity, covering a 
diverse set of process and product knowledge.   
• Knowledge management is also invoked as a means to sharing knowledge across 
a diverse set of stakeholders. 
 
2.1.1.2 WHO Guidelines GMP for Pharmaceutical Products:  Main Principles – Annex 2 
The current version of the WHO Good Manufacturing Practices for Pharmaceutical 
Products:  Main Principles (WHO, 2014) includes an expectation for managing product 
knowledge across the lifecycle as follows: 
 
The PQS appropriate to the manufacture of pharmaceutical products should 
ensure that…product and process knowledge are managed throughout all 
lifecycle stages. 
 
The responsibility for KM is identified as an expectation to be defined in establishing a 
contract with a separate manufacturing organisation but the term is not expressly 
defined.   
 
2.1.1.3 EudraLex Volume 4 – Good Manufacturing Practice (GMP) Guidelines (Part I) 
In EudraLex Volume 4 (Good Manufacturing Practice guidelines), Chapter 1 
(Pharmaceutical Quality System) (European Commission, 2012), the following 
expectations are established (emphasis in bold added by the researcher):   
 
A Pharmaceutical Quality System appropriate for the manufacture of medicinal 
products should ensure that…Product and process knowledge is managed 
throughout all lifecycle stages 
 and 
Continual improvement is facilitated through the implementation of 
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quality improvements appropriate to the current level of process and product 
knowledge.  
 
2.1.1.4 PIC/S Guide to Good Manufacturing Practice for Medical Products 
No specific expectations of KM across the lifecycle are noted within PIC/S Guide to Good 
Manufacturing Practice for Medical Products (Part 1, Chapter 1) (PIC/S, 2018), with the 
exception of a reference to contractual agreements where the responsibility for KM 
should be appropriately noted.  However, the expectations for managing knowledge are 
noted as part of a firm’s PQS similar to that of EudraLex Volume 4 Part 1 (European 
Commission, 2012) (emphasis in bold added by the researcher):  
 
A Pharmaceutical Quality System appropriate for the manufacture of medicinal 
products should ensure that…Product and process knowledge is managed 
throughout all lifecycle stages…[and] continual improvement is facilitated 
through the implementation of quality improvements appropriate to the current 
level of process and product knowledge. 
 
2.1.2 Industry guidance 
This section includes a review of pharmaceutical Industry Guidance12 literature from 
industry associations and other authorities.  This review focused on the expectations for 
KM across the product lifecycle.    As discussed previously in this thesis, there is a general 
lack of pharmaceutical industry guidance for KM.  However, recently there have been 
some developments within the industry towards addressing this gap. 
 
2.1.2.1 ISO 
In November 2018 the International Organisation for Standardisation published its first 
ever guidance on KM in the form of International Standard ISO 30401:2018(E), 
Knowledge Management Systems – Requirements (ISO, 2018).  This standard 
acknowledges in the introduction that KM has no single accepted definition, and no 
global standards predate the subject standard.  The standard also stated there are many 
 
12 The concept of industry guidance literature in the pharmaceutical industry is important as these are 
typically documents authored by cross-functional SME teams and undergo a peer-review commenting 
process for broad sector input.  Input to these guides is often sought from industry, academia, and 
regulatory authorities.  These guidance documents typically help industry understand how to satisfy 
regulations, adopt good practices, etc.   
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well-known barriers to KM and confusion with other disciplines.  In addition, the 
standard describes the importance of KM in a generalised manner to an organisation’s 
success.  
 
The standard does not deeply address specific KM approaches, nor does it use the word 
‘tacit’ (however it does state that at one-point knowledge includes ‘insights and know-
how’ as common vernacular for tacit knowledge).  The standard is useful in particular 
for organisations looking to set up or improve their KM programs.  It addresses a 
lifecycle of knowledge activities and inventories KM enablers, including culture.  It 
covers the expectations of leadership, policy, roles and responsibilities, and support 
requirements (e.g., communications).  The standard has not seen rapid uptake, with 
nearly half of survey respondents in the Knoco13 2020 KM survey (Knoco, 2020)  
unaware of the standard or not intending to buy or use it, and only a very small 
percentage (2%) are seeking or have achieved certification.  In the opinion of the 
researcher, this should change over time as more become familiar with its contents and 
the importance of KM.   
 
2.1.2.2 ISPE 
In 2019 ISPE chartered a team to create a Good Practice Guide for Knowledge 
Management, and the researcher was invited to be a member of the subject matter 
expert authoring team.  ISPE Good Practice Guides are premier industry guidance 
documents which are authored by industry subject matter experts, and through a 
governance process are peer reviewed by industry.  The following is an excerpt from the 
ISPE Knowledge Management Good Practice Guide charter14. 
 
Knowledge Management – one of the two identified enablers of ICH Q10. The 
publication of ICH Q10 in 2008 saw the formal designation of Knowledge 
Management  (KM) as a key enabler for an effective Pharmaceutical Quality 
System.  Since then, the industry has acknowledged the importance of managing 
knowledge across the lifecycle to enhance process understanding, improve 
 
13 Knoco was established in 1999 by key members of BP’s (British Petroleum) global KM Consulting 
team, who had been recognised in the 1990s as pioneers in the field of KM.  www.knoco.com.  
14 The charter is not published, but the charter was available to the researcher as a member of the SME 
author team for the guide. 
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decision making and enable more robust risk management. ICH Q10 and the 
forthcoming Q12 discuss the expectations for firms to proactively manage 
product and process knowledge citing the potential of more efficient and 
effective regulatory oversight (e.g., ICH Q12).  There are currently few resources, 
and NO INDUSTRY GUIDANCE available which address the role of Knowledge 
Management specifically for the pharmaceutical industry. 
 
The chartering of an ISPE Good Practice Guide team for Knowledge Management is an 
important recognition of the significance of KM and the need for industry guidance.  This 
ISPE Guide was published nearly concurrently with this thesis in May 2021 (ISPE, 2021b) 
and will be discussed in further detail in Chapter 10.   
 
2.1.2.3 BioPhorum 
In March 2020 BioPhorum published a peer-reviewed case study titled Knowledge 
Mapping for the Biopharmaceutical Industry:  A Test Case in CMC15 Business Processes 
from Late-Stage Development to Commercial Manufacturing (BioPhorum Operations 
Group, 2020).  The purpose of the document was to demonstrate a ‘best practice KM 
methodology to capture a process-based knowledge map for a major business process’ 
– in this case for the CMC business process from late-stage development to commercial 
manufacturing.  The intent was to illustrate the knowledge mapping method, produce 
a company agnostic knowledge map as a reference for the industry, to highlight the 
common issues with ‘knowledge flows’ where improvements can be made, and to 
highlight the detailed tacit knowledge which exists in the business process.  This 
knowledge map was created by 18 individuals from 12 different organisations, as listed 
in the referenced document (BioPhorum Operations Group, 2020).  The researcher was 
an invited member of the team and was responsible for providing the knowledge 
mapping process and trained the team on knowledge mapping.  While not official 
guidance, this guide will serve a model of knowledge mapping for others to follow as 
well as having created a useful industry asset in the form of the subject knowledge map.   
 
 
15 Chemistry, Manufacturing and Controls (CMC) of a medicinal product is the body of information that 
defines not only the manufacturing process itself but also the quality control release testing, 
specifications and stability of the product (Genpact, 2021) 
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2.1.3 The Pharmaceutical Regulatory Science Team  
The Pharmaceutical Regulatory Science Team (PRST) based in TU Dublin has continued 
to progress research on quality risk management, knowledge management and related 
topics covered by ICH Quality Guidelines, most recently ICH Q12 (ICH, 2019).  The PRST 
was founded in 2005 in response to the drive for a paradigm shift in quality from the 
international regulatory community.  PRST actively engages with global industry and 
regulators to address the challenges and opportunities of implementing Science and 
Risk based decision making and manufacturing approaches.  PRST research emphasis is 
on the development of patient-focused strategies to enable those involved in the 
manufacture of drug products to meet the evolving international regulatory 
expectations ensuring the availability of high-quality medicinal products.  
 
An overview of the research topics, currently active researchers (with primary topic) 
and key regulatory and industry developments is depicted in Figure 2-4.  One of the 
powerful characteristics of the PRST research structure is that research is not done in 
‘silos’ – there is a high degree of research cross-over between these important PQS 
topics which brings diverse viewpoints and further strengthens the validity of the 
research overall.  The PRST are all active members of industry conferences and publish 
regularly.   
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Figure 2-4 – PRST journey in regulatory science research 
2.1.3.1 Research by the PRST:  Knowledge management 
This most relevant research for this research study is the work of Calnan and Kane.  
Calnan’s 2015 thesis, Protecting the Patient:  Enhancing the Quality of Pharmaceutical 
Products (Calnan, 2014a) explored the unacceptable risks that patients are exposed to 
due to challenges which exist in the complex pharmaceutical product lifecycle.   
 
Calnan’s exploration of KM as an ‘orphan enabler’ to the PQS established the 
foundations for the PRST in KM.  Calnan discussed the concepts of tacit and explicit 
knowledge, the concept of knowledge flow and the link between the importance of 
capturing and applying knowledge to an effective PQS.  Calnan also proposed that the 
elements of the PQS (product performance and product quality monitoring system, 
CAPA, change management and management review) should operate through well-
integrated and balanced enablers of KM and QRM.   
 
Calnan explored the topics of being excellent and cultural excellence, in addition to the 
aforementioned knowledge excellence focus.  A key output from the research was a 
construct of the Building Blocks of Cultural DNA of Quality (Figure 2-5), in which these 
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elements of knowledge excellence, cultural excellence, patient focus and being excellent 
converge to create a culture of quality.     
 
 
Figure 2-5 – Building blocks of the cultural DNA of quality (Calnan, 2014a) 
The primary research output of Calnan’s work was the Excellence Framework (Figure 
2-6), a combination of the cultural excellence of a learning organisation with excellence 
in knowledge creation and utilisation, in order to deliver operational excellence based 
on a relentless restlessness for improvement.  The model is dynamic and encourages 
one to analyse the current situation for improvement opportunities, to assimilate the 
findings to create new knowledge and then use this knowledge to take action, decisions 
and deliver solutions.  Reflection is promoted to confirm the effectiveness of the action 
taken and share lessons learned.   
 
Figure 2-6 – The Excellence Framework (Calnan, 2014a) 
Calnan’s work also produced additional KM-related outputs, including a KM e-journal 
published by ISPE, an informative history of product quality, and a detailed literature 
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review, including that of knowledge management, found in Chapter 2 of Calnan’s thesis 
(Calnan, 2014a).   
 
The second closely related research study was carried out by Kane, culminating with the 
2018 thesis on A Blueprint for Knowledge Management in the Biopharmaceutical Sector 
(Kane, 2018).  Kane’s focus was on exploring the level of adoption and capability of KM 
in the biopharmaceutical sector.  In finding a general lack of maturity in the sector, 
Kane’s research produced a collection of assets for the sector to leverage to unlock their 
knowledge.  The primary output of the research was a new framework entitled the 
Pharma KM Blueprint (Figure 2-7).   
 
 
Figure 2-7 – The Pharma KM Blueprint (Kane, 2018) 
This framework provided a construct of principles, models and tools summarised as 
follows:  
 
1. Managing Knowledge as an Asset – addresses the need to value and maintain 
knowledge assets in the same way as physical assets within an organisation. 
2. The Pharmaceutical Product Knowledge Lifecycle Model (PPKL) (Figure 2-8) 
addresses the challenge of enabling knowledge flow in order to increase 
visibility, to access and use the product and process knowledge assets across the 
product lifecycle. 
3. The House of Knowledge Excellence Framework (Figure 2-9) demonstrates a 
framework developed to implement a systematic KM programme linked to 
strategic objectives of an organisation, incorporating KM practices, pillars 
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(people, process, technology, governance), and enablers to support the effective 
management and flow of knowledge assets.  
4. Knowledge Management Effectiveness Evaluation provides a practical KM 
diagnostic tool that may be used to identify and evaluate areas of opportunity 
and to track progress on closing knowledge gaps. 
 
 
Figure 2-8 – Pharmaceutical Product Knowledge Lifecycle Model (PPKL) (Kane, 2018)  
 
 
Figure 2-9 – The House of Knowledge Excellence (Kane, 2018) 
Of primary relevance to this thesis is the PPKL model.  The features of the model include:  
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• The vision for end-to-end (E2E) product and process knowledge asset visibility, 
transparency, and availability in order to enable knowledge flow of critical 
knowledge to those that need it throughout the product lifecycle.  
• The addition of a new lifecycle phase of New Product Introduction (NPI) to 
replace the Technology Transfer lifecycle phase.  
• That Technology Transfer is an activity that may occur multiple times across the 
product lifecycle.  
• The addition of a new E2E process to capture the Technical Product Support and 
Continual Improvement activities that occur across the product lifecycle.  
 
This model provides a helpful anchor to the management of product knowledge and the 
focus on technology transfer as a focal part of this thesis, in particular to the concepts 
that knowledge must be managed end-to-end throughout the product lifecycle, that 
technology transfer is a repetitive activity across the product lifecycle, and capturing 
the end-to-end knowledge can aid in continual improvement.   
 
The House of Knowledge Excellence framework is relevant in particular to the chapter 
in this thesis which proposes a toolkit for knowledge management during technology 
transfer (Chapter 7).  The researcher co-developed this framework with Kane and was 
co-author of the book chapter in which it is described (Kane and Lipa, 2018).   
 
Kane’s work also produced a thorough literature review on KM, found in Chapter 2 of 
Kane’s thesis (Kane, 2018).  As such, the literature review conducted in this thesis did 
not repeat all of these specifics and instead builds on this literature review (and that of 
Calnan), with a focus on aspects of relevance to the planned research for this study and 
developments since Kane’s research concluded.  Together, the combined literature 
review across these three theses captures a rich and comprehensive review of the KM 
literature, especially relative to the biopharmaceutical industry.  
 
These assets will be further referenced throughout this thesis where appropriate.  
Kane’s work is further summarised in a monograph entitled Advancing Knowledge 
Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry (Kane and 
Lipa, 2020).  
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In addition, the results of a survey entitled Knowledge Management Implementation, A 
Survey of the Biopharmaceutical Industry were published in May 2020 by ISPE (Kane et 
al., 2020).  This survey was a follow on from Kane’s research and reported on current 
state of KM implementation, including status of KM implementation, areas of KM focus, 
primary KM approaches, cultural issues.  This survey report further confirmed the 
relatively low maturity and high variability in which KM is being pursued in the industry.   
 
2.1.3.2 Research by the PRST:  Post-approval changes (ICH Q12) 
Research is underway currently by Ramnarine (Ramnarine, 2020) examining how an 
effective PQS could transform post-approval change management to, in turn, solve the 
continual improvement and innovation challenge faced by the industry.  Among other 
challenges, this research also looks at how knowledge and knowledge management 
enable post-approval changes (PACs).  Figure 2-10 is a representation of how product 
knowledge grows across the product lifecycle.  In principle there will always be more 
knowledge available than is captured in the CTD (Common Technical Document, i.e., the 
regulatory filing).   
 
 
Figure 2-10 – Maintaining product knowledge in the PQS vs. regulatory filings (Ramnarine, 
2020) 
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‘Timely knowledge management’ is required to manage this knowledge effectively and 
to in turn be able to apply a firm’s knowledge to identify the need for a change, to 
manage the risk associated with the change, implement the change and to ensure the 
change was successful.  Of note, KM was identified as a top priority to gain regulatory 
flexibility.  Ramnarine et al. explain the role of KM in maintaining a state of control, 
facilitating continual improvement and management of post-approval changes through 
the PQS in Figure 2-11 (Ramnarine et al., 2019). 
 
 
Figure 2-11 – Managing post-approval changes through the PQS (Ramnarine et al., 2019) 
2.1.3.3 Additional research & contributions by the PRST 
Additional work by the PRST is embedded and referenced throughout this research 
study, including those works carried out by the researcher summarised elsewhere in 
this thesis and the work of PRST colleagues such Kevin O’Donnell (O’Donnell, 2020).  In 
addition, the PRST has published multiple monographs since 2018 on the topics of QRM 
and/or KM.   
 
2.1.4 Knowledge management – Knoco 2020 benchmarking survey 
The majority of significant developments since the completion of Kane’s research and 
the start of this research study have been captured in other sections within this 
literature review.  One additional development was the issuance of the Knoco 2020 
Global Survey of Knowledge Management and associated report (Knoco, 2020).  Surveys 
were also conducted by Knoco in 2014 and 2017 and these are reviewed in detail in the 
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literature review contained in Kane’s thesis (Kane, 2018), of which select highlights are 
shared here.  These important surveys are the only one of their type and breadth but 
are industry-agnostic and there is not a specific category for pharmaceuticals, so sector-
specific assessments of results or changes over time for pharmaceutical are not 
possible.  Further, the goals of KM across sectors are not as focused on the quality 
management system as there are many additional drivers for KM in organisations.  
Regardless, these data summarised below are useful to understand a bigger focus on 
KM at the global level.  Given the sector choices provided by the survey, the researcher 
anticipates most participating organisations in the pharmaceutical sector would have 
labelled themselves as Professional, Scientific and Technical Services or Manufacturing.   
 
The 2020 survey received a total of 453 responses, up from 427 in 2017 and 386 in 2014.  
The trend of KM importance is rising in a significant percentage of responses at 71%, 
with a small 5% minority indicating the importance of KM is on the decline.  The survey 
also assessed cultural issues that act as barriers to KM programs, which are important 
clues to a transformation change management focus in support of KM.  Results are 
summarised in Figure 2-12, and show that the leading barrier to KM programmes was 
short-term thinking followed by lack of openness to sharing.  
 
 
Figure 2-12 – Cultural issues acting as barriers to knowledge mgmt. (Knoco, 2020) 
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Many additional results are available in the Knoco survey (Knoco, 2020).  These specific 
results were selected by the researcher based on their relevance to this research effort 
and anticipated outcomes.   
 
2.1.5 Summary – knowledge management across the product lifecycle 
Reviewing regulatory expectations in aggregate for management of product and 
process knowledge across the lifecycle, the researcher draws the following conclusions: 
 
• There are broad and consistent expectations across an array of authoritative 
sources for product and process knowledge to be managed proactively across 
the product lifecycle 
• Increased knowledge is the means to drive continual improvement 
• Knowledge lies in multiple formats, including documents (explicit knowledge), 
experience (tacit knowledge) and an array of sources which in reality are a mix 
of explicit and tacit knowledge, including development history, change history 
(with rationale), and problem history with associated resolutions, among others   
• These knowledge sources are relevant to the given product, but may be 
leveraged across products as ‘prior knowledge’ 
• Knowledge leads to understanding and risk reduction which in turn leads to 
improved patient outcomes.  Knowledge should not only include ‘what works’ 
for a given product or process but also should include learning from ‘failures’ 
(e.g., experiments with unexpected outcomes) 
• There are several linkages between KM and QRM (discussed further in section 
2.2) 
 
Yet, In the opinion of the researcher, it appears there is a general lack of industry 
guidance for KM, especially when compared to available literature on QRM.   It is noted 
that there has been recent activity which may be starting to address this gap. 
 
There are potentially exciting developments on the research front that will continue to 
raise awareness of the need to improve KM, including this research study.  It is worth 
mentioning the annual Knowledge Management Conference held by APQC is alive and 
well and would have hosted it’s 25th Anniversary Event in May of 2020 (APQC, 2020), 
although regrettably cancelled due to the COVID-19 pandemic.  The researcher has 
been a regular attendee and a steering committee member for 3 of the past 5 years, 
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and attendance at this conference has continued to grow.  This conference is a premier 
event for KM globally and is an annual event which draws approximately 400 attendees 
across a highly diverse industry base.  The conference is on track to resume in October 
of 2021. 
 
2.2 Quality Risk Management and Knowledge Management 
A detailed literature review on QRM and KM was conducted as part of this study with 
two primary focus areas as outlined below.  This literature review was published in a 
peer-reviewed journal, the Journal of Validation Technology (Lipa, O’Donnell and 
Greene, 2020c), with the findings summarised below. 
 
The first area of focus of the literature review was an exploration of available literature 
to understand how QRM and KM have been related in other studies and other 
industries.  The review strongly suggested that the interplay between managing risk and 
managing knowledge is not new.  For the last 20+ years this has been a topic of 
discussion spanning finance, legal, information technology, aerospace, corporate risk 
management, military, and other domains.  The findings are consistent, in that there is 
a direct relationship between knowledge and risk – more knowledge one has leads to   
increased understanding and decreased uncertainty – and therefore to lower risk.   
 
The second area of focus of the literature review was on regulatory guidance, examining 
the relationship between risk and knowledge in the guidance as a means to better 
characterise any interdependency between risk and knowledge, as well as RM and KM.  
The review suggest that collectively the themes of knowledge and risk, along with KM 
and RM as structured means to manage each, are prevalent and persistent across the 
diverse set regulatory literature reviewed.  The review also sought to look beyond 
explicit and obvious descriptions stating how RM and KM are linked.  The intent was to 
examine the more subtle instances of how knowledge and risk are connected, in 
addition to KM and RM, even though these latter terms are used less frequently 
(especially KM).   Further, the review also reflected on the FDA’s vision of science and 
risk-based quality for the 21st century (US FDA, 2002) given the inseparability of 
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knowledge and science.  According to the WHO guideline on Quality Risk Management 
(WHO, 2013), an ‘effective and secure knowledge management system’ is crucial to 
quality risk management.  This WHO guideline also highlights the expectations for using 
not only documented knowledge (i.e., explicit knowledge), but also establishes the 
expectation for using the knowledge 'in the heads of people’ where experience and 
expertise are critical (i.e., tacit knowledge).   
 
As this literature review demonstrated, knowledge and risk bear a clear relationship, 
with knowledge being recognised as both an input and an output to quality risk 
management. This leads to greater control of risks to quality through increased 
understanding.  The pairs are each interwoven:  knowledge & risk, and knowledge 
management & risk management.   
 
Furthermore, a key concept is that ‘risk varies inversely with knowledge’ (Fisher, 1907).  
The researcher challenged this as a potential over-simplification and asserted that risk 
varies inversely with knowledge applied, indicating the need for the knowledge to be 
created, identified, stored, accessible and ‘flow’ on demand to when and where it is 
needed.  The researcher developed the following figure (Figure 2-13) to illustrate this 
point, that risk is a function of knowledge application, and knowledge application is in 
turn a function of knowledge flow, availability, capture (and more).  Therefore, risk is 
also dependent on knowledge flow, availability, capture (and more), highlighting the 
need for robust KM processes to maximise risk reduction.   
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Figure 2-13 – Risk varies inversely with knowledge applied 
Further implications from this literature review will be explored in Chapter 5 of this 
thesis. 
 
2.3 Technology Transfer and Knowledge Management 
The next section of the literature focuses on KM in technology transfer. 
 
2.3.1 Regulatory guidance 
Regarding technology transfer, ICH Q10 (ICH, 2008) states technology transfer activities 
including new product transfers during development through manufacturing and 
transfers within or between manufacturing and testing sites for marketed products are 
both in scope of ICH Q10.   
 
In section 3.1 on Lifecycle Stage Goals, ICH Q10 provides arguably a pivotal goal 
statement for technology transfer being primarily about knowledge transfer as follows 
(emphasis in bold added by the researcher):   
 
The goal of technology transfer activities is to transfer product and process 
knowledge between development and manufacturing, and within or between 
manufacturing sites to achieve product realisation. This knowledge forms the 
basis for the manufacturing process, control strategy, process validation 
approach and ongoing continual improvement. 
 
Risk varies inversely with Knowledge Applied








Risk = f (knowledgeapplied) 
Meaning:  Risk is a function of knowledge application…the more knowledge, the less risk
Knowledgeapplied = f (K flow, K availability, K capture, K accuracy, …) 
Meaning:  for knowledge to be applied, it must be available, it must flow to when and where it is 
needed, it must have been captured, it must be accurate, …;  all direct goals of a KM program
© Martin Lipa 2020
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ICH Q10 proceeds to provide application insights for each lifecycle stage (i.e., 
pharmaceutical development, technology transfer, commercial manufacturing, and 
product discontinuation) for each of the four PQS elements, including (i) Process 
Performance and Product Quality Monitoring System, (ii) Corrective Action and 
Preventive Action (CAPA) System, (iii) Change Management System and (iv) 
Management Review of Process Performance and Product Quality.  Key points relating 
to technology transfer include strong interdependencies with KM practices, including 
that technology transfer should be a learning opportunity to grow knowledge about a 
product (‘Knowledge obtained during transfer and scale up activities can be useful in 
further developing the control strategy’), that acquired knowledge should be applied 
both feedback and feedforward basis (‘CAPA can be used as an effective system for 
feedback, feedforward and continual improvement’) and that it sets up the role of 
knowledge management to manage explicit knowledge for change management (‘the 
change management system should provide management and documentation of 
adjustments made to the process during technology transfer activities’).  
 
In the introduction of Annex 7 to the WHO guideline on Transfer of Technology in 
Pharmaceutical Manufacturing, the following principle is presented citing the 
expectation for management of explicit and tacit knowledge as part of technology 
transfer (WHO, 2011) (emphasis in bold added by the researcher):  
 
Transfer of technology is defined as “a logical procedure that controls the 
transfer of any process together with its documentation and professional 
expertise between development and manufacture or between manufacture 
sites”. It is a systematic procedure that is followed in order to pass the 
documented knowledge and experience gained during development and or 
commercialisation to an appropriate, responsible and authorised party.  
 
Further in this guideline, KM is mentioned but not specifically defined: 
 
In the event that the RU [receiving unit] identifies particular problems with the 
process during the transfer, the RU should communicate them back to the SU 
[sending unit] to ensure continuing knowledge management.  
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Management of knowledge is clearly inferred throughout the document, including in 
section 5 where process history, reasons for changes, and problems and outcomes are 
examples of types of knowledge referenced.  Chapter 8 of the WHO guideline includes 
a list of documentation (explicit knowledge) to be transferred.   
 
2.3.2 Industry guidance (pharmaceutical industry-specific) 
This section includes a review of pharmaceutical Industry Guidance literature from 
industry associations and other authorities with a focus on technology transfer.  The 
scope of literature surveyed includes: 
 
• WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing – 
Annex 7 (WHO, 2011) 
• NIHS Japan:  Guideline for Technology Transfer (NIHS, 2005) 
• ISPE:  Good Practice Guide:  Technology Transfer, 2nd Edition (ISPE, 2014) 
• ISPE:  Good Practice Guide:  Technology Transfer, 3rd Edition (ISPE, 2018) 
• PDA:  Technical Report No. 65: Technology Transfer (PDA, 2014b) 
• PDA:  Technical Report No. 65: Technology Transfer16 
• PDA Technology Transfer Industry Survey (via Interest Group Report out at PDA 
2019 Annual Meeting and 2019 Technology Transfer Industry Survey (Seymour 
et al., 2019) 
• Technology and Knowledge Transfer - Keys to Successful Implementation 
(Gibson and Schmitt, 2014) (published by PDA, although not an official Technical 
Report) 
 
In general, these guidance present frameworks, processes, and considerations for 
conducting technology transfer from which individual companies construct their 
respective technology transfer business processes.  Of particular interest in this review 
is an evaluation of whether the guidance documents include guidance on expectations 
for knowledge management and knowledge transfer, as well as any further guidance on 
how this might be accomplished.  The first step was an assessment of the extent to 
which key concepts including knowledge transfer, knowledge management and tacit 
knowledge (and synonym ‘know-how’) are present.   
 
16 This PDA Technical Report is currently under revision, but the revision has not been published in time 
for inclusion in this thesis.  The researcher has been invited to provide feedback on the upcoming 
revision which is further explained in section 10.3. 
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A further qualitative assessment of the literature was conducted by the researcher on 
how well these documents introduced these concepts, including how well they are 
collectively explained, whether they provided illustrative examples, and whether they 
provided guidance / tips on ‘how’.  Details are provided in the corresponding paper 
(Lipa, Kane and Greene, 2019), and are summarised by the researcher as follows: 
 
• Technology transfer guidance is typically very ‘document-centric’ (i.e., focused 
on explicit knowledge) 
• Knowledge management, with a focus on explicit knowledge, is identified in 
guidance but is lacking in practical application as the researcher observed the 
following: 
o Lack of supporting principles or guidance on how to manage or transfer 
knowledge effectively 
o This absence of guidance may be starting to change, but perhaps still not 
enough or fast enough given lag time for industry awareness, 
interpretation, and application 
• ‘Tacit’ knowledge is rarely recognised as a source of knowledge, nor is there 
guidance on how to manage or transfer 
• Technology transfer risks of failure do not acknowledge concepts of insufficient 
knowledge transfer or availability in the future. 
 
Regarding ISPE guidance on technology transfer, the second edition of the Good 
Practice Guide (ISPE, 2014) was included as a baseline for comparison against third 
edition, in order to evaluate any changes over time.  The third edition (ISPE, 2018) lists 
five key rationale for the revision, one of which is ‘Recognition that knowledge 
management is a critical component of effective technology transfer…’.  It is clear in the 
results summarised by the researcher, the presence of knowledge management and 
related concepts has been significantly strengthened beyond a starting baseline from 
the second edition, suggesting recognition of the need to provide further details in 
guidance.   
 
Regarding PDA guidance on technology transfer, the PDA Tech Transfer Interest Group 
at the 2019 PDA Annual Meeting shared the results of a recent survey which they 
conducted on technology transfer (Seymour et al., 2019).  The survey was intended to 
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assess the current practices and future needs for improving the technology transfer 
process as an input to a planned revision of PDA Technical Report 65, Technology 
Transfer (PDA, 2014b).  The survey covered: 
 
• Demographics 
• Types of Technology Transfer Performed 
• The Technology Transfer Process 
• Use of Multi-Disciplinary Teams 
• Technology Transfer Tools 
• Challenges 
 
The researcher attended the conference session where the PDA Technology Transfer 
survey results were presented (Haas, 2019) and the results were subsequently 
published by PDA (Seymour et al., 2019).  In response to the survey question “What are 
the top three areas for which a PDA guidance would enhance technology transfer?”, 
approximately 40% of respondents included Knowledge Management as one of their 
top 3 priorities as illustrated in Figure 2-14. 
 
 
Figure 2-14 – PDA technology transfer survey (Haas, 2019) 
In the opinion of the researcher, there are also underlying correlations with KM in many 
other survey questions.  For example, when asked “What do you see as your biggest 
obstacles for technology transfers?”.  The top two replies were Communication/ 
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Collaboration and Timeliness of Deliverables.  While not specifically cited nor labelled as 
a knowledge transfer challenge, it is highly likely that structured knowledge transfer 
would dramatically address these obstacles.  Notably, Risk Assessment Considerations 
was the most frequent challenge area, identified as a challenge by nearly 70% of the 
respondents.  This suggests an indirect dependency on knowledge and knowledge 
management.  Risk and knowledge are interdependent, as will be explored in Chapter 
5. 
 
Of note, during the PDA conference, the discussion on KM in the Technology Transfer 
Interest Group (IG)  session focused heavily on a ‘master plan’ for KM which primarily 
focused on documents and information with no references to tacit knowledge, ‘know-
how’, learning from failures, experience, or any other non-explicit knowledge 
management inferences.  These master plans are useful in that they highlight key 
activities which generate knowledge, but they do not expressly identify tacit knowledge 
nor assess the effectiveness of knowledge transfer.   
 
There was also a link established at the PDA conference between KM and ‘soft skills’ as 
shown in Figure 2-15.  Some of these could perhaps be extended to traditional KM 
practices (like a community of practice to communicate broadly).  However, it is the 
opinion of the researcher that in the main, these items tagged as KM ‘soft skills’ as 
proposed by PDA are indeed important but are generally not KM-related skills.  The 
researcher sees this as a risk of possible confusion on the intent behind KM, especially 
if this is carried through to the revision of Technical Report 65, Technology Transfer 
ongoing in 2021.  
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Figure 2-15 – Knowledge management and ‘soft skills’ (Haas, 2019) 
In addition, PDA has published an insightful book on technology transfer, aptly titled 
Technology and Knowledge Transfer:  Keys to Successful Implementation and 
Management (Gibson and Schmitt, 2014).  Aside from providing an excellent history and 
outline of technology transfer, it begins to describe knowledge transfer elements.  
Although many of the KM-related elements are somewhat information technology 
centric (i.e., IT system), there are supportive concepts for KM (including that of tacit 
knowledge) with multiple references to knowledge transfer, knowledge management, 
‘know-how’ and how culture can support knowledge transfer.  Although also a PDA 
publication, it is not evident to the researcher whether this resource and associated 
concepts within are being pulled into the revision of the PDA Technical Report on 
technology transfer as it remains to be seen what emerges in the final document.   
 
2.3.3 Exploring the foundations of Technology Transfer and Knowledge Transfer 
A literature review was conducted to explore the current state of knowledge transfer 
during technology transfer, in general and in the pharmaceutical industry, including 
associated challenges, principles, and models or frameworks.   
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2.3.3.1 Technology transfer 
It was not so long ago in 2003 when Kremic (Kremic, 2003) asserted technology transfer 
does not have a universal meaning but rather has broad connotations and is very 
contextual.  Shortly after in 2004 Reisman (Reisman, 2005) stated ‘technology transfer 
is an emerging field of knowledge in which institutional interest is rapidly expanding.’ 
Cases are noted in use by firms for competitive advantage, governments towards 
economic progress and social development, universities for commercialisation and 
licensing of research outputs (Audretsch, Lehmann and Wright, 2014; de Wit-de Vries 
et al., 2019) and for government research institutions to give access to new technologies 
to taxpayers (Schacht, 2012).  Reisman continued:  
 
As is often the case in an emerging area or discipline, its descriptive as well as 
normative theories and data available are fragmented and disjointed. There is 
no general theory, model or structure for the field17…the very definition of 
technology transfer differs across the many disciplines addressing technology 
transfer, and the scope of transfer has rarely been delineated or systematically 
analysed.  Currently, transfer can be understood only in a limited way from a 
strict disciplinary framework and/or a specific aspect.  
 
Well over a decade has passed and there is little evidence to this changing significantly.  
Dubickis and Gaile-Sarkane (Dubickis and Gaile-Sarkane, 2017) assert that the concept 
of technology transfer is not easy to define, citing a study from Sazali and Raduan in 
2011 which identified nearly 30 different viewpoints on technology transfer (Wahab, 
Rose and Suzana, 2012).  Ismail et al in 2016 (Ismail, Hamzah and Bebenroth, 2018) 
defined technology transfer as ‘the process of transferring or disseminating technology 
from its origin to a wider distribution, to more people and places.’ 
 
Specific to the pharmaceutical industry, the definition of technology transfer also 
appears – surprisingly given the highly regulated nature of the industry – not singularly 
defined.  The definition is stated differently across a variety of less formal channels 
 
17 The researcher found this lack of maturity very surprising, having assumed that the practice of 
technology transfer would have been more established and consistent.  This was a key learning for the 
researcher.  Furthermore, Reisman’s quote noted here could perhaps similarly be applied to knowledge 
management, perhaps just a few years behind technology transfer in its own maturity journey 
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including conference presentations, articles by consultants and marketing materials.  
The definitions of technology transfer identified from seemingly authoritative sources 
are as follows: 
 
• WHO guidelines on transfer of technology in pharmaceutical manufacturing 
(WHO Technical Report Series, No. 961, Annex 7) (WHO, 2011): ‘a logical 
procedure that controls the transfer of any process together with its 
documentation and professional expertise between development and 
manufacturing or between manufacturing sites.’ 
• Pharmaceutical Research and Manufactures of America’s (PhRMA) Quality 
Technical Committee in 2003 defined technology transfer as: ‘The body of 
knowledge available for a specific product and process, including critical-to-
quality product attributes and process parameters, process capability, 
manufacturing and process control technologies, and quality systems 
infrastructure.’  (cited by Millili (Millili, 2011)) 
• ICH Q10 (ICH, 2008) states the goal of technology transfer rather than labelling 
it a definition.  This seems to be a commonly adopted working definition by the 
industry: ‘The goal of technology transfer activities is to transfer product and 
process knowledge between development and manufacturing, and within or 
between manufacturing sites to achieve product realisation.’ 
 
This latter was used as the definition of technology transfer in a 2015 paper titled 
Overview of Best Practices for Biopharmaceutical Technology Transfers (Abraham et al., 
2015), authored by a team across six biopharmaceutical companies.  The authors 
explain in their paper, technology transfer is a key foundational component in product 
commercialisation and is more than just the transfer of documents; it relates to all 
aspects of the transfer of knowledge and experience to the commercial manufacturing 
unit to ensure consistent, safe, and high-quality product.  They further assert that 
understanding how to streamline and improve technology transfers is complicated by 
companies using different terminology and ways of working regarding technology 
transfer.  The authors define key terminology associated with technology transfer and 
propose a process overview with key activities and milestones, from which the 
researcher has re-framed from a table to the process view show in Figure 2-16. 
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Figure 2-16 – Key activities and milestones in biopharmaceutical technology transfer 
 
2.3.3.2 Knowledge transfer 
Kwan et al. (Kwan and Cheung, 2006) describe knowledge transfer as ‘the process 
through which one unit (e.g., group, department, or division) is affected by the 
experience of another.’  In addition, they note that knowledge transfer is treated by 
most researchers as a black box. They propose that a process view that emphasises the 
sequence of events would provide insights on the nature of the inner workings of 
knowledge transfer. However, few researchers have explicitly suggested a process 
model for the knowledge transfer, and of the conceptual models and frameworks 
found, they observed them to be diverse and based on theories from various disciplines. 
Kwan et al. subsequently proposed a knowledge transfer management system (KTMS) 
to support needs across the different stages of their proposed knowledge transfer 
process model (Motivation, Matching, Implementation, Retention) in which appropriate 
knowledge management tools were applied at each stage of the process. 
 
Liyanage et al. (Liyanage et al., 2009) describe knowledge transfer as ‘the conveyance 
of knowledge from one place, person or ownership to another.’  Successful knowledge 
transfer means that transfer results in the receiving unit accumulating or assimilating 
new knowledge. A thorough review of literature reveals that many authors and 
researchers have failed to provide a clear-cut definition for knowledge transfer, and at 
times, it has been discussed together with the term ‘‘knowledge sharing.’’ 
 
Dixon (Dixon, 2017) suggests ‘a general call to encourage more knowledge sharing or 
transfer is not very effective because there are many ways to transfer knowledge.’  
Dixon proceeds to propose a knowledge transfer framework based on two questions, 
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(i) ‘What is the transfer problem you are trying to solve?’ and (ii) ‘What type of 
knowledge do you want to transfer?’  From these inputs, Dixon proposes how the 
knowledge can be harvested or captured, and how the knowledge can then be 
transferred. 
 
Ward et al. (Ward, House and Hamer, 2009) conducted a study of existing models and 
frameworks for knowledge transfer and inventoried 28 generalised frameworks in the 
literature and identified five common components.  This led the authors to the proposal 
of a conceptual framework embodying those five common components as:  
 
i. the problem 
ii. the knowledge 
iii. the context barriers or supports 
iv. the interventions 
v. the utilisation 
 
The model developed by Liyanage et al. is presented as a figure (Liyanage et al., 2009) 
and is reproduced here in Figure 2-17.  This model highlights the need to address a 
number of questions prior to the implementation of a transfer mechanism: 
 
• Who needs the knowledge (receiver)? 
• What units (in the supply chain) are involved in the knowledge transfer process? 
• What is the most appropriate ‘‘source’’ to acquire the required knowledge 
(awareness)? 
• What is/are the type(s) of knowledge to be transferred? 
• How should it be transferred (modes of knowledge transfer)? 
• What are the factors that will influence on the process of knowledge transfer 
and what is their level of impact? 
• What can we do to enhance the factors that positively influence on the process 
of knowledge transfer and what can we do to avoid/lessen the impact of the 
factors that negatively influence on the process of knowledge transfer? 
• What mechanisms should be used by the receiver to ultimately utilise the 
knowledge? 
• Did the knowledge transfer process successfully achieve its goals (performance 
measurement)? 
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Figure 2-17 – Knowledge transfer process model (reproduced) (Liyanage et al., 2009) 
Liyanage et al. (Liyanage et al., 2009) assert that knowledge leads to organisational 
value when it is used to effectively make decisions, solve problems, and produce 
effective performance. Thus, successful application of knowledge during a knowledge 
transfer process usually results in one or more of the following: 
 
• reduced errors (e.g., by not repeating mistakes) 
• improved quality (e.g., by using best of breed practices) 
• speeding up decision making (e.g., by getting better cross-functional 
coordination) 
• lower costs (by quickly identifying expertise) or provide value for money 
• speeding up training (e.g., by attending to common mistakes and learning from 
best practices) 
• learning and innovation 
 
Specific to tacit knowledge considerations, Foos et al. (Foos, Schum and Rothenberg, 
2006) explored the factors which influence the transfer of tacit knowledge between 
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partners based on a qualitative and quantitative analysis, including a study of three 
companies charged with integrating external technology.  They found that trust, early 
involvement, and due diligence influence the extent of meeting technology transfer 
expectations and tacit knowledge transfer expectations. They also assert that the 
subject of tacit knowledge transfer, content, and process is poorly understood and 
lacking formal process.  To explore this idea further they carried out a survey on 
knowledge transfer.  About two-thirds of their survey respondents indicated they were 
attempting to integrate tacit knowledge, while 92% reported no formal process for 
tacit knowledge transfer.  Foos et al. (Foos, Schum and Rothenberg, 2006) also 
suggested there is clear evidence that intentional management mechanisms for tacit 
knowledge management are needed, and that they will differ from those for more 
explicit types of knowledge.  Finally, while managers and project leaders saw the value 
of tacit knowledge, there were different perceptions of the goals of successful 
knowledge transfer and a lack of processes to manage its process.  They noted project 
managers may feel they have tacit knowledge transfer in hand, but they have not 
managed to transfer the knowledge needed for long-term product management.  
 
Malik (Malik, 2002) highlights ‘know-how’ must be learned and acquired. The difficulties 
associated with embedded ‘know-how’ transfer they identified include: 
 
• Knowledge on how to use a technology  
• What the technology is capable of 
• The tacit components of knowledge embedded in the technology 
• Difficulties in interpreting technological codified knowledge 
 
Kumar and Ganesh (Kumar and Ganesh, 2009) state knowledge transfer is not a 
complete replication of knowledge in a new location; rather, it involves the modification 
of some existing knowledge to a different context, ‘what is transferred is (usually) not 
the underlying knowledge but rather applications of this knowledge in the form of 
solutions to specific problems.’  This insight further highlights the need for 
interpretation and context to be shared (tacit knowledge).   
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The process of knowledge transfer is not, per se, a mere transfer of knowledge, (Seaton, 
2002)  as cited by Liyanage et al. (Liyanage et al., 2009), it requires an additional type of 
knowledge:  the knowledge about how to transfer knowledge.  As an example, instead 
of saying ‘this is what I know,’ the process of knowledge transfer goes one step further 
to say, ‘this is what my knowledge means for you.’ Thus, contextualisation is important 
for knowledge transfer to be effective.  
 
Rathore et al. (Rathore et al., 2017) conducted a study specific to the biopharmaceutical 
industry, looking at the role of knowledge management in development and lifecycle 
management with a specific focus on knowledge management tools to support Quality 
by Design (QbD) related tasks.  Their paper acknowledges the shift towards extraction 
of ‘know-how’ and tacit knowledge as opposed to classic explicit ‘data capture’ 
approaches which represent a new direction for the field [of knowledge management], 
however the authors did not address this further in their paper.  They also 
acknowledged that knowledge from transfer activities is not sufficiently covered by 
knowledge management current tools, for which they provide a functional 
classification.  
 
2.3.3.3 Knowledge transfer and technology transfer 
Galbraith (Galbraith, 1990) studied 32 ‘core manufacturing technology transfers’, 
including pharmaceutical technology transfers, examining success of the transfers and 
other factors such as sources of cost and lost productivity.  Galbraith noted that studies 
of manufacturing technology transfer underline two important facts:  (i) any type of 
technology transfer involves not only the movement of equipment and people, but also 
the flow of critical information or ‘know-how’ between donor and recipient 
organisations; and (ii), there are significant direct costs attached to the transfer and 
management of this knowledge.  The direct costs associated with transfers are twofold: 
resource costs to perform the transfer; and productivity and ‘know-how’ loss.  On 
studying the 32 transfers, Galbraith reported the initial percentage productivity loss 
experienced by the recipient facilities ranged between a low of 4% to a high of 150%, 
averaging a 34% initial productivity loss. The time it took to recover lost productivity 
ranged between 1 month to 13 months, however 10 of the transfers never reached pre-
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transfer productivity levels or were considered failures for other reasons (31% failure 
rate).  Galbraith (Galbraith, 1990) associated a set of risks for technology transfer 
success, including misplaced documents, distance between facilities, the recipient’s 
previous experience with incoming transfers, and transferring complex process in early 
stages of development. 
 
Malik (Malik, 2002) asserted that a number of knowledge transfer models for 
technology transfer have not recognised fully that intra-firm transfers are two-way 
iterative processes and not simply one-way linear processes.  Malik then proposed an 
interactive model highlighting factors influencing the technology transfer process (e.g., 
culture of trust), the mode of transfer and a feedback loop.  Liyanage et al. (Liyanage et 
al., 2009) have reinforced the need for a feedback loop and incorporated it into their 
proposed model (Figure 2-17).   
 
Gorman (Gorman, 2002) in his paper Types of Knowledge and Their Roles in Technology 
Transfer presents a taxonomy of knowledge with respective roles in technology 
transfer, distinguishing between four types to refine the distinction between tacit and 
explicit knowledge.  The four types are: 
 
• Information (what) 
• Skills (how) 
• Judgment (when) 
• Wisdom (why) 
 
Table 2-2 created by the researcher as a summary of the article text provides an 
overview of each, along with the related types of each explicit and tacit knowledge. 
 
Table 2-2 – Types of knowledge and their role in technology transfer (Gorman, 2002) 
Type of 
Knowledge 
Description Explicit Tacit 
Information 
(what) 
Declarative, knowing that Information, 
facts 
Contextualisation 
of facts, knowing 
when and where 
valid 
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Type of 
Knowledge 
Description Explicit Tacit 
Skills (how) Procedural, knowing how Algorithms Heuristics,  
rules of thumb 
Judgment 
(when) 
• Recognising a problem is similar to one 
whose solution path is known, knowing 
when to apply a particular procedure 
• Accumulated facts structured in ways 
that facilitate problem solving 
• Ability to recognise cues 
• ‘Feel’ for what will or won’t work 
• Result of accumulated implicit learning 





• The ability to reflect on status quo, 
question prevailing mental models and 
evolve 
• Requires moral imagination (i.e., to 
step outside one’s self-view, 
assumptions and bias and be able to 
creatively envision new possibilities)  
Codes  





Barros et al. (Barros et al., 2020) conducted a comprehensive literature review of the 
interaction between knowledge management and technology transfer published in 
2020 in an attempt to better define the context of the relationship between the 
concepts.  They found that most studies where knowledge management and technology 
transfer co-occur focused on the private sector and on technology transfer for attaining 
innovation, customer orientation and acquiring technological abilities.  The university-
industry relationship was also observed, in which universities create and transfer 
knowledge to support industry goals.  There were many references to the need and 
importance of knowledge transfer although no information on knowledge transfer 
frameworks and no specifics to the pharmaceutical industry were given. 
 
2.3.4 Summary – technology transfer and knowledge transfer 
Given the subject literature, the researcher drew several conclusions from the review.   
 
• There exists regulatory and industry guidance for how to do technology transfer 
that include expectations for knowledge management, yet these guidances are 
very general in nature, provide no direction on ‘how,’ and largely neglect tacit 
knowledge. 
• Technology transfer itself is a relatively ‘young’ practice, lacking in clear 
definition – including for the pharmaceutical industry – and is highly contextual.   
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• Knowledge transfer models identified are quite academic and theoretical; 
importantly they raise underlying drivers such as motivations, capacity and 
other factors but neglect to define a pragmatic and deployable framework, nor 
provide any information on the ‘how.’   
• Tacit knowledge (‘know-how’) is recognised as critical for overall successful 
knowledge and technology transfer, yet there appears to be a general lack of 
processes for formal tacit knowledge transfer.  People know it’s important but 
don’t know how to do it.   
 
Notably, although there were selected pharmaceutical industry references in 
aggregated studies involving technology transfer and knowledge transfer cited above 
(Galbraith, 1990; Barros et al., 2020), there was no evidence of a focus on knowledge 
transfer frameworks (or models or processes) for pharmaceutical technology transfer, 
aside from documentation turnover lists (WHO, 2011; PDA, 2014b; ISPE, 2018).  
 
Given the highly knowledge-dependent definitions of pharmaceutical technology 
transfer, the dependence on and transfer of both explicit knowledge (e.g., documents) 
and tacit knowledge (e.g., expertise) is central to the intent and paramount to the 
success of a pharmaceutical technology transfer.  Bruce Davis, an industry subject 
matter expert on technology transfer (e.g., as demonstrated by leading the 
development of the current ISPE Good Practice Guide on Technology Transfer (ISPE, 
2018)) presented a paper entitled an Introduction to Technology Transfers, Basics & 
Principles at the ISPE 2019 Annual Meeting (Davis, 2019) which the researcher attended 
in person.  Davis’ presentation focused heavily on knowledge management and its 
importance to technology transfer, citing ICH Q10 (ICH, 2008).  Davis shared his 
professional insights during his presentation, including: 
 
Understanding the knowledge and really solid project management coming 
together is what makes for a successful technology transfer … If you don’t have 
product & process understanding you cannot do a successful technology transfer.  
 
Lastly, as stated by Malik (Malik, 2002), ‘technology transfer represents one of the most 
knowledge intensive and problematic relationships in a firm.’  Yet there is no evidence 
the pharmaceutical industry has solved the knowledge transfer conundrum through a 
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framework, guidance or other visible progress, even though the success of the industry 
is highly dependent on it.    
 
2.4 Domains of knowledge:  knowns and unknowns 
Where knowledge is involved, a majority of the literature discussed to this point is about 
what is known, or what one might describe as known-knowns.  The researcher has an 
interest in broadening this lens to understand the opportunity to explore what is 
unknown as part of a more holistic approach to transferring knowledge and managing 
risk.  
 
Drew in 1999 (Drew and Whitehill, 1999), in support of how knowledge management 
supports strategy development, published a knowledge portfolio matrix along two 
simple axes:  knowledge content and knowledge awareness.  The knowledge content 
axis represents ‘do we know (or not)?’, while the knowledge awareness axis represents 
‘are aware that we know it (or not)?’ (Figure 2-18).   
 
 
Figure 2-18 – Knowledge portfolio (Drew and Whitehill, 1999) 
The researcher finds this a helpful thought model to use to think more comprehensively 
about knowledge management, inclusive of knowledge transfer, and risk management 
across the entire product lifecycle as it consciously prompts a reflection on recognised 
gaps in our knowledge (i.e., “we don’t know what will happen if …”).   
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Others have followed similar thinking such as Browning (Browning and Ramasesh, 2015) 
who proposed that many unknowns are knowable and through a set of processes called 
directed recognition, risk could be reduced.  Many of these processes, in the opinion of 
the researcher, are in knowledge management or closely related processes and related 
behavioural approaches.  Marshall et al. (Marshall et al., 2019) also explored ‘four states 
of risk forecasting knowledge,’ following the same four quadrant categories as Drew, 
with a powerful model to decrease risk through increasing one’s risk radar. 
 
The researcher synthesised these insights to create a representation (Figure 2-19) into 
a four-quadrant grid of knowns and unknowns.  The labels in each of the boxes in Figure 
2-19 form a helpful thought model to simplify these concepts.  For example – what are 
the facts (known-knowns), what questions (known-unknowns) do we have, what do we 
know will work but don’t know why (intuition, or unknown-knowns) and where might 
we explore next (unknown-unknowns).   These can be helpful triggers to build into 
knowledge management practices to uncover important knowledge – in particular tacit 
knowledge – on which to make decisions and direct future efforts to acquire new 
knowledge and in turn reduce risk.  The researcher expects this thought model would 
also be of significant benefit to the process of quality risk management.   
 
 
Figure 2-19 – Knowns and Unknowns  
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2.5 Literature review summary 
This literature review has covered diverse territory – regulatory guidance, industry 
guidance, academic research, risk and knowledge management concepts, technology 
transfer literature, knowledge transfer literature, and the arguably abstract world of 
‘unknown-unknowns.’  Key points relative to each section have been summarised at the 
close of each section.  In aggregate this literature review helps confirm the problem 
pursued by this research study, along with its complexity, and also provides substrate 
to refer back to during framework development to help test the outputs from this study.   
 
The next chapter will present the research design, methodology, and methods applied 
for this study, and share various perspectives of the researcher.  
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Chapter 3:  Research Design, Methodology, and Methods  
 
The purpose of this chapter is to outline the research design, methodology, and 
methods.  This includes the researcher’s worldview and insider perspective, the 
research questions and associated methodology and methods applied, the research 
timeline and ethics and privacy considerations. 
 
3.1 The researcher’s worldview 
It is necessary for any researcher to be conscious of how they view the world, notice 
and process stimuli, formulate positions, communicate such positions, and employ a 
variety of other processes.  Otherwise, the researcher would risk being blind to their 
assumptions and biases.  There are entire fields of study for such philosophical 
concepts, including definitions of ontologies and epistemologies.  Ontology involves the 
study of ‘being’ and is concerned with ‘what is,’ including the nature of existence and 
structure of reality (Crotty, 1998).  Epistemology involves a way of looking at the 
relationship between the knower and the known (Guba and Lincoln, 1994) and how we 
know what we know (Crotty, 1998).   
 
This researcher’s ontological belief is that reality is what works and is what is most useful 
and practical.  The researcher’s epistemological belief is that reality is known through 
using many tools of research that reflect both objective and subjective evidence 
(Creswell and Poth, 2017). 
 
A worldview is defined by Guba as ‘a basic set of beliefs that guide action’ (Guba, 1990).  
Creswell uses the term worldview to describe four general philosophical orientations 
about the world and the nature of research that a researcher brings to a study (Creswell 
and Creswell, 2020).  These are widely discussed in the literature and shown below in 
Table 3-1. 
 
Table 3-1 – Four worldviews (Creswell and Creswell, 2020)  
Postpositivism  Constructivism 
• Determination • Understanding 
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Postpositivism  Constructivism 
• Reductionism 
• Empirical observation and measurement 
• Theory verification 
• Multiple participant meanings 
• Social and historical construction 
• Theory generation 
Transformative Pragmatism 
• Political 
• Power and justice oriented 
• Collaborative 
• Change-oriented 
• Consequences of actions 
• Problem-centred 
• Pluralistic 
• Real-world practice oriented 
 
The researcher most closely associates with the worldview of pragmatism, with a 
problem-centred, real-world practice-oriented study.  This worldview is reinforced 
throughout this thesis, including the desire to deliver meaningful and useful outcomes 
as a result of this research study.  The researcher has a bias toward ‘fit-for-purpose’ and 
practical approaches to understand and solve problems, based on the researcher’s 
experience with lean six sigma18 and a variety of other management sciences19 as a 
means to improve operational performance.   
 
Furthermore, the research topic is positioned well in the worldview of pragmatism, 
given the relative immaturity in awareness and practice of KM in the pharmaceutical 
industry as explored in Chapter 2.  A purely theoretical view of KM can likely be 
conceptually modelled, perhaps even using fluid dynamics principles as carried out by 
Smith (Smith, 2005).  However, it is the researcher’s belief that if KM cannot be seen as 
tangible, actionable, of value, and able to deliver benefits to patients and businesses 
alike in the real world, the practice risks being seen as a ‘management fad and fashion.’ 
In fact, some have already attacked KM as being too utopian of an idea (Wilson, 2002).  
Thus, the research study aimed to solve the problem of the lack of KM adoption in the 
real work of pharmaceutical manufacturing, taking a pragmatic approach focusing not 
on the research methods, but on the research problem and developing solutions to 
address it. 
 
18 A methodology for improving customer satisfaction and improving business processes through a 
structured set of techniques and tools to reduce variability and improve performance of processes that 
are value added and aligned with customer desires. (Six Sigma Daily, 2020) 
19 The use of scientific methods and ideas to understand business and management problems and 
decisions, or the formal study of management; Management science is concerned with designing and 
developing new and better models of organisational excellence. (Cambridge, 2020) 
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Pragmatism is concerned with applications, what works and solutions (Patton, 1990); 
this is the primary objective of the researcher to move the industry forward by 
understanding the current state (i.e., as is) and delivering solutions to educate and 
demonstrate what is possible (i.e., what could be).   
 
Mixed-methods research is particularly well-suited for a pragmatic worldview, as the 
researcher can adapt the methods to the most appropriate means to characterise the 
problem and the solution (Creswell and Creswell, 2020).  Further detail on these 
methods is presented in section 3.4 of this chapter. 
 
3.2 The researcher’s insider perspective 
As stated in Chapter 1 (section 1.3), the researcher is employed in pharmaceutical 
industry and has been for 20+ years.  Prior to his career move to knowledge 
management, the researcher started his career in pharmaceutical manufacturing, in a 
site-based science and technology role, on the receiving end of technology transfers 
supporting process demonstrations of small molecule APIs.  In this role, the researcher 
gained experience as a stakeholder of technology transfer.  The researcher has also 
spent nearly a decade in a global engineering role starting up new GMP manufacturing 
facilities, being responsible for the specification, design, build, and validation of highly 
complex shop floor automation systems.  As such, the researcher was part of several 
technology transfers, working to automate the manufacturing of the product and 
processes being transferred, typically new product introductions from research and 
development.  During this time, the researcher also gained deep experience with 
computer system validation, including the concepts of configuration management, 
which included robust processes for tracking documents and other critical information 
associated with the state of a GMP control system.  Unbeknownst to the researcher at 
the time, these practices were a form of knowledge management and perhaps a prelude 
to the researcher’s knowledge management career.   
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Given the researcher’s employment in the industry, experience with technology 
transfer, and decade of experience in knowledge management, the researcher 
acknowledges having an insider perspective and undertaking insider research. The term 
‘insider research’ is used to describe research projects where the researcher has a direct 
involvement or connection with the research setting (Robson, 1993), cited by (Rooney, 
2005).  The idea behind the ‘insider perspective’ is that it can be seen as having both 
‘pros and cons’ (i.e., advantages and disadvantages) as categorised by Greene (Greene, 
2014).  A synopsis by the researcher of each category based on Greene’s description is 
as follows:   
 
• Pros (advantages):   
o Knowledge:  Insider researchers often do not have to worry about 
orienting themselves with the research environment and/or 
participants; they can ask more meaningful questions and better 
understand the history and practicality of the research topic.  
o Interaction:  Insider researchers are more familiar with the group under 
study, know how to approach individuals, and are more likely to engage 
in discussing issues. 
o Access:  Insider researchers will know how to gain access and may have 
existing contacts within the group under study.   
 
• Cons (disadvantages): 
o Too subjective:  Insider researchers risk having narrow perceptions due 
to familiarity and normalisation with the group under study, thus 
impacting the ability of the researcher to be objective.  In addition, there 
is increased risk of assumptions based on prior knowledge and/or 
experience. 
o Biased:  Insider researchers risk bias as the researcher may be considered 
too close to the group under study.  This bias may influence study 
methodology, design, and/or results.  Insider researchers must not fear 
bias, but must be aware of the potential for bias and take steps to 
mitigate it. 
 
With this awareness, the researcher sought to fully capitalise on the advantages and 
work to mitigate the risks inherent in the disadvantages.  There are several advantages 
for this research study based on the researcher’s knowledge, past interaction, and 
access, including: 
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• Knowledge of past KM research 
• A network of practitioners in the sector, inclusive of industry, academia, 
regulators, and several industry organisations (e.g., ISPE, PDA, et al.) 
• Experience with application of KM both within and beyond the pharmaceutical 
industry 
• Familiarity on related topics, including risk management, technology transfer 
and data analytics 
 
Specific to the risks associated with the disadvantages (i.e., subjectivity and bias), the 
researcher worked to mitigate these risks through: 
 
• Using a mixed methods approach (see section 3.4), where multiple sources of 
both qualitative and quantitative data were considered where possible 
• Balance in these research methods, which included leveraging insights from 
multiple cohorts of stakeholders (i.e., academia, regulatory and industry) during 
diverse interactions such as philosophical dialogues, interviews, focus groups 
and surveys  
• Awareness of the risk of ‘group think’ and as such, partnered on research 
activities with people outside of the researcher’s normal ‘circle’ 
• Publishing and presenting through a variety of channels and venues, including 
articles subject to peer review by different editorial boards, to promote further 
objectivity and limit bias 
 
While a member of industry for many years now, the researcher also recognised the 
value of stepping outside of the industry view and adopting an academic persona as a 
part of this research study.  This allowed the researcher to bring objectivity, enhancing 
the connection and access to both academia and regulators through philosophical 
dialogue, interviews, and other research interactions.  By this means, this research study 
helped bridge the triad of industry, regulatory, and academia perspectives in delivering 
its results by balancing the theory, practice, and application of regulation.   
 
Finally, although the researcher was employed by a major pharmaceutical company at 
the time of this research study, this study was undertaken as a matter of personal 
interest and passion for the research topic, independent of the researcher’s employer. 
Therefore, the researcher’s perspectives, methods, and results were not influenced by 
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their employer nor did they hold any commitment back to the employer as a sponsor of 
this research.  
 
3.3 The research questions 
The original research proposal, titled An exploration of end-to-end product knowledge 
in the pharmaceutical industry, was submitted to the Technological University Dublin 
(then Dublin Institute of Technology)20 College of Sciences and Health, School of 
Chemical and Pharmaceutical Sciences in September 2018 and accepted in October 
2018.  The research proposal presented at the time was based on the following two 
hypotheses21:   
 
1. KM adoption in the pharmaceutical industry (henceforth ‘industry’) has been slow 
as described by Kane in 2018 (Kane, 2018).  The first hypothesis of this study is that 
the industry does not have a holistic, end to end view of what it knows about its 
products across the product lifecycle, nor how to best ensure this knowledge 
‘flows’ to ensure the best possible product outcomes.  These outcomes include 
product realisation through a readily available, cost effective and high-quality 
product to patients, as well as additional business outcomes of operational 
efficiency and a workforce that has the knowledge it needs to do its best work. 
 
2. A second hypothesis is, as identified by Kane (Kane, 2018), tacit (e.g., experiential) 
knowledge is an afterthought during product development and not recognised as 
a critical knowledge asset.  The industry lacks recognition of the importance of 
tacit knowledge nor has it a means to best capture and access this knowledge 
across the product lifecycle in particular key activities such as technology transfer.   
  
Concepts and associated queries were derived from these hypotheses based on 
preliminary observations from the research during literature review, initial engagement 
of the public during early presentations about the research study, and from 
philosophical dialogues with TU Dublin PRST members.  Concepts 1 and 2 were nascent 
at the start of the research, based on the recent research outputs of Kane (Kane, 2018), 
as follows: 
 
20 The researcher was a student at Dublin Institute of Technology, which merged with two other Irish 
institutions to become Technological University Dublin in January 2019. 
21 These hypotheses statements were adapted during the course of the study for improved clarity as 
presented in Chapter 1, section 1.4. 
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Concept 1:  Knowledge and management thereof are critical to the realisation 
of an effective PQS, and knowledge management has been positioned as an 
enabler to the PQS, yet there is a lack of guidance for what knowledge should 
be managed or how organisations might go about this. 
 
Associated Queries: 
• Are knowledge and knowledge management important to the PQS?  Why? 
• Is there guidance on knowledge management for the industry, including for 
knowledge-intensive processes such as technology transfer? 
• Is knowledge transfer effective during technology transfer? 
 
Concept 2:  The importance of tacit knowledge is under-recognised, and the 
industry lacks the means to effectively recognise, manage and transfer tacit 
knowledge, putting it at risk of being under-utilised or lost.  Incomplete tacit 
knowledge transfer can have long term impacts on product manufacturability.   
 
Associated Queries: 
• Is tacit knowledge important to the PQS? 
• How does one ‘recognise, manage and transfer’ tacit knowledge? 
• What are the benefits to improving tacit knowledge transfer? 
 
During the course of this research study with the realisation of the lack of connectivity 
between QRM and KM as described in Chapter 1, a third hypothesis emerged and 
influenced the direction and focus of the research study.  This hypothesis is as follows: 
 
3. Quality risk management and knowledge management are not adequately 
integrated to ensure the best possible risk-based decisions.  Strengthening this 
relationship between QRM and KM has the opportunity to improve patient-
focused outcomes across the product lifecycle through reduced risk to product 
quality and availability.   
 
Concepts and associated queries derived from the third hypothesis are as follows: 
 
Concept 3:  Knowledge and risk are inherently inter-related, yet this relationship 
is not well recognised.  As such, the industry has not maximised the opportunity 
to apply thoughtful knowledge management to ensure the best possible risk-
based decisions from quality risk management, nor for quality risk management, 
to inform knowledge management. 
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Associated Queries: 
• What is the relationship between knowledge and risk? 
• What is the relationship between knowledge management and risk 
management? 
• What is the benefit to patients of better understanding and exploiting the 
relationship between knowledge management and quality risk 
management? 
 
Two distinct research questions evolved from the three hypotheses during the course 
of the research, given as follows: 
 
1. Research question 1 (RQ1):  How can the interdependency between knowledge 
management and quality risk management be clearly described in a manner that 
links the two PQS co-enablers to deliver the best possible risk-based decisions? 
2. Research question 2 (RQ2):  How can technology transfer benefit from a robust 
and standardised approach to knowledge management to ensure the effective 
transfer of both explicit and tacit knowledge, leading to improved realisation of 
the goals of the PQS? 
 
3.4 Research study design, methodology, and methods 
The researcher, based on his ontological and epistemological stances and resulting 
worldview, selected a mixed methods approach for this study.  Specifically, a mixed 
methods experimental (intervention) design was selected for both research questions, 
given the desire to develop pragmatic solutions that could be immediately evaluated 
through an actual or simulated intervention (e.g., application of a framework). The 
concept of a mixed methods experimental (intervention) design as illustrated by 
Creswell is depicted in Figure 3-1 (Creswell and Creswell, 2020).   
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Figure 3-1 – Mixed methods experimental (intervention) design as illustrated by Creswell 
(Creswell and Creswell, 2020) 
From Figure 3-1, it can be seen that experimental intervention can include exploratory, 
sequential, convergent, and explanatory sequential designs.   
 
The design for this research followed a similar concept to Figure 3-1 and utilised both 
qualitative and quantitative methods with exploratory sequential, convergent, and 
explanatory sequential core designs in series [(QUAL à Quan) + QUAL + (QUAN à 
Qual)]22.  This design was selected to establish a baseline understanding prior to the 
intervention (i.e., exploratory), assess the effectiveness of the intervention (to inform 
refinement of the intervention), and follow the intervention with an explanatory phase.   
 
Figure 3-2, developed by the researcher, illustrates the methodology with supporting 
rationale and research methods (RM-1a through RM-1e) for research question 1 (RQ1).   
 
 
22 Notations used to designate mixed methods research design; capitalisation indicates emphasis over 
lowercase, “+” indicates convergent design,”à” indicates sequential design, “[…]” indicates a series 
(Creswell and Creswell, 2020) 
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Figure 3-2 – Research Methodology and Methods for Research Question 1 
 
For research question 2 (RQ2), the same overall methodology was used (i.e., mixed 
methods experimental (intervention) design), with minor variations to the research 
methods applied (RM-2a through RM-2e) as appropriate for RQ2.  This is illustrated in 
Figure 3-3.   
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Mixed methods experimental (intervention) design for RQ1 
















• To document the need for an 
intervention
• To compile baseline information
Rationale:
• To understand how the 
participants are experiencing the 
intervention
Rationale: 
• To receive participant feedback 
to revise / change the 
intervention
• To help explain how the 


















Exploratory Sequential Explanatory Sequential
Convergent
  74 
 
Figure 3-3 – Research Methodology and Methods for Research Question 2 
 
Once the initial research methodology was identified, the researcher applied for ethics 
approval from the TU Dublin Research Ethics & Integrity Committee, as is discussed in 
the next section. 
 
3.5 Ethics and privacy 
The initial research plan was submitted to Technological University Dublin (at the time 
Dublin Institute of Technology) on 21-Nov-2018 and received approval from the 
Research Ethics & Integrity Committee on 28-Jan-2019.  All research activities were 
conducted in accordance with TU Dublin’s Ethical Guidelines (TU Dublin, no date).  
Specifically, the researcher: 
 
• Sought formal consent from interview participants prior to any research activity 
being undertaken.  Formalised consent forms were provided to the 
interviewees, along with information packets in advance of interviews.  The 
interviews did not proceed without consent granted.   
• Handled and stored personal information in a strictly confidential manner, in a 
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• Used data gained during this research study solely for the purpose of this 
research study.  
• Did not (and will not) have any power over any of the involved research subjects, 
each of whom agreed voluntarily to participate. 
 
The researcher also undertook formal Research Integrity Training sponsored by TU 
Dublin and received competency-based certificates for the domains of Engineering and 
Technology and Social and Behavioural Sciences.  These modules train researchers on 
their professional responsibilities and on how to deal with complex issues that can arise 
while planning, conducting, and reporting research.   
 
Part Two of this thesis follows (including Chapters 4 through 7) and presents many of 
the research activities and corresponding outputs, including a process model for KM, a 
framework to integrate knowledge and risk, and a framework to enhance knowledge 
transfer during technology transfer.  
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Part Two:  Advancing KM and Developing QRM-KM Connectivity 
 
Part Two explores the relationship between knowledge and risk and the opportunity to 
better integrate knowledge management and quality risk management.  In response to 
findings of this exploration, potential solutions are provided through a newly proposed 
model and multiple frameworks. 
• Definition of a Process Model for Knowledge Management (Chapter 4) 
• Re-imagining the QRM-KM interdependency with a novel framework to connect 
QRM and KM (Chapter 5) 
• A definition of requirements to improve knowledge transfer during technology 
transfer (Chapter 6) and associated framework and toolkit to enhance 
knowledge transfer effectiveness (Chapter 7) 
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Chapter 4:  A Process Model for Knowledge Management 
 
Anticipating the opportunity for KM to be better integrated with QRM, the purpose of 
this chapter is to propose a Knowledge Management Process Model as a means to 
advance the understanding of the ‘how’ behind high level KM concepts. 
 
Not only is the integration between QRM and KM severely lacking in practice today 
(Lipa, O’Donnell and Greene, 2021) but also the level of adoption and maturity of KM in 
the pharmaceutical industry is far behind that of QRM as presented in Chapter 1.  While 
many factors highlighted in Chapter 1 are well out of the control of the researcher (e.g., 
the existing body of literature for QRM vs. KM), there was one concept identified where 
the researcher could work to influence immediately:  The understanding of what 
knowledge management is.  The following section describing a process model for 
knowledge management is a summary of a peer-reviewed paper by the researcher 
published in the Journal of Validation Technology (Lipa, O’Donnell and Greene, 2020a). 
 
4.1 Introducing a Knowledge Management Process Model 
The practice of KM presents a diverse and adaptive set of practices to enhance 
knowledge flow and application. A well-designed, holistic, and systematic KM program 
will strengthen QRM through the availability of critical knowledge, including product 
knowledge, process knowledge, platform knowledge, and other relevant knowledge.  
Such a KM program can support the curation, sharing, and dissemination of knowledge 
which can subsequently be transferred and applied to inform decisions and achieve 
other objectives.   
 
Typically, this knowledge resides in documents housed in repositories or can be found 
within communities, lessons learned, best practices, experiences, and expertise.  This 
can also include knowledge from other products, other sites, or other modalities, as well 
as knowledge from past changes, from prior risk assessments, and a wide variety of 
other sources.   
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The researcher had long recognised that it was challenging to concisely explain the 
‘how’ behind KM, often using the analogy that ‘knowledge management is about getting 
knowledge to flow.’  But what is the ‘double-click’ on this flow concept?  Upon reflection 
of this question – on how best to explain KM and how to do so in a manner familiar to 
the pharmaceutical sector – the researcher decided to attempt to do so by using the 
quality risk management process diagram as the basis.   
 
The ICH Q9 QRM process model (ICH, 2005) is depicted in Figure 4-1 and provides an 
informative visualisation of the process of risk management.  Included in the process 
model is a depiction of the key steps and sub-steps within a risk management process, 
the sequence of steps including relationships between steps and feedback loops, and 
supportive or enabling elements to the core process (e.g., Risk Management tools). 
 
 
Figure 4-1 – ICH Q9 QRM process model (ICH, 2005) 
Starting with the ICH Q9 QRM process model as a framework and then applying 
common definitions of KM included in Chapter 2 (section 2.1), drawing upon multiple 
philosophical dialogs with thought leaders in QRM and KM, and over 10 years of 
professional experience, the researcher through multiple iterations created a 
Knowledge Management Process Model as depicted in Figure 4-2.  
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Figure 4-2 – Knowledge Management Process Model 
This new Knowledge Management Process Model features traceability to the definition 
of KM in ICH Q10 (i.e., ‘systematic approach to acquiring, analysing, storing, and 
disseminating information…’) (ICH, 2008).  Each of these activities defined in ICH Q10 
are represented in the model.  In the opinion of the researcher, this process model 
further significantly enhances the ICH Q10 definition through additional context, details, 
and mapping of interactions within the model.  Similar to the QRM process model, this 
model includes a depiction of the key steps and sub-steps within a KM process, the 
sequence of steps including relationships between steps and feedback loops, and 
supportive or enabling elements to the core process (e.g., Knowledge Management 
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The following are highlights of the model: 
 
1. Knowledge is acquired (created) through a variety of important processes and 
activities.  This knowledge must flow into the knowledge management construct 
to be ‘managed’ (i.e., to be systematically curated, shared, and disseminated for 
future use). 
2. The overall process of knowledge management is divided into two main 
activities.  A phase for knowledge curation, where knowledge is intentionally 
captured and subsequently identified, reviewed, and analysed as appropriate.  
Curation23 is defined as ‘the action or process of selecting, organising, and 
looking after the items in a collection’.  This activity involves proactively 
stewarding and caring for the knowledge assets of the organisation to ensure 
they are available and suitable for use when needed.  The second phase is 
knowledge dissemination, where the importance of not only knowledge storage 
but also visibility and availability (inclusive of accessibility) are highlighted.  Of 
note, knowledge dissemination may be on a ‘pull’ and/or a ‘push’ basis, meaning 
it can be ‘pulled’ on demand by a process (e.g., obtain specifications for 
technology transfer) or it can be ‘pushed’ to those that need to know (e.g., 
sharing a lesson via a community or by building into a business process). 
3. The ‘how’ for these two major activities is accomplished through KM practices24.  
Practices should be employed for both explicit knowledge (e.g., content 
management, taxonomies, search) and tacit knowledge (e.g., communities of 
practice, expertise location, lessons learned).  These KM practices are best 
supported by a series of enablers (e.g., standardised processes, sponsorship, and 
training) (Kane and Lipa, 2018). 
4. Knowledge communication, exchange, and sharing represents the sharing of 
knowledge and learning based on the mindsets and behaviours of an effective 
knowledge culture (Kane and Lipa, 2018), where people can ask questions, learn 
 
23 https://www.lexico.com/en/definition/curation  
24 KM practices, also referred to as KM approaches, capabilities, methods and tools, are the standard 
and repeatable means by which knowledge is managed.  These are akin to the QRM practices, such as 
the “Risk Management Methods and Tools” found in Annex 1 of ICH Q9 (ICH, 2005) 
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from each other, and make connections to learn and grow their individual 
knowledge and collectively that of the organisation.    
5. Knowledge is applied to a variety of important processes and activities.  
Knowledge is an indispensable asset which powers a variety of critical processes 
and enables the best possible DECISION (or other desired process outcome) for 
QRM and many other processes. 
6. A feedback loop is included for the growth and evolution of knowledge which 
provides an input to future processes and also grows the knowledge base of the 
organisation. 
 
To illustrate the similarity to the ICH Q9 QRM process model (ICH, 2005), Figure 4-3 
provides a side-by-side comparison of the two process models. 
 
 
Figure 4-3 – KM Process Model as an analogue to QRM process model 
 
This new process model was reviewed as part of the industry SME author team 
developing the ISPE Good Practice Guide for Knowledge Management (ISPE, 2021b), of 
which the researcher is a member.  The industry SME author team ratified use of this 
Knowledge Management Process Model as a central element to the ISPE Guide, 
featured as its own chapter in the guide.  The researcher made a further original 
Familiar representation of QRM 
as per ICH Q9 (Figure 1)
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contribution to the ISPE Good Practice Guide for Knowledge Management by providing 
a detailed discussion on each activity in the model.  This is presented as Chapter 4 in the 
ISPE Guide (of which the researcher was the lead author).   
 
One can envision the benefit to improved understanding and decreased uncertainty by 
‘unlocking’ the knowledge of the organisation in the manner described in the 
Knowledge Management Process Model, as well as to many other benefits of knowledge 
access and availability for resolving investigations, post-approval changes, and more. It 
is the discipline of KM that makes this a reality.  Having aligned KM and QRM as dual 
enablers, the researcher was curious to further explore their interrelationship.  Chapter 
5 of this thesis describes this work. 
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Chapter 5:  Re-Imagining the QRM–KM Interdependency 
 
The purpose of this chapter is to investigate the current state of integration between 
QRM and KM as dual PQS enablers and to introduce a framework to convey a vision for 
improved integration and the benefits which could arise as a result of this integration.  
This chapter first builds on a detailed literature review conducted by the researcher 
(Lipa, O’Donnell and Greene, 2020c) and published in a peer-reviewed journal, the 
Journal of Validation Technology.  Subsequently, the development of the framework to 
connect risk and knowledge is described in detail in a peer-reviewed paper by the 
researcher (Lipa, O’Donnell and Greene, 2020a). The following sections of this thesis 
represent key insights from these papers. 
 
5.1 A look at the connectivity between QRM and KM 
Arguably, the most familiar representation of the QRM and KM relationship originates 
from the ICH Q10 PQS model (ICH, 2008) where the two enablers are positioned 
adjacent to each other, but notably not connected (Figure 5-1).  
 
 
Figure 5-1 – KM and QRM as adjacent yet disconnected enablers of the PQS 
Key insights gained during the course of this research from literature review and other 
inputs on risk, risk management, knowledge, and knowledge management, include: 
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• Risk varies inversely with knowledge, or more accurately risk varies inversely 
with knowledge application, suggesting that knowledge has to be available and 
actively used in the reduction of risk; given the overarching goal of risk 
management is to minimise risk, this relationship suggests one should maximise 
knowledge and its application to inform risk 
• Knowledge is both an input and an output to the risk management process which 
in turn informs risk; essentially, knowledge weaves in and out of the various 
activities within the risk management process  
• Knowledge management is about knowledge flow and ultimately knowledge 
application 
• Quality risk management can enable the best outcomes and further reduce risk 
to patients by leveraging the best available knowledge about products, 
processes, and platforms, including prior knowledge  
• Quality risk management is a discrete event in applying knowledge to inform 
decisions (i.e., the basis of risk-based decision making) 
• The goal of KM is to deliver the best available knowledge to the right person, at 
the right time in order to make the right decision and/or give the right advice 
 
It would then seem logical that QRM and KM should be thoughtfully connected in some 
manner to ensure the best knowledge is available and applied to ensure the best 
possible risk-based decisions are made in support of an effective PQS. In a manner of 
speaking, knowledge is the currency of managing risk. 
 
There is broad agreement on the concept that QRM and KM should be linked in some 
way as confirmed through a survey by the researcher issued to industry and regulators.  
The full details of this survey are published in Level3 (Lipa, O’Donnell and Greene, 2021),  
and will be discussed in detail when considering the holistic impact of this research 
study in Chapter 10.  But for now, focusing on the question which solicited their opinion 
of how interdependent QRM and KM are as theoretical concepts, 97% of respondents 
indicated QRM and KM are highly interdependent (Figure 5-2). 
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Figure 5-2 – How Interdependent are QRM and KM as theoretical concepts? (Lipa, O’Donnell 
and Greene, 2021) 
 
However, when asked about how integrated QRM and KM are in practice today, the 
answer was very different.  Eighty-four percent (84%) indicated QRM and KM are only 
partially integrated in practice and 13% indicated QRM and KM are not integrated at all.  
Only one respondent (3%) indicated QRM and KM were intentionally integrated (Figure 
5-3).   
 
 
Figure 5-3 – Across the industry and in general terms, how integrated do you think QRM and 
KM are in practice today? (Lipa, O’Donnell and Greene, 2021) 
The reasons for this may not be surprising given the lagging nature of KM adoption in 
the industry (Chapter 1), suggesting that KM is not adequately understood and/or 
sufficiently defined and mature.   
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Furthermore, in the opinion of the researcher, there is a fundamental gap in 
understanding of the opportunity (and expectation) to exploit the synergy between 
these two critical disciplines.  The discipline of QRM – with good intent – has been 
focused on how to “do QRM,” and the discipline of KM has similarly been focused on 
how to “do KM.”  Yet there is little evidence QRM has fully engaged with KM (e.g., 
through the definition of QRM requirements of KM), nor has KM fully embedded itself 
in QRM as a practice.   However, should not the pursuit of the best possible risk-based 
decisions (and the associated risk reduction to patients) be a sufficiently important 
reason to address this gap?   
 
5.2 Development of the Risk-Knowledge Infinity Cycle 
In response to this important opportunity, the researcher sought to address this gap 
through better defining the QRM-KM relationship.  The researcher believed there is an 
opportunity for broad impact across many stakeholder groups with an increased 
appreciation of such a synergistic relationship, including QMS practitioners, KM 
practitioners, the leadership, and other stakeholders in a firm’s PQS, regulators, and 
ultimately patients.   
 
Building off of the rudimentary cyclical concept depicted in Figure 1-3, in partnership 
with a thought leader on QRM25 and after several philosophical dialogues and iterations, 
the researcher worked to develop a new and novel framework to connect QRM and KM.  
The researcher desired to convey certain attributes – including connectivity, balance, 
flow, and duality.  The researcher also wanted to convey the continuous, ongoing 
learning that should happen across a product lifecycle, during which knowledge is 
routinely growing (even if it is a reaffirmation of what is already known).  Finally, the 
researcher sought to ensure the framework featured a ‘closed-loop’ process26 to 
reinforce that risk and knowledge are inextricably linked.  In response to these inputs, 
 
25 The researcher solicited input from Dr. Kevin O’Donnell who is a recognised thought leader on QRM 
and is the rapporteur of the current team to revise ICH Q9.   
26 “the complete path followed by a signal as it is fed back from the output of a system to the input and 
then back to the output” (dictionary.com) 
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the researcher proposed a new framework, the Risk-Knowledge Infinity Cycle (or RKI 
Cycle), as presented in Figure 5-4. 
 
 
Figure 5-4 – The Risk-Knowledge Infinity Cycle 
This framework is intended to enable the visualisation and understanding of the Risk-
Knowledge relationship in a new and practical way, supported with descriptive details 
and an example provided in the referenced peer-reviewed paper (Lipa, O’Donnell and 
Greene, 2020a).  In summary, key features of this framework include: 
 
(i) the interwoven relationship between knowledge and risk, where knowledge 
feeds in to inform risk and risk informs what is known, including the need to 
acquire new knowledge: knowledge and risk inform each other.  
(ii) the inverse relationship previously established, where increased knowledge 
leads to decreased risk.  Figure 5-5 below provides a visualisation of this 
concept over time for a product.  In the early stages of a product’s lifecycle, 
risk is high since knowledge is low.  Risk can be immediately reduced through 
the application of prior knowledge, and risk is further reduced through 
increasing and applying knowledge by other means, including development 
activities, manufacturing experience, and risk review.  A well-characterised 
product for which there is an abundance of knowledge will result in lower 
risk. 
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Figure 5-5 – Decreasing risk though increasing applied knowledge over time 
(iii) the concept of flow:  that knowledge should effortlessly flow to inform risk, 
and likewise, risk seamlessly informs knowledge. 
(iv) the cycle is continuous and perpetual, as suggested by the use of the infinity 
symbol and the word infinity appearing in the framework title.  Knowledge 
is always evolving and should be applied to inform risk (even if it reaffirms 
what is already known to grow confidence in risk controls), and one will 
always learn about new risks and the performance of risk controls, thus 
generating both new knowledge and the need for new knowledge.  
 
Turning attention to an example of RKI Cycle application focused on the PQS as defined 
by ICH Q10 (ICH, 2008) can help illustrate the relationship between quality risk 
management and knowledge management as illustrated in Figure 5-6. 
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Figure 5-6 – The Risk-Knowledge Infinity Cycle applied to ICH Q10 
As illustrated in Figure 5-6, QRM and KM are interdependent and in unison enabling the 
PQS.  The two ICH Q10 co-enablers are not distinct but are in fact interwoven: 
knowledge informing quality risk, quality risk creating knowledge, knowledge informing 
quality risk….  This is consistent with research by Lengyel (Lengyel, 2019) who asserts 
‘risk management and knowledge management have been shown to exhibit a reciprocal 
relationship.  Risk management identifies knowledge gaps and knowledge management 
is a means of identifying resources to fill those gaps.’  Observations in applying the RKI 
Cycle framework to ICH Q10 include the following:   
 
(i) The recognition of QRM (node 2) and KM (node 5) being separate, distinct 
disciplines in support of the PQS yet interdependent on each other for 
ultimately reducing risk to patients. 
(ii) This cycle can repeat for each phase of the QRM cycle, including when new 
knowledge is acquired, and with each pass through the cycle, knowledge is 
increased while risk is decreased. 
(iii) Consistent with the underlying framework, the interwoven relationship 
between knowledge and risk (and knowledge management and risk 
management), the inverse relationship of increasing knowledge leading to 
decreased risk, the concept of flow, and the continuous and perpetual cycle 
are each relevant to the goals of the PQS.  
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Further details on the RKI Cycle, a description of each of the six nodes in the cycle and 
an example of the cycle for a Sterile Filling Line risk assessment are available in the 
referenced paper (Lipa, O’Donnell and Greene, 2020a).    
 
Upon socialisation of this framework within the sector via the survey discussed earlier 
in this chapter (Lipa, O’Donnell and Greene, 2021), preliminary feedback has been 
overwhelmingly positive.  When asked whether this framework is helpful in visualising 
the relationship between risk and knowledge, 84% responded ‘yes’ as illustrated in 
Figure 5-7. 
 
Figure 5-7 – Do you find this framework helpful in visualising the relationship between risk and 
knowledge 
Additional feedback to this framework will be discussed, along with anticipated 
benefits, in Chapter 10.   
 
Linking back to the origin of this chapter where QRM and KM are represented as distinct 
enablers, the researcher proposed that the PQS could be better represented with QRM 
and KM as the basis for a united PQS foundation, and also directly linked to the PQS 
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Figure 5-8 – A re-framed and united PQS foundation 
 
Having first established a Knowledge Management Process Model as a means to 
improve understanding of KM (Figure 4-2) and now having further established the RKI 
Cycle framework to address the important disconnect between QRM and KM, the 
researcher was ready to shift focus to improve KM for the product lifecycle.  The 
researcher selected the lifecycle stage of technology transfer, given the challenges 
typically associated with technology transfer as reported by Kane (Kane, 2018), 
highlighted during the literature review, and witnessed by the researcher in his 
professional experience.  Furthermore, not only does technology transfer have a direct 
impact on the ability to achieve the goals of the PQS, but industry trends suggest that 
the frequency and complexity of technology transfers is expected to increase (McKinsey 
& Company, 2019a, 2019b; O’Halloran, Heavey and Ciccarelli, 2019), making technology 
transfer a key area to drive improvement.  The following chapter will explore this 
opportunity in further detail.  
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Chapter 6:  The Opportunity to Improve Knowledge Transfer 
During Technology Transfer 
 
The purpose of this chapter is to characterise the current state of KT during technology 
transfer and define requirements for a future framework to address as a means to 
improve KT.  
 
6.1 Current state of knowledge transfer during pharmaceutical technology 
transfer  
To understand the current state of KT during a pharmaceutical technology transfer, a 
series of research activities were undertaken, including a literature review (see Chapter 
2, section 2.3), a survey, and interviews with industry experts and regulatory authorities.  
This work has been published in a peer-reviewed paper in the Journal of Validation 
Technology (Lipa, Kane and Greene, 2019).  This section presents a summary of this 
peer-reviewed paper which notably received external recognition in the form of the 
2020 Author of the Year Award by the Journal of Validation Technology (IVT Network, 
2020). 
 
6.1.1 Survey on knowledge transfer during technology transfer 
The researcher, as a presenter at the seminar, An Audience with Regulatory, Academia, 
and Industry, on The Role of Effective QRM & KM in Product Realisation for Patients in 
the 21st Century on 04-April-2019 at Technological University Dublin conducted an 
audience survey.  The presentation and survey results are presented in detail as part of 
a published monograph (Lipa and Kane, 2019) and summarised below.  The survey was 
designed to assess the audience perspectives on each the importance and effectiveness 
of KT to enable an effective and efficient technology transfer.  The survey forms were 
filled out by hand in session and no identifying information was collected.  Fifty-six (56) 
responses were received.   
 
While several insights can be derived from the survey, the primary finding is depicted in 
Figure 6-1 evaluating the importance versus the effectiveness for each explicit KT and 
tacit KT.   
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Figure 6-1 – Importance vs. effectiveness for explicit and tacit knowledge transfer 
 
In summary, while explicit and tacit knowledge are each considered highly important to 
effective and efficient technology transfer (axis y1 (blue)), explicit KT effectiveness is 
only marginally effective with notable room for improvement (axis y2 (orange)).  
Furthermore, tacit KT is regarded as somewhat ineffective.   
 
6.1.2 Expert interviews:  international industry experts and regulatory authorities 
Four experts were interviewed in mid-2019 to explore their perspectives on the 
importance of KT as a part of technology transfer, on the effectiveness of each explicit 
and tacit KT, and expectations for tacit KT.  The experts were selected in a matrix fashion 
where two were based in the EU and two based in the USA, and two were industry SMEs 
and two represented regulatory authorities.  An analysis is included in the associated 
paper (Lipa, Kane and Greene, 2019). 
 
Upon analysis of the interview transcripts, the following key themes emerged:  
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1. Knowledge transfer could be improved and would have meaningful positive 
impact to technology transfer outcomes, including cost, quality and product 
availability.   
2. Some companies appeared to do well but this is the exception, not the norm. 
3. Transparency on the level of process understanding was critical to a productive 
regulatory dialog. 
4. Often knowledge gets ‘stuck’ (e.g., someone’s judgement it is not important, 
buried in long documents, captured in an unusable format). 
5. On average, knowledge transfer effectiveness of explicit knowledge was 
marginal and there is wide variation. 
6. On average, knowledge transfer effectiveness of tacit knowledge was ineffective 
to marginal and there is wide variation. 
7. Successful technology transfer requires human to human interactions, 
preferably face to face and time to walk through the details of a process to 
explore details, sensitivities, what is not known, etc. 
8. There was a clear desire that we must get better at technology transfer as an 
industry. 
 
6.1.3 Current state of technology transfer knowledge transfer  
A current state assessment was drawn from three independent research activities 
(literature review, survey, and expert interviews).  The findings across these three 
distinct activities correlated well and suggested these key observations: 
 
1. Overall, knowledge transfer is critical to a successful and sustainable 
technology transfer.  Ineffective knowledge transfer can have a long-lasting 
impact on the ability of the receiving site to provide cost-effective, high-quality 
products with the desired availability.   
2. Knowledge to be transferred associated with a technology transfer is biased 
toward explicit knowledge (e.g., documents).  This explicit knowledge is critical 
to the success of the transfer, yet the industry is only marginally effective at it – 
it is clearly not a strength.  There is some supporting guidance on explicit 
knowledge that should be transferred, but not prescriptive means on how to do 
this or how to measure effectiveness.   
3. Tacit knowledge associated with technology transfer is not widely recognised 
as an asset to be transferred, nor is there evidence to suggest the 
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pharmaceutical industry does it effectively.  There is limited understanding on 
what tacit knowledge is, why it was important, and how it can be transferred, 
including how to measure effectiveness of the transfer.  Furthermore, there is 
little acknowledgement of tacit knowledge in industry guidance for technology 
transfer, although there are a few recent developments where tacit knowledge 
and related concepts (e.g., ‘know-how’) were acknowledged to be important to 
transfer but without any guidance on how this might happen (Lipa, Kane and 
Greene, 2019).  
4. Regulators and industry are generally well aligned on these issues and their 
impact.  Both recognise the opportunity – and the need – to improve KM for the 
good of patients. 
 
These findings supported the problem statements being explored at the start of this 
research, namely, that knowledge does not ‘flow’ readily through technology transfer, 
and that tacit knowledge is critical but is not effectively managed or transferred.  The 
subsequent research activities to develop a KT framework and associated toolkit to 
improve KT proceeded with the aim to address this opportunity.   
 
6.2 Defining requirements for knowledge transfer during technology transfer  
The purpose of this section is to explore the KT challenges associated with technology 
transfer (i.e., the problem) to gain a clearer understanding of the needs, and from this 
deeper understanding to identify the requirements a framework for technology transfer 
KT (i.e., the solution) should address.  This section is presented as a summary of a peer-
reviewed paper published in the PDA Journal of Pharmaceutical Science and Technology 
(Lipa, Greene and Calnan, 2021). 
 
6.2.1 Common challenges to technology transfer knowledge transfer  
There are many potential challenges for effective KT during technology transfer.  Each 
one of these potential challenges presents a failure mode to effective KT and therefore, 
to sustained technology transfer success.  Based on the current state assessment, 
literature review, interviews with experts (both industry and regulatory authorities), the 
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experience of the researcher (both in KM and in technology transfer), and various 
philosophical dialogues, the researcher identified six KT challenges.  Figure 6-2 
developed by the researcher illustrates these challenges in the context of technology 




Figure 6-2 – Challenges associated with technology transfer knowledge transfer 
Challenge 1:  Narrow focus on the ‘golden batch’27 which was often regarded as the 
‘minimum required’ by the receiving site to successfully manufacture the product. The 
focus tended to be on transferring the knowledge required for ‘what goes right.’  
Knowledge associated with ‘what goes wrong’ is often not transferred.   
 
Challenge 2:  Knowledge transfer was heavily biased toward documents, while tacit 
knowledge (‘know-how’) was not methodically transferred.  KT was typically focused 
on document transfer (i.e., explicit knowledge). While some tacit KT activities do occur 
on an ad hoc basis (e.g., staff at the receiving unit witnessed a batch being 
manufactured at the sending unit), these attempts at tacit KT tended to be unstructured 
 
27 The term ‘golden batch’ has been commonly attributed to batch process automation.  The researcher 
uses this term with some caution not intending this to be the ‘perfect batch trend’ but rather to convey 
the scenario which progresses to plan without any deviations from the expected outcomes.   
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and highly variable in approach.  Therefore, while explicit knowledge may be transferred 
to the receiving unit, often valuable tacit knowledge was not transferred and may be 
lost. 
 
Challenge 3:  Knowledge ‘leakage’* occurred when valuable experience and learnings 
were not captured, recognised, or considered relevant.  This included useful 
knowledge such as failed experiments, the ‘why’ behind decisions, unexplored risks, 
improvement opportunities (quality, cycle time, yield), other product/process 
experience known by experts but never written down, and knowledge that is less 
structured or formal that figuratively ‘went to PowerPoint to die’ (e.g., lessons learned, 
important decisions in governance reviews, etc.).   
 
*A word about knowledge leakage:  The researcher would like to call out the usage of the 
concept knowledge ‘leakage’ in these challenges.  The researcher naively (and at the time, 
hoped creatively) labelled these challenges with this concept when trying to describe what 
was happening in practical terms.  Simply – that knowledge was being lost, or dissipating, or 
‘leaking’ from the boundaries where it was once known to be (e.g., the project team).  Upon 
a review of the literature, the researcher was surprised to learn knowledge leakage was an 
established concept, and there are nominally two broad definitions of ‘knowledge leakage’ 
in existing literature:  (i) ‘knowledge and capability shortage. This refers mainly to 
turnover, i.e., individuals retire, move to another organisation, or leave an organisation due 
to other reasons. Regardless of the specific form of turnover, those individuals take their tacit 
knowledge and relational capital with them and it is often the case that there is no one in the 
organisation experienced and skilled enough to replace them.’ (Durst and Ferenhof, 2014).  
And (ii) simply, ‘the loss of knowledge intended to stay within a firm’s boundaries’ (Durst, 
Aggestam and Ferenhof, 2015).  This latter definition seems to have received more attention 
in the literature, due to attention on risk of loss of intellectual property and associated 
competitive advantage – whether the loss is intentional or not – through partnerships, 
technology transfers, software development projects or other collaborations.  However, the 
literature also states that the topic of knowledge leakage is not well characterised or 
understood, and more research is required (Durst, Aggestam and Ferenhof, 2015).   
 
Given this ambiguity about the concept of knowledge leakage the researcher proposes a 
practical definition of knowledge leakage for the purposes of this thesis with the hope it will 
garner further study:  that knowledge leakage refers to unintended loss, dissipation, 
mismanagement, lack of structure or any other mechanism which renders knowledge 
which was known to no longer be: 
a) Accessible 
b) Findable (whether one cannot find the knowledge or who has the knowledge) 
c) Usable (e.g., through missing context) 
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d) One simply does not know the knowledge exists   
 
Like a hole in a bucket of water – what was once there and available is no longer able to be 
applied to the benefit of the product or process.  And of note, it does not need to leak beyond 
a firm’s boundaries to cause a negative impact to a product or process, just out of control, 
memory or some other boundary.  Perhaps this definition could be argued to be a subset of 
definition (i) above in that it represents a ‘knowledge and capability shortage’ at the point of 
need.  Regardless, if knowledge is viewed as an asset, it should not be allowed to leak, just as 
one would not want money to unintentionally leak out of one’s bank account. 
 
Challenge 4:  Knowledge ‘leakage’ due to lack of structured and standardised 
knowledge management approaches.  Knowledge was not findable or accessible when 
needed.   
 
Challenge 5:  Knowledge ‘leakage’ through loss of staff experience due to turnover. 
Knowledge dissipated and was not available when needed due to routine staff 
transitions, especially over the lengthy duration of the product lifecycle.  
 
Challenge 6:  The technology transfer itself caused obstructed knowledge flow 
(project context and/or process). This was due to certain knowledge transfer barriers 
between pharmaceutical development and commercial manufacture during technology 
transfer activities.  Such barriers related to process complexity, low staff competency at 
the receiving site, differences in time zones, language issues, cultural differences, etc. 
 
Furthermore, based on a review of the guidance documents, the researcher concluded 
that technology transfer is typically seen as a linear, once-through process. Given the 
absence of focus on KT to begin with, there is no evidence whatsoever to suggest a 
mechanism to reflect if and how knowledge transfer outcomes were achieved (or were 
not).  Such a pause to reflect on progress to a plan would seem to be a valuable 
opportunity in pursuit of effective transfers, ongoing learning, and continual process 
improvement.  A closed-loop KT framework – enabled by robust KM approaches – could 
address this gap and would in turn improve the corresponding technology transfer 
outcomes.  This is supported by the literature (Malik, 2002; Kremic, 2003) suggesting 
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that knowledge transfer during technology transfer should include a feedback loop to 
ensure the effectiveness of KT and a learning opportunity for the sending site.  
 
6.2.2 Defining requirements for a technology transfer knowledge transfer framework  
Having identified the key challenges believed to cause ineffective KT during technology 
transfer, the research focus turned toward exploring the requirements for a KT 
framework to proactively prevent this loss of critical knowledge.  First, returning to the 
six challenges to KT identified previously and employing a CTQ tree28, five high-level 
requirements of a KT framework were identified and listed below (I-V):  
 
I. Knowledge transfer is guided by an intentional and robust plan 
II. Knowledge transfer is best enabled by a culture that values knowledge as an 
asset 
III. Standardised approaches for KM are established both for explicit and for 
tacit knowledge 
IV. Tacit knowledge is uncovered and transferred during technology transfer 
V. Knowledge transfer effectiveness is measured and an action plan to address 
any gaps and opportunities is prepared 
 
From the five high-level requirements, 16 detailed requirements were identified to 
provide further granularity of solution requirements.  While the five high-level 
requirements essentially act as principles, these next level requirements were identified 
to be more specific and actionable.  These were grouped as follows: 
 
• Knowledge to be transferred 
• Knowledge transfer process 
• Knowledge flow enablers and detractors 
• Degree of change from sending unit to receiving unit 
 
Further details on the requirements and processes used to define them can be found in 
the referenced peer-reviewed paper (Lipa, Greene and Calnan, 2021).  A summary 
 
28 A CTQ tree or, Critical to Quality tree, is a technique used to identify the needs of the customer (i.e., 
the outputs from a process) and translate the needs into measurable product and process requirements 
(Six Sigma Daily, no date) 
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Figure 6-3 – Mapping problem statement to requirements for a technology transfer knowledge 
transfer framework 
 
6.3 Evaluation of knowledge transfer framework requirements  
With the KT problem better defined and the solution requirements preliminarily 
identified, it was a good opportunity to pause and benchmark against the findings from 
the literature review.  In the absence of a definitive framework, recall Ward et al. (Ward, 
House and Hamer, 2009) conducted a study of existing frameworks for knowledge 
transfer and inventoried 28 generalised frameworks in the literature and identified five 
common components.  They then proposed a conceptual framework embodying those 
five common components including: 
 
i. the problem 
ii. the knowledge 
iii. the context barriers or supports 
iv. the interventions 
























































(1) Narrow Focus on the “golden 
batch” 
(2) Knowledge transfer is heavily 
biased toward documents, while 
tacit knowledge is not 
methodically transferred 
(3) Knowledge leakage as valuable 
experience and learnings not 
captured, recognized or 
considered relevant 
(5) Knowledge leakage through 
loss of staff experience 
(4) Knowledge leakage due to lack 
of structured and standardized 
knowledge management 
approaches 
(6) Context of the technology 
transfer causing obstructed 
knowledge flow 
Challenges
more specific problem statements
Ineffective Knowledge Transfer 
during Technology Transfer 
(both explicit and tacit 
knowledge)
Problem Statement
Knowledge exists (it was created to begin with)
Knowledge leakage is minimized through systematic 
knowledge capture
Knowledge is identified (a ‘known known’)
A holistic plan for knowledge transfer
Change recognized as a risk & learning opportunity
Plan to capture / grow knowledge
Knowledge leakage minimized through standard KM 
approaches
Standard KM processes followed
Standard KM processes are effective
Barriers / obstruction to knowledge flow recognized
KM processes ‘in the flow’ of work
Organizational pressure / motivations recognized
Capability & Competency of Receiving Unit known
Mindsets & behaviors for managing knowledge
Tacit knowledge is recognized as important
Knowledge leakage is minimized through retention of 
critical knowledge
Detailed Requirements for a Knowledge Transfer Framework
(I) Knowledge Transfer is guided by 
an intentional and robust plan
(IV) Tacit knowledge is uncovered 
and transferred during technology 
transfer
(II) Knowledge Transfer is best 
enabled by a culture that values 
knowledge as an asset
(III) Standardized approaches for KM 
are established both for explicit and 
for tacit knowledge
(V) Knowledge transfer is measured 
and results in an action plan to 
address gaps and opportunities
High Level Requirements
Drivers for effective Knowledge Transfer
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Figure 6-4 – Conceptual framework of the knowledge transfer process (Ward, House and 
Hamer, 2009) 
A gap assessment of the KT framework requirements proposed by the researcher 
(depicted in Figure 6-3) was conducted against the proposal by Ward et al.  The 
assessment result is shown in Table 6-1, as a means to evaluate whether the 
requirements are complete in addressing all components identified by Ward et al. 
(Ward, House and Hamer, 2009). 
 
Table 6-1 – Proposed requirements by researcher vs. conceptual knowledge transfer 





How researcher’s technology transfer knowledge 





Problem The subject technology transfer with associated context, 
assessed by the holistic plan for knowledge transfer 
Yes 
Knowledge Knowledge to be transferred (requirements grouping)  Yes 
Context barriers 
or supports 
Knowledge flow enablers & detractors (requirements 
grouping), degree of change (requirements grouping) 
Yes 
Interventions Knowledge transfer processes (requirements grouping) Yes 
Utilisation The subject technology transfer with associated progress 
versus technology transfer plan, including assessment by 
the holistic plan for knowledge transfer outcomes of the 
technology transfer and sustained performance,  
Yes 
 
While highly qualitative, the detailed KT framework requirements derived 
independently within this thesis are verified to address all five common components of 
KT frameworks found in the literature, suggesting this set of requirements addresses all 
key components commonly found in KT frameworks.   
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Armed with this basic understanding of the needs of a solution, the researcher 
proceeded to develop a framework to enhance KT during technology transfer, the 
details of which are discussed in Chapter 7. 
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Chapter 7:  A Proposed Framework and Toolkit to Enhance 
Knowledge Transfer during Technology Transfer 
 
 
The purpose of this chapter is to present a framework to enhance the effectiveness of  
KT during technology transfer, the Knowledge Transfer Enhancement Framework, or KTE 
Framework.  The framework is further supported by a corresponding toolkit, the KTE 
Toolkit which is also presented.  This section is presented as a summary of a peer-
reviewed paper published in the PDA Journal of Pharmaceutical Science and Technology 
(Lipa, Greene and Calnan, 2021). 
 
In addition to the framework and toolkit, this chapter also provides supporting materials 
for implementation of the framework, including a mapping of the framework to the 
technology transfer process and a high-level metrics plan. 
 
7.1 A knowledge transfer framework for pharmaceutical technology transfer 
Having identified the detailed requirements in Chapter 6 (section 6.2) and given the 
desire to have a simple, closed-loop process that was both widely known and pragmatic 
in nature, the researcher selected the PDCA, or Plan-Do-Check-Act model, as a starting 
basis to build upon.  This model made popular by Deming (ASQ, 2019) is an iterative and 
cyclical means to improve a given process. 
 
To leverage the cyclical nature of the PDCA and make the framework more relevant to 
KT during technology transfer, the intent and description of each stage was adapted as 
follows and depicted in Figure 7-1 which is presented as the Framework for Knowledge 
Transfer Enhancement, or KTE Framework: 
 
1. Knowledge Transfer (KT) Readiness Planning (Plan) 
2. KT Execution (Do) 
3. KT Effectiveness Assessment (Check) 
4. KT Action Plan (Act) 
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Figure 7-1 – The KTE Framework on a page 
The referenced paper (Lipa, Greene and Calnan, 2021) by the researcher includes 
further details on each stage of the KTE Framework. 
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7.2 A knowledge transfer toolkit for pharmaceutical technology transfer 
Supporting the KTE Framework is a KTE Toolkit, consisting of a series of practices to 
support the ‘how’ behind knowledge transfer.  These KM practices are introduced in the 
referenced peer-reviewed paper (Lipa, Greene and Calnan, 2021).  Table 7-1, KTE Toolkit 
on a Page, provides a listing of the tools and practices, a brief intent statement for each 
(“Use it to…”), and next steps to implement each tool or practice, which in some cases 
may involve future research study.  While further development of this toolkit will 
certainly be of value through thoughtful definition and identification of proven 
practices, in the opinion of the researcher with the intent of each framework stage and 
tool defined, organisations should feel empowered to start to address these gaps on 
their own.   
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Table 7-1 – KTE Toolkit on a Page 
KTE Stage  |  KTE Tool Use it to… Next steps to implement tool / practice 
KT Readiness Planning  
1.1 – KT Risk Factor Assessment Reduce risk to technology transfer 
Define through future study; Based on socialisation of these concepts of knowledge transfer 
challenges, organisations can immediately incorporate into technology transfer risk 
assessments 
1.2 – KT Plan Build knowledge transfer into technology transfer 
Basic outline to define knowledge to be transferred (e.g., from knowledge map) and how 
(KM/KT practices to be utilised and built into project) can be immediately built into 
technology transfer plans or supporting knowledge transfer plans.  This should include a plan 
for appropriate training.  Future study to define a template would likely be of benefit.  
1.3 – KT Mindsets & Behaviours Create shared team understanding of the need to manage knowledge as an asset These concepts are preliminary explored in Chapter 9 and warrant future study 
KT Execution  
2.1 – KT Community of Practice 
(CoP) KM best practice to standardise knowledge flow 
Best practices for CoPs exist (Kane and Lipa, 2018); Define tech transfer-specific CoP through 
future study 
2.2 – Standard KM Practices KM best practice(s) to standardise knowledge flow Many common practices exist and can be applied (Kane and Lipa, 2018; ISPE, 2021b) 
2.3 – KT Knowledge Map Identify knowledge to be transferred 
Define through future study; basic expectations exist via BPOG Knowledge Map (BioPhorum 
Operations Group, 2020) and explicit document lists found in ISPE (ISPE, 2018), PDA (PDA, 
2014b) and other technology transfer guidance documents 
2.4 – KT ‘What if’ Assessment KM practice to surface and transfer tacit knowledge Refer to Simple Practices paper (Lipa, Kane and Greene, 2020) 
2.5 – Tech Transfer Knowledge 
Sharing 
KM practice to surface and transfer tacit knowledge, 
enable rapid continual improvement Refer to Simple Practices paper (Lipa, Kane and Greene, 2020) 
KT Effectiveness Assessment  
3.1 – Explicit KT Checklist KM best practice to standardise knowledge flow Audit against KT Plan and knowledge map 
3.2 – Tacit Knowledge Turnover KM practice to surface and transfer tacit knowledge Refer to Simple Practices paper (Lipa, Kane and Greene, 2020) 
3.3 – Lessons Learned KM best practice – use to surface and transfer tacit knowledge & foster continual improvement 
Leverage existing proven practices for Lessons Learned / After Action Review (ISPE, 2018; 
Kane and Lipa, 2018) 
3.4 – KT Summary Report Assess completion of KT Audit against goals in KT Plan and completion of items 3.1 through 3.3 
KT Action Plan  
4.1 – KT Action Plan Act on learnings, including process improvement, knowledge capture and informing control strategy 
Basic action plan resulting from above actions, including open items from knowledge transfer 
summary report, actions identified during tacit knowledge transfer and lessons learned 
4.2 – Receiving Unit KM Plan KM best practices to maintain and grow transferred knowledge at RU 
KM plan for the receiving unit to sustain and grow product knowledge; Potential to define 
through future study 
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One area in particular the researcher explored was that of tacit knowledge transfer.  
Given the general neglect of tacit knowledge (as characterised multiple times in previous 
chapters), the researcher had an interest in advancing the dialogue on meaningful tacit 
knowledge transfer techniques, while also creating a model for several of the tools 
proposed in the KTE Toolkit.  The results are captured via a case study in a paper by the 
author, Simple Practices to Facilitate the Flow of Valuable Tacit Knowledge during 
Biopharmaceutical Technology Transfer: A Case Study (Lipa, Kane and Greene, 2020).  
This case study was also presented as part of a presentation at the 2021 PDA Annual 
Meeting (Lipa, 2021a) and is featured in the ISPE Good Practice Guide on Knowledge 
Management (ISPE, 2021b).   
 
In summary, the researcher, while involved with a complex technology transfer for a 
multi-valent vaccine, led the design of two tacit knowledge transfer practices 
(Technology Transfer Batch Execution Review and Tacit Knowledge Turnover Assessment) 
and consulted on a third (What if…?).  Drawing on best practices in KM, each of the tacit 
knowledge transfer practices share common elements, including: 
• Standardised business processes for knowledge capture and transfer (and 
codification to explicit knowledge, where appropriate) 
• Basic governance to ensure prioritisation and follow through on important 
actions 
• Enabling mindsets for sending and receiving site personnel, including ‘safe to 
share’ and a sense of inquisitiveness, including active engagement and 
participation from people, such as experts from the sending site and members 
from the receiving site 
The general process for Technology Transfer Batch Execution Review is illustrated in 
Figure 7-2, highlighting a relatively simple set of questions that can be pursued before 
and after batch execution to create meaningful dialogue, ideas, questions, and exchange 
of information.  Coupled with the common elements (e.g., governance), these processes 
were highly effective in generating valuable insights. 
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Figure 7-2 – Technology Transfer Batch Execution Review 
These three tacit knowledge transfer processes delivered significant positive impact to 
the success of the technology transfer in reducing cost and risk through proactive 
learning and improved right-first-time execution.  Technology Transfer Batch Execution 
Review, for example, resulted in 52 proactive actions which in turn prevented 43 
potential deviations in the quality system.  Furthermore, there was overwhelmingly 
positive stakeholder feedback on the contribution of this process to continual 
improvement ‘on a near real-time basis.’  This practice and the other two tacit 
knowledge transfer processes are presented in further detail in the referenced paper 
(Lipa, Kane and Greene, 2020).   
 
7.3 Feedback on the KTE Framework  
Importantly, the KTE Framework was not developed in a vacuum.  In addition to the 
experiences of the researcher, the framework was informed by the literature, the 
current state assessment and resulting derived requirements, and by feedback via 
interviews.  Interviews to solicit feedback on a preliminary iteration of the KTE 
Framework were conducted between December 2019 and February 2020 to solicit 
feedback from industry SMEs on technology transfer, senior leaders, and a regulatory 
authority.  The intent was to gain insights on potential benefits from the framework, 
A. Pre-batch review
Create focus, alignment & situational awareness
• What is new, unique or difficult?
• What changed since last time?
• How did it go last time?





B. Post-batch review 
Pause to reflect, learn and improve
• What was supposed to happen?
• What actually happened?
• Was there a difference and why?
• What can we learn?
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whether the framework was logical, and whether it was workable (i.e., practical to 
implement).   
 
7.4 Practical application of the KTE Framework to technology transfer 
To demonstrate the application of the KTE Framework and associated KTE Toolkit to a 
technology transfer project, the researcher leveraged a five-step overview of the 
technology transfer process described by Abraham et al. (Abraham et al., 2015) to 
create the following process flow. 
 
 
Figure 7-3 – Key activities and milestones in biopharmaceutical technology transfer 
 
Using the technology transfer flow steps as headings, a matrix was developed by the 
researcher and is shown in Figure 7-4.  Beneath each of the five steps of the technology 
transfer process, a mapping of the respective KTE stages and KM practices are 
presented.  
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Figure 7-4 – A matrix indicating where the KTE Framework and KTE Toolkit can be applied to the 
technology transfer process 
7.5 Metrics for the KTE Framework 
A measurement system is critical to ensure an objective is achieved and to provide a 
tangible means to assess progress.  The ultimate outcome of an effective KT is in support 
of the goals of ICH Q10 (ICH, 2008) and informing QRM to, in turn, reduce risk to patients 
(Chapter 5).  However, in practice, measurement of these outcomes is difficult since 
they come along after the technology transfer is complete, and they are often 
confounded with other improvement initiatives (i.e., improvements often cannot be 
attributed specifically to KT effectiveness).  Also, in the experience of the researcher, 
success in KM is often about what didn’t happen rather than what did happen in the 
future (said differently, with effective KM, issues can be averted or solved quickly and 
risks can be managed before major issues occur, therefore attribution to the success of 
KM can be difficult to establish).   
 
It is envisaged that the KTE Framework will be primarily measured by a set of leading 
metrics proposed by the researcher, intended to assess progress and activity in applying 
the framework.  These metrics are typically considered leading indicators as they are 
predictive in nature of an outcome.  In the case of the KTE Framework, the research 
activities to determine the current state and challenges with technology transfer KT 
(Chapter 6) have already established the impact of not having structured KT approaches 
STAGE 1:
KT PLANNING
RISK FACTOR ASSESSMENT ◉
KT PLAN ◉
MINDSETS & BEHAVIORS ◉ ◉ ◉ ◉ ◉
STAGE 2: 
KT EXECUTION
TECH TRANSFER COP ◉ ◉ ◉ ◉ ◉
STANDARD KM ◉ ◉ ◉ ◉ ◉
KNOWLEDGE MAP ◉
“WHAT IF…?” ◉ ◉
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in place.  Therefore, metrics tied to the KTE Framework deployment can establish an 
initial baseline to demonstrate structured KT approaches.  When used, they can provide 
a degree of confidence in improving both KT and technology transfer outcomes.  It is 
fully anticipated these metrics will evolve and be refined over time based on feedback.  
A preliminary metrics plan for the KTE Framework is listed in Table 7-2. 
 
Table 7-2 – KTE Framework metrics plan 
Leading Indicator Target Value 
Knowledge transfer Plan:  plan in place and approved, 
including KT Risk Factor Assessment and KT Readiness 
Assessment 
Yes 
Knowledge transfer plan:  progress to plan Execution is on plan (scope and 
schedule) 
Team enrolled in knowledge transfer mindsets and 
behaviours, through onboarding, team chartering or 
other appropriate means 
>95% enrolled 
Knowledge management maturity at sending site At least standardised (mid-level 
maturity) 
Knowledge management maturity at receiving site At least standardised (mid-level 
maturity) 
Closure of knowledge-related actions identified during 
technology transfer (e.g., those identified during risk 
assessments and tacit knowledge transfer exercises such 
as What If? and Tacit Knowledge Turnover) 
>90% of high priority items 
closed within 3 months 
Closure of actions from lessons learned / after action 
reviews conducted in-process during technology transfer 
and at the conclusion of technology transfer 
>90% of high priority items 
closed within 3 months 
Closure of actions identified in Knowledge Action Plan , 
including feedback and feed forward actions on the 
transferred product and process, as well as on the 
business processes of technology and knowledge transfer 
>90% of high priority items 
closed within 3 months 
Knowledge transfer completion is measured as part of 
overall technology transfer metrics 
Yes 
KM-practice specific measures, as appropriate based on 
KM practices selected 
Varies, based on knowledge 
management practices applied.   
 
Lagging indicators, which indicate past performance, can also be used for technology 
transfer outcomes, are listed in Table 7-3.  Due to the latency to measure such 
outcomes, a mix of leading and lagging measures is recommended.   
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Table 7-3 – Lagging measures for technology transfer using the KTE Framework 
Lagging Indicator Target  
directional and qualitative, relative to 
company’s baseline performance 
Deviations during PPQ Fewer deviations 
Process reproducibility  Increased reproducibility 
Process robustness / performance Increased robustness performance 
Measures of risk reduction for successful 
technology transfer 
Lower residual risk 
Technology transfer completed on schedule  Tighter schedule adherence 
Technology transfer completed on budget Tighter budget adherence 
 
7.6 Summary – KTE Framework 
In summary, the KTE Framework presented in this chapter is positioned as one potential 
solution to improve KT during technology transfer.  This framework has been based on 
learnings from the literature, other KT models, a well-informed set of requirements, 
feedback from industry experts, leaders and regulatory authorities, peer reviewers of 
the related paper, and the experience of the researcher.  Further information on how 
the KTE Framework provides a means for feedback (e.g., to inform future transfers) and 
feed-forward (e.g., to inform the control strategy) is explored in the referenced paper 
(Lipa, Greene and Calnan, 2021). 
 
Part three which follows, including Chapters 8 and 9, which explored how the RKI Cycle 
could be applied across the product lifecycle to extend its reach and impact.   
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Part Three:  The RKI Cycle across the Product Lifecycle and 
Knowledge Culture as a Catalyst 
 
Part Three demonstrates how the RKI Cycle can be applied across the product lifecycle, 
including: 
• Three examples with a focus on each KM across the product lifecycle, change 
management during commercial manufacturing, and the link between QRM, 
KM and data analytics (Chapter 8). 
• This part also explores the concept of knowledge culture, including a review of 
current cultural issues which are barriers to knowledge management in the 
pharmaceutical industry, existing definitions of knowledge culture outside of 
the pharmaceutical industry, and benchmarking the corollary of quality culture.  
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Chapter 8:  Demonstrating How the RKI Cycle Can be Applied 
Across the Product Lifecycle 
 
Given the findings of this research on the importance of connecting QRM and KM and 
ensuring the effective management of knowledge – coupled with the evidence that this 
is not done well in practice today – an important opportunity to maximise the impact of 
these findings is presented.  The purpose of this chapter is to demonstrate examples of 
how the RKI Cycle can be applied across the product lifecycle as depicted in ICH Q10 
(ICH, 2008) (Figure 8-1).   
 
 
Figure 8-1 – The product lifecycle as depicted by ICH Q10 (ICH, 2008) 
 
The first of three examples focuses on managing knowledge across the product lifecycle 
to ensure knowledge availability for managing risk (in addition to operational benefits).  
This first example takes a broad view across all four stages of the end-to-end product 
lifecycle and is centred primarily on node 5 of the RKI Cycle (Figure 8-2, as presented in 
Chapter 5 and the related peer-reviewed paper (Lipa, O’Donnell and Greene, 2020a). 
 
 
Figure 8-2 – The Risk-Knowledge Infinity Cycle as applied to ICH Q10 
 
The second example features an application of the RKI Cycle within a single lifecycle 
stage, the commercial manufacturing stage of the product lifecycle.  Specifically, this 
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example highlights the PQS element of change management and illustrates how the RKI 
Cycle is ‘continuous and perpetual’ (Chapter 5, section 5.2).  This example presents four 
common change triggers flowing through the RKI Cycle, each starting at a different 
node, either 1, 3, 4, or 6 (Figure 8-2).  
 
The third example demonstrates how the RKI Cycle can provide a tangible mechanism 
for data analytics to generate knowledge and enable risk reduction, by injecting new 
knowledge derived from data analytics into node 4 (Figure 8-2). 
 
These first two examples have been published in two separate papers and are 
summarised in the following sections of this chapter.  The first paper which maps stage-
appropriate KM methods and tools across the lifecycle was published in Level3 (Lipa and 
Kane, 2021) and subsequently used in Chapter 5 of the ISPE Good Practice Guide on 
Knowledge Management (ISPE, 2021b).  At the time of this thesis submission, the 
second paper featuring the RKI Cycle for change management during commercial 
manufacturing has been accepted by ISPE and is planned to be released in May 2021 as 
the subject of a global webcast (Lipa and Mulholland, 2021).  The third example was the 
subject of a presentation given by the researcher at the launch of the Guide to Data 
Analytics for Pharmaceutical Manufacturing (PMTC, 2020) by the Pharmaceutical 
Manufacturing Technology Centre29.   
 
8.1 Managing knowledge across the product lifecycle (Example 1) 
A key concept inherent in the product lifecycle is that knowledge will grow over time 
through planned (e.g., development studies, prospective process changes) and 
unplanned (e.g., investigations, risk control failures) activities.  A key tenant of the RKI 
Cycle is that knowledge should be effectively managed (at node 5) to ensure it is 
available and can be applied to reduce risk and support continual improvement (as 
illustrated by Figure 5-5).    
 
 
29 The Pharmaceutical Manufacturing Technology Centre (PMTC), http://www.pmtc.ie  
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To date, this thesis has focused on the technology transfer stage of the product lifecycle.  
Stepping back to take the entire product lifecycle into account, one can envision that 
knowledge is increasing at every stage as depicted in Figure 8-3.  This depiction by no 
means suggests there are a finite number of RKI cycles for the four lifecycle stages; 




Figure 8-3 – The RKI Cycle as knowledge increases across the product lifecycle 
 
One might expect the emphasis of KM plans and practices to vary slightly from stage to 
stage based on the applicable knowledge-intensive activities in each stage.  The 
following sections consider each of the lifecycle stages separately, including 
considerations of each phase introduced by Kane’s PPKL model (Kane, 2018) as 
introduced in Chapter 2 (section 2.1.3.1).  
 
8.1.1 Pharmaceutical Development 
Considering Pharmaceutical Development, labelled as Product Development in the PPKL 
model (Kane, 2018), examples of knowledge-related activities include (ISPE, 2011): 
 
• Application of prior knowledge for risk assessments to determine areas of study 
• Development work to capture new knowledge 
• Ongoing risk assessment and risk control 
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Knowledge management should be a key enabler to Product Development through 
standardised methods and tools delivering on the following capabilities:   
 
• Access to prior knowledge (platform technologies, other products, expertise in 
the company (individuals & CoEs), external scientific literature, prior learnings & 
lessons, etc.) 
• Capture of new knowledge during early development work (both what worked 
and what did not), including both explicit and tacit knowledge 
• The record of product development, including scientific knowledge, supporting 
design choices, and other decision rationale 
 
8.1.2 Technology Transfer 
Considering Technology Transfer (new product introduction and In-line transfers), 
examples of knowledge-related activities (WHO, 2011; PDA, 2014b; ISPE, 2018), as 
explored in detail in Chapter 6, include: 
 
• Application of knowledge for risk assessments 
• Comprehensive knowledge transfer, including tacit knowledge 
• Opportunity to learn more about the product and process 
• Supporting the goal to ensure a right-first time transfer, robust process and a 
fully capable receiving site 
 
Knowledge management should be a key enabler to Technology Transfer through 
standardised methods and tools delivering the following capabilities, as explored in 
detail in Chapter 7:   
 
• Access to comprehensive product and process knowledge, including 
development and manufacturing history (e.g., key decisions, learnings from 
failures, changes, etc.) 
• Access to subject matter experts / personnel with process experience 
• Capture of new learnings including increased knowledge and understanding of 
product/process, lessons learned, etc. 
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8.1.3 Commercial Manufacturing 
Considering Commercial Manufacturing (inclusive of Continual Improvement) examples 
of knowledge-related activities include (ICH, 2008): 
 
• Ongoing knowledge build through accumulated manufacturing experience 
• Lifecycle management, including planned and unplanned changes  
• Seeking to minimise disruptions to product availability by rapid problem solving 
and solving problems at root cause 
 
Knowledge management should be a key enabler to Commercial Manufacturing 
through standardised methods and tools delivering the following capabilities:   
 
• Capture of new learnings, including increased knowledge and understanding of 
product/process, lessons learned, etc.  
• Knowledge visibility and availability across the full product lifecycle (including 
development) to ensure broad access to knowledge to support process 
monitoring, continual improvement, change management, investigations, etc. 
• Support for problem solving and sharing of best practices and improvements 
across the supply chain and back to development organisation 
 
8.1.4 Product Discontinuation 
Considering Product Discontinuation, examples of knowledge-related activities include 
(ICH, 2008): 
 
• Knowledge transfer for archival and future access on demand 
• Harvesting learnings to inform 'prior knowledge' 
 
Knowledge management should be a key enabler to Product Discontinuation through 
standardised methods and tools delivering the following capabilities:   
 
• Capture of knowledge in a complete and structured manner to allow for future 
access (e.g., stability, complaints, etc.) 
• Capture of learnings including insights for platform knowledge and other 
potential 'prior knowledge' 
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Given these high-level understandings of the necessary knowledge capabilities for each 
stage of the product lifecycle, the researcher suggested suitable KM methods and tools 
can be applied to each stage, which are presented in the next section.   
 
8.1.5 Product lifecycle stage-appropriate KM methods and tools to ensure knowledge 
availability 
The researcher suggested that current established KM methods and tools can be 
employed to provide the necessary means to effectively manage knowledge in a 
standardised and consistent manner, ensuring the best possible knowledge is available 
to maximise the reduction of risk via the RKI Cycle.   
 
To illustrate this, Table 8-130, created by the researcher, provides a preliminary mapping 
of KM methods and tools required to satisfy the conceptual needs of each product 
lifecycle stage.  This table has been accepted by the ISPE Good Practice Guide on 
Knowledge Management SME author team and is featured in Chapter 5 of the ISPE 
Guide.  Following Table 8-1, a description for each KM method or tool is provided in 
Table 8-2.   
 
 
30 Note – column heading labels have been adjusted post-publication in Level3 to improve clarity of the 
text as it relates to this thesis 
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Table 8-1 – Stage-appropriate KM methods & tools across the product lifecycle 
Lifecycle Stage Knowledge-related activites 
(activities where knowledge is required)
Knowledge Capabilities Required
(How Knowledge Management can provide benefit) 
Common KM elements for Product Development  phase X X X X X X
Access to prior knowledge (platform technologies, other 
products, expertise in the company (individuals & CoEs), 
external scientific literature, prior learnings & lessons, et al)
X X X X X X X
Capture of new knowledge during early development work 
(both what worked and what didn't) X X X X X X X X
The record of product development, including scientific 
knowledge and supporting design choices and other decision 
rationale
X X X X X X X X X
Common KM elements for Technology Transfer  phase X X X X X
Access to comprehensive product and process knowledge, 
including development and manufacturing history, including 
key decisions, learnings from failures, changes, etc.
X X X X X X X X X X X X
Access to subject matter experts / personnel with process 
experience X X X X X
Capture of new learnings including increased knowledge and 
understanding of product/process, lessons learned, etc. X X X X X X X X X X
Common KM elements for Commercial Manufacturing  phase X X X X X X
Capture of new learnings including increased knowledge and 
understanding of product/process, lessons learned, etc. X X X X X X X X X X
Knowledge visibility and availability across the full product 
lifecycle (including development) to ensure broad access to 
knowledge to support process monitoring, continual 
improvement, change management, investigations, et al
X X X X X X X X X X X
Support for problem solving and sharing of best practices and 
improvements across the supply chain and back to 
development organization
X X X X X X X X X X X
Common KM elements for Product Discontinuation  phase X X X X
Capture of knowledge in a complete and structured manner to 
allow for future access (e.g. stability, complaints, etc.) X X X X X X X X
Capture of learnings including insights for platform knowledge 
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Note 1:  Illustrative concepts, not an exhaustive listing
Note 2:  References below to knowledge refer to both  explicit and tacit knowledge
Note 3:  Additional concepts or complexity may be introduced when multiple entities are involved
Product 
Development
- Application of prior knowledge for risk 
assessments to determine areas of study
- Development work to capture new 
knowledge






- Application of knowledge for risk 
assessments
- Comprehensive knowledge transfer
- Opportunity to learn more about the 
product/process
- Supporting the goal to ensure a right-


















































































































- Ongoing knowledge build through 
accumulated manufacturing experience
- Lifecycle management, including 
planned and unplanned changes
- Seek to minimize disruptions to 
product availability by rapid problem 




- Knowledge transfer for archival and 
future access on demand
- Harvesting learnings to inform 'prior 
knowledge'
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Table 8-2 – Description of KM methods & tools 
KM Method or Tool Description  
Planning & Requirements Definition 
KM Maturity Assessment  A means to objectively measure maturity of KM effectiveness based on various attributes such as process, culture, technology, etc. 
Knowledge Mapping 
A structured means to document the knowledge needed for a business 
process, a functional group, a role, etc.  Used to understand knowledge 
requirements and identify gaps.  
Product KM Plan A strategy document to define the plan for how the knowledge associated with a product will be managed across the lifecycle of the product. 
Knowledge Transfer Plan A strategy document to define the plan for how the knowledge transfer will be managed.  
Site / Functional Area KM 
Plan 
A strategy document to define the plan for how the knowledge associated 
with a site or functional group will be managed. 
Mostly Explicit-based 
Content Management 
A structured31 means to manage documents and other explicit knowledge 
(e.g., videos, pictures, etc.).  Typically includes the end-to-end lifecycle of 
content (e.g., creation, tagging, storage, delivery).  Applies to both GMP and 
non-GMP content which may be managed in separate systems. 
Taxonomy & Search 
Taxonomy is a structured means to describe and tag content (and potentially 
other features such as synonyms, semantics, etc.), and a means to deliver 
results through a robust, integrated search enabled by such a taxonomy. 
Platform Knowledge Base 
A structured means to define the scope of platform knowledge (explicit and 
tacit) and corresponding approaches to manage this in a consistent way to 
ensure knowledge visibility and availability across the product lifecycle. 
Product Knowledge Base 
A structured means to define the scope of product knowledge (explicit and 
tacit) and corresponding approaches to manage this in a consistent way to 
ensure knowledge visibility and availability across the product lifecycle. 
Mostly Tacit-based 
Communities of Practice A structured means to connect groups of people with a shared need or interest 
After Action Review / 
Lessons Learned 
A structured means to surface learnings from the experiences of people, 
often associated with a project or other business process, and subsequently 
capture and implement these learnings to support continual improvement.  
Expertise Location A structured means to identify important expertise and/or experience in the organisation and connect to it on demand.  
Decision Rationale 
Capture 
A structured means to capture decision rationale and ensure it is available in 
the future when needed. 
Tacit Knowledge 
Retention & Transfer 
Practices 
A variety of structured means to identify, prioritise, transfer and retain tacit 
knowledge (i.e., ‘know-how’ and other knowledge ‘in people’s heads’) 
Enabling Elements 
KM Roles Standardised roles for managing knowledge consistently, such as community stewards, KM leads, and others. 
KM Training Training on appropriate KM topics to build awareness and competency of individuals in the organisation. 
Knowledge-valuing 
culture 
Mindsets and behaviours which value the knowledge of the organisation as 
an asset (e.g., capturing and sharing lessons, seeking to leverage prior 
knowledge) 
Sponsorship, Governance, 
Metrics & Other enablers Best practices to enable effective and sustainable KM.    
 
31 Structured = Standardised and inclusive of people, process, technology, and governance 
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The capabilities and corresponding mapping of KM methods and tools presented in 
Table 8-1 and Table 8-2 above is preliminary in nature and based on the experiences of 
the researcher. While an in-depth study was conducted for technology transfer (Chapter 
6 and Chapter 7), resulting in the KTE Framework and KTE Toolkit, defining additional 
requirements for the other three lifecycle stages (i.e., product development, 
commercial manufacturing, and product discontinuation) would further expand this 
research and suitable frameworks for the other three stages could be developed. 
 
8.2 RKI Cycle application to change management during commercial 
manufacturing stage (Example 2) 
While the previous section on managing knowledge across the product lifecycle 
illustrated an end-to-end application of the RKI Cycle, this second example focuses more 
in depth on change management during commercial manufacturing.  
 
Commercial manufacturing is typically the longest stage of the product lifecycle and as 
such provides an abundance of opportunities for knowledge capture, flow, and 
application across numerous activities. ICH Q10 lists four PQS elements (ICH, 2008) that 
are substantially dependent on the application of QRM and KM, as Process Performance 
and Product Quality Monitoring, Corrective Action / Preventative Action (CAPA), Change 
Management and Management Review of Process Performance and Product Quality.  
Effective change management is central to the achievement of one of the objectives of 
ICH Q10, being the objective of continual improvement. Thus, change management was 
selected as an appropriate element to illustrate the application of the RKI Cycle, as it is 
the element that is typically the most standard across companies.  
 
The triggers for change management may vary as described in a recent PIC/S 
recommendation paper (PIC/S, 2019), which lists examples of potential change triggers 
(or reasons to raise a change proposal), as follows: 
 
• Upgrades to equipment or facilities 
• Improvements in raw materials 
• Improvements in manufacturing performance and consistency (to reduce 
variability, improve yield, etc.) 
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• Enhancements in manufacturing capacity 
• Corrections of quality issues 
• Addressing signals from the PQS such as deviations, complaints/adverse events, 
corrective action and preventative action (CAPA), product quality review, 
operational review metrics, management review, new regulations, compliance 
gaps, implementing innovation, or continual improvement initiatives 
The list above gives a diverse range of reasons for triggering a change. Some changes 
are evidence-based, supported by existing process and product knowledge. However, 
others, particularly those proposing new or innovative changes, may have a level of 
uncertainty and, consequently, will rely more on QRM for successful outcomes 
(Mulholland and Greene, 2020).  At a practical level, these differences mean that the 
change proposals can commence at different nodes on the RKI Cycle. 
 
 
Figure 8-4 – Potential 'entry points' for the RKI Cycle 
 
To demonstrate this, four change triggers were evaluated and their ‘entry points’ on the 
RKI Cycle are determined as follows:   
 
• Novel, new or innovative changes:  entry at node 1 
• A risk control failure:  entry at node 3 
• Introducing a Disruptive or Transformational Technology:  entry at node 4 
• Continuous Improvement or Process Optimisation:  entry at node 6 
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An example of each was reviewed via a case study, which is available in the referenced 
webinar (Lipa and Mulholland, 2021) and upcoming paper.   
 
For the purpose of this thesis, the first case study which was for a novel, new or 
innovative change, is presented below.    
 
Case Study 1 
Novel, new or innovative 
changes:   




A change enters at the earliest point in the RKI Cycle. This is the entry point for 
anything new, novel, or innovative. This is because, while the change proposal will be 
supported by a certain amount of information, probably of external origin, there will 
usually be a deficit of tacit knowledge about the ‘to-be’ process within the 
organisation, leading to uncertainty and risk. The impact on the current and future 
states must be fully understood in order to approve the change and to have a 
controlled implementation plan. The change proposal must be supported by a quality 
risk management process to identify the hazards, understand their significance, and 
establish the correct risk controls. This requires the application of the complete RKI 
learning cycle, starting with knowledge-driven risk assessments, where knowledge is 
an input to those risk assessments.   
 
Example: Company X identifies an improvement opportunity based on changing an 
in-process test method. The ‘new’ method will reduce the cycle time between 
sampling and result. The proposed method is an established technology in other 
industries. Therefore, there is a volume of literature on its application and the 
supplier of the technology can supply training and technical support. However, it is 
‘new’ to this operation and process. There is concern whether the data produced by 
the new technology will be readily interpretable with respect to product and process 
control, and whether the higher sensitivity of this technology will result in unknown 
outcomes and unforeseeable results. These are uncertainties that represent real 
hazards and concerns. 
 
In this case, the change proposal should be treated with the full RKI Cycle, from the 
initial starting point (node 1). QRM will establish the hazards and risks that must be 
controlled. It will evaluate the likelihood of those hazards occurring, the risk levels 
associated with them and the appropriate controls and/or responses. Any concerns 
or uncertainties that are deemed to be unacceptably high will require further 
research or off-line studies to resolve. (Nodes 1-3 on RKI Cycle). The change proposal, 
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when approved, will be implemented with a supporting implementation and 
monitoring plan to ensure that knowledge and understanding are gained, evaluated, 
and used to refine or improve the implementation plan, where necessary. (Nodes 4-
6 on the RKI Cycle). 
 
 
8.3 The RKI Cycle as a mechanism for data analytics to reduce risk (Example 3) 
A third example of applying the RKI Cycle involves data analytics.  This opportunity was 
realised when the researcher was invited to present at the launch of the Guide to Data 
Analytics for Pharmaceutical Manufacturing (PMTC, 2020) by the Pharmaceutical 
Manufacturing Technology Centre.  The paper introducing the RKI Cycle (Lipa, O’Donnell 
and Greene, 2020a) is cited by this PMTC guide, and in preparing for the speaking 
engagement (Lipa, 2020b) the researcher reflected on the role the RKI Cycle could play 
as a mechanism for data analytics to generate knowledge and enable risk reduction.  The 
PMTC guide acknowledges such a need, stating:  
 
Data and data analytics are drivers for knowledge and knowledge generation, 
and can support KM and QRM systems, which should better inform risk 
management activities.   
 
Furthermore, the PMTC guide states: 
 
Data becomes knowledge through the vehicle of data analytics. Knowledge is a 
critical milestone that can be integrated and built upon to develop process 
understanding. Value is realised through such understanding. 
 
This can be envisaged through a common representation linking data, information, and 
knowledge (Figure 8-5) as presented to PMTC (Lipa, 2020b).  This figure, adapted from 
work by Rowley (Rowley, 2007) and Kane (Kane, 2018), represents the ‘top’ of the 
pyramid as insight & understanding, created starting from data and information 
contextualisation to create knowledge, and then from knowledge application through 
insight and understanding to support evidence-based decision making.  Data analytics 
is a means of contextualisation of data.  
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Figure 8-5 – Data, Information, & Knowledge in support of evidence-based decision making 
 
Relating this to the RKI Cycle, the focus of node 4 is to acquire, grow, capture, and retain 
new knowledge.  It is here that new knowledge derived from data analytics should be 
injected into the cycle so that this knowledge becomes effectively managed and made 
visible and available via nodes 5 and 6 (Figure 8-6).  This knowledge can then be applied 
to risk management via nodes 2 and 3 to support evidence-based decision making.   
 
 
Figure 8-6 – Data analytics can inject new knowledge into the RKI Cycle 
 
Further details linking data analytics, knowledge, and risk reduction are available in the 
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While the pyramid shown in Figure 8-5 is often cited to descriptively relate data, 
information, and knowledge, this example application is about the ‘vertical integration’ 
of this pyramid (i.e., via data analytics to provide context to data and create knowledge), 
which has not been extensively studied.  Further study on this is an opportunity 
highlighted in Chapter 12 of this thesis.  
 
8.4 Summary – RKI Cycle application across the product lifecycle 
As these examples illustrate, there are many potential applications where the RKI Cycle 
can be applied to relate and connect important activities throughout the PQS elements 
and across the product lifecycle.  The researcher believes this is just the beginning of 
how the RKI Cycle can be used in this manner; the RKI Cycle has the opportunity to 
become a central, integrating framework with seminal impact for the industry and can 
lead to improved risk- and evidence-based decision making.  
 
Chapter 9 follows describing an exploration into the concept of a knowledge culture as 
a means to define mindsets and behaviours for an organisation to excel in effectively 
managing knowledge across the lifecycle and further accelerate the impact of the RKI 
Cycle. 
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Chapter 9:  Knowledge Culture as a Catalyst to Accelerate RKI 
Cycle Adoption and Impact 
 
Having presented the RKI Cycle, with examples of its application across the product 
lifecycle, this final chapter in this part of the thesis explores a key factor:  knowledge 
culture.  Understanding and addressing the current organisational barriers to 
widespread KM adoption was an important factor in unlocking knowledge for use across 
the product lifecycle.   
 
Organisational culture32 is a major barrier to change in many organisations.  While there 
are many aspects to the culture of an organisation, this chapter focuses on exploring 
what a knowledge culture could be for the pharmaceutical industry.  Industry-specific 
insights on the concepts of quality culture and cultural issues that act as barriers to KM 
are explored, including a view to understanding how they impact the RKI Cycle.  A 
formative knowledge culture position for an organisation is proposed by the researcher 
with the intent of initiating dialogue and future research on the topic.   
 
9.1 Attributes of quality culture 
When developing a position of what a knowledge culture could look like for a 
pharmaceutical organisation, the researcher started first by exploring quality culture as 
a theme, as it has received significant attention in recent years.  A 2014 survey by 
Corporate Executive Board (CEB), Creating A Culture of Quality (Srinivasan and Kurey, 
2014), identified substantial savings opportunities for a company with a highly 
developed ‘culture of quality’ where an average savings of $350 million per year could 
be gained as a result of not having to fix mistakes.  The survey authors concluded that 
only four attributes need to be reviewed to actually predict a culture of quality:  
Leadership Emphasis, Message Credibility, Peer Involvement and Employee Ownership, 
as described in Table 9-1. 
 
32 An organisation's culture consists of shared beliefs and values established by leaders and 
communicated and reinforced through various methods, ultimately shaping employee mindsets and 
behaviours for how to act. Organisational culture sets the context for everything an enterprise does 
(adapted (SHRM, 2021)) 
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Table 9-1 – The four essentials of quality as per 2014 CEB Culture of Quality Survey (Srinivasan 




Managers are told that quality is a leadership priority. Managers 
‘walk the talk’ on quality. When evaluating employees, bosses 
emphasise the importance of quality.  
Message Credibility Messages are delivered by respected sources. Workers find that 
communications appeal to them personally. Messages are 
consistent and easy to understand.  
Peer Involvement Most employees have a strong network of peers for guidance. 
Peers routinely raise quality as a topic for team discussion. Like 
members of a sports team, peers hold one another accountable.  
Employee 
Ownership 
Workers clearly understand how quality fits with the job. Workers 
are empowered to make quality decisions. Workers are 
comfortable raising concerns about quality violations and 
challenging directives that detract from quality. 
 
PDA published a Quality Culture Survey Report in 2015 (Patel et al., 2015) and identified 
the top five attributes that can serve as surrogates for quality culture as: 
 
• Management communication that quality is everyone’s responsibility 
• Site has formal quality improvement objectives and targets 
• Clear performance criteria for feedback and coaching 
• Quality topics included in at least half of all-hands meetings 
• Collecting error prevention metrics 
 
PDA have aggregated these results and other content related to quality culture and 
launched a website dedicated to the topic, PDA Quality Culture – PDA Resources for 
Developing a Mature Quality Culture (PDA, no date). 
 
ISPE published a Cultural Excellence Report in 2017 (ISPE, 2017) describing quality 
culture as follows (bold added for emphasis by the researcher):  
 
Quality culture is a feature of organisational design that fosters cross-functional 
ownership of quality. It treats quality not as a hindrance for success, but as a 
necessity that allows the company to make decisions that best benefit patients 
…Quality culture refers to the expressed and implied ways in which an 
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organisation operates, affects quality performance and supply chain 
excellence, and ensures patient-focused outcomes. 
 
From these three sets of insights (i.e., from CEB, PDA and ISPE), there appears no evident 
singular definition of quality culture, but clear themes emerge, including visible 
leadership commitment, the omnipresence of quality outcomes in all actions, the 
active engagement of all staff, and of the importance of related mindsets, attributes 
and cultural enablers.   
 
9.2 Attributes of a culture effective in managing knowledge 
To understand what a culture effective in managing knowledge could look like (i.e., a 
knowledge culture), the researcher also found it was helpful to start by understanding 
cultural issues that act as barriers to use and adoption of knowledge management and 
their impact to the RKI Cycle.  Literature on barriers to KM was also reviewed.   
 
9.2.1 Cultural attributes that act as barriers to KM in the pharmaceutical industry 
The Knoco Survey on Knowledge Management 2020 (Knoco, 2020) included a question 
on barriers to KM.  Cultural issues was one of eight choices given, and it ranked as the 
highest barrier to KM, with more votes for it than for lack of prioritisation and support 
from leadership, lack of KM incentives, lack of KM roles and accountabilities, lack of 
defined KM approach, and three additional barriers.  Similarly, in the pharmaceutical 
industry-specific KM implementation survey published by ISPE in May 2020 (Kane et al., 
2020), cultural issues also ranked as the top barrier, tied with lack of prioritisation and 
support from leadership, from a list of the same potential barriers.   
 
Both surveys went a step further and also asked a question on specifically which cultural 
issues have proven to be barriers from 10 provided choices.  The choices of cultural 
issues as barriers were the same in both surveys.  Table 9-2 created by the researcher 
summarises the top five cultural issues from each of the two surveys. 
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Table 9-2 – Top cultural issues as barriers to KM 
Barrier Rank Knoco Survey (Knoco, 2020) ISPE Survey (Kane et al., 2020) 
1 Short term thinking* Short term thinking* 
2 Lack of openness to sharing* Lack of performance drive 
3 Secrecy Lack of acceptance of new ideas 
4 Lack of challenge to the status quo Lack of honesty in sharing 
5 Lack of empowerment Lack of openness for sharing* (tie) 
Preferring invention to reuse (tie) 
*Items in bold were identified as top 5 barriers in both surveys 
 
Only the top five barriers were selected (of 10 total choices) to allow for simple 
prioritisation, and there was also an evident gap between the barrier five and the next 
highest-ranked barrier in both surveys, which supports this rationale.  On review of the 
results, short-term thinking is a clear cultural issue, ranking as the top barrier in both 
surveys.  Lack of openness to sharing is the other cultural issue that ranked in the top 
five of both surveys. Selecting these two barriers and for the purpose of this research, 
the additional barriers from the ISPE survey with its specific focus on the pharmaceutical 
industry, a prioritised list of six cultural issues facing KM in the pharmaceutical industry 
is proposed as follows: 
 
• Short term thinking 
• Lack of openness for sharing 
• Lack of performance drive 
• Lack of acceptance of new ideas 
• Lack of honesty in sharing 
• Preferring invention to reuse 
 
Furthermore, the researcher in his professional experience has witnessed each of these 
cultural issues as barriers to KM; with this in mind, the next section explores the impact 
these six cultural issues can have on adopting the RKI Cycle.   
 
9.2.2 The impact of cultural issues on the RKI Cycle 
Considering the overarching goal of the RKI Cycle is to connect the disciplines of QRM 
and KM to ensure the best possible knowledge supports the best possible risk-based 
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decision, one can immediately see by mapping the six cultural issues onto the RKI Cycle 
how they can be barriers to supporting optimal QRM and KM (Figure 9-1). 
 
 
Figure 9-1 – Cultural issues as threats to the RKI Cycle (illustrative) 
 
Although each cultural issue is likely to impact multiple steps of the RKI Cycle, Figure 
9-1 highlights illustrative examples.  For example, at RKI Cycle node 3, if short-term 
thinking is prevalent, knowledge associated with risks and through their risk 
assessments may not be captured optimally for future reuse.  Short-term thinking has 
also been identified as a cultural barrier for effective KM (node 5) and can impact 
capturing sufficient context for future use during QRM (node 2).  Lack of a performance 
drive will impact continuous improvement at node 6.  If there is lack of openness or 
honesty in sharing, the best available knowledge of the organisation certainly is not 
flowing into QRM activities (nodes 1 and 2).   
 
These cultural issues almost certainly impact QRM and other processes as well.  The 
culture of an organisation – which starts with values and manifests in mindsets and 
behaviours – is not confined to KM alone, but is rooted across many, if not all, processes 
within an organisation.   
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9.2.3 Cultural attributes that are supportive of KM in the pharmaceutical industry 
When exploring cultural attributes that are supportive of KM, a literature review 
revealed insights into the meaning of a ‘knowledge culture’.  Oliver and Kandadi (Oliver 
and Reddy Kandadi, 2006) on a study of literature propose the following definition of 
knowledge culture:   
 
A way of organisational life that enables and motivates people to create, share 
and utilise knowledge for the benefit and enduring success of the organisation. 
 
Oliver and Kandadi then identified 10 factors which influenced the development of 
knowledge culture in large, distributed organisations as follows: 
 
1. Leadership 
2. Organisational structure (to include knowledge management roles (as opposed 
to knowledge management jobs)) 
3. Evangelisation (of the value of knowledge management activities to employees) 
4. Communities of practice 
5. Reward systems 
6. Time allocation 
7. Business processes (through embedding knowledge management in important 
knowledge intensive processes) 
8. Recruitment (through consideration of knowledge sharing etiquette of potential 
employees) 
9. Infrastructure (e.g., knowledge portals) 
10. Physical attributes (e.g., office layout) 
 
The researcher found the proposed definition insightful, although in the opinion of the 
researcher, the factors, while entirely valid, are more ‘physical’ or ‘environmental’ than 
behavioural-based.  Milton and Lambe (Milton and Lambe, 2016) proposed a model 
consisting of 10 dimensions to an organisational learning and knowledge management 
culture summarised by the researcher in Table 9-3.  Dimension 1 (supportive) is 
associated with learning culture and knowledge-valuing behaviours (e.g., open), and 
Dimension 2 (detracting) represents the antonym (e.g., defensive).  
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Open  Defensive 
The extent to which people feel comfortable having their 
performance (including mistakes) analysed for learning 
purposes. 
Honest  Dishonest 
The extent to which people will filter knowledge and 
information when communicating with peers or senior 
leaders; sometimes known as ‘transparency’. 
Empowered Disempowered The extent to which people feel able to act on knowledge, independent of approval from their leaders. 
Learner Knower The extent to which people put a value on acquiring new knowledge. 
Need to share Need to know The extent to which people offer their knowledge to others rather than keeping it secret. 
Challenge Acceptance 
The extent to which people seek to understand why things 
are the way they are; about intellectual curiosity and 
challenge the status quo. 
Collaborative  Competitive The extent to which people identify with and share in the success of others. 
Remembering  Forgetting 
The extent to which people acknowledge and incorporate 
the past when making plans for the future and the extent to 
which they consciously record decisions, judgments, 
knowledge, etc. for future reference.  
Strategic 
patience Short-termism 
The extent to which people consider the ‘bigger picture’ and 





Complacency The extent to which organisations acknowledge there is always room for improvement.   
 
Finally, ISO 30401 Knowledge management systems – Requirements addresses 
knowledge management culture in Annex C (ISO, 2018) as follows: 
 
Knowledge management culture is a supportive element of the organisational 
culture. A culture where the behaviours of seeking, sharing, developing and 
applying knowledge are encouraged and expected supports the establishment 
and application of the knowledge management system within the organisation. 
There is also a personal dimension to a knowledge management culture, where 
ultimately each individual has responsibility to demonstrate commitment 
through their own behaviour and interactions. A knowledge management 
culture acknowledges the value of individual and shared knowledge, as it 
benefits the organisation. 
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These insights were considered in the following section in the development of a 
proposed ideal knowledge culture for the pharmaceutical industry.   
 
9.3 A proposed ideal ‘knowledge culture’ for the pharmaceutical industry 
The researcher, having reflected on a philosophical dialogue with a senior leader 
responsible for pharmaceutical product commercialisation, proposed a knowledge 
culture must be engrained in an organisation much like that of a safety mindset:  safety 
is everyone’s responsibility, not just those who report into the safety organisation.  The 
same analogy holds true for quality and should also be adopted for managing 
knowledge.  Ensuring safety in everything one does, building in quality, and managing 
knowledge are each ways of working, formed by how people think and act (i.e., 
mindsets and behaviours) in the organisation, which is a key component of an 
organisational culture.  Furthermore, these ways of working are not unique to safety, 
quality, or managing knowledge but can be synergistic with each other.  For example, 
using KM processes to reflect after a safety incident or connecting quality risk 
management practitioners in a community of practice built on KM best practices.  In the 
opinion of the researcher, it is the convergence of these ways of working where 
organisations can create clarity for their staff in how they are expected to act on a daily 
basis, rather than having distinct sets of behaviours across many topics (e.g., safety, 
quality, knowledge management, diversity & inclusion, operational excellence, etc.). 
 
The researcher explored how the convergence of these ways of working could evolve 
by applying the insights gained in the previous sections, including the definition of 
quality culture (section 9.1), the top cultural issues facing knowledge management 
(section 9.2.1), the literature review on knowledge culture (section 9.2.3), and the 
researcher’s professional experience.  A formative definition of knowledge culture was 
proposed as follows: 
 
A knowledge culture is one that demonstrates excellence in applying the best 
knowledge through an inherent bias to continuously reflect, learn, improve, 
share, grow, and transfer knowledge in order to positively affect quality 
performance, supply chain excellence, and ensure patient-focused outcomes. 
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This definition covers the what and the why of a knowledge culture.  How such a 
knowledge culture might be achieved can also be benchmarked from the recurring 
themes in the definitions of quality culture, described through four attributes as follows: 
 
• Visible leadership commitment to establish a vision, set expectations, and to 
create organisational alignment. 
• Managing knowledge as a way of working is linked to the organisation’s 
strategic objectives, delivering value in quality, operational benefits, and 
organisational and individual development opportunities.  
• Active engagement of all staff, through application of organisational change 
management techniques. 
• Well communicated mindsets and behaviours (as informed by the top cultural 
issues identified in section 9.2.1), reinforced by reward systems 
o Big picture thinking 
o Seeking and sharing ‘by default’ 
o Pursuit of excellence (including to pause, reflect and learn) 
o Embracing inclusion and innovation  
o Leading with transparency 
o Managing knowledge as an asset 
 
An early illustration of this knowledge culture proposal is given below in Figure 9-2. 
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This proposal of a knowledge culture is preliminary in nature and is based on two key 
assumptions:  the validity of the definition of a quality culture and the accuracy of the 
cultural barriers facing KM in the pharmaceutical industry.  Further insight will be gained 
as the industry advances in quality culture and these learnings in what quality culture is 
and how it is achieved can inform the journey on knowledge culture.  In regard to 
advancing the understanding of the cultural barriers to KM, this could be through 
additional data gathering (e.g., surveys) as well as feedback during application of the 
RKI Cycle and other outputs of this study.  
 
Lastly and most importantly, any such knowledge culture needs to be adapted to fit the 
specifics of an organisation, including alignment with the mission of the organisation 
and consideration of the current organisational culture.  Although well-suited for this 
study, this is certainly a topic which warrants further research.   
 
9.4 Summary – A proposed ‘knowledge culture’ for the pharmaceutical 
industry 
Imagine an organisation where such a knowledge culture exists and can bring to bear 
the power of the collective knowledge of the entire organisation to innovate, solve 
problems, and make the most informed risk-based decisions.  Indeed, such a culture 
would be a catalyst for RKI Cycle adoption and acceleration of its impact.   Patients, as 
stakeholders of the product produced by the industry should not expect any less, 
especially as they await innovative new therapies for unmet medical needs or face 
product availability issues for critical therapies they depend on.   
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Part Four:  Outcomes and Impact, Conclusions, and Opportunities 
for Future Research 
 
Part Four brings this research study thesis to a close by: 
• Examining outputs, outcomes and impact (Chapter 10) 
• A review of conclusions drawn from the research findings (Chapter 11) 
• Presenting opportunities for future research (Chapter 12) 
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Chapter 10:  Outputs, Outcomes, and Impacts of this Research 
Study 
 
The purpose of this chapter is to describe the outputs, outcomes, and impacts of this 
research study (where applicable and known at the time of writing this thesis) as related 
by Figure 10-1 (UCD, no date).   
 
 
Figure 10-1 – The link between inputs and impacts (UCD, no date) 
 
The approach at the outset of this study was to regularly consult and seek opinions and 
insights of various stakeholders across the pharmaceutical sector with the research 
activities to ensure the research was focused on problems that ultimately have an 
impact to the patient.  This approached worked well for this study.   
 
This study used a mixed methods approach and resulted in a series of outputs, the 
majority of which were disseminated in peer-reviewed papers and discussed in previous 
chapters of this thesis.  These outputs include: 
 
• Knowledge Management Process Model (Chapter 4) 
• RKI Cycle (Chapter 5) and related contexts and concepts derived from this 
framework (e.g., RKI Cycle as applied to ICH Q10) (Chapter 5 and Chapter 8)  
• KTE Framework and KTE Toolkit (Chapter 7), including the related outcomes of: 
o A current state assessment of knowledge transfer during technology 
transfer (Chapter 6) 
o Processes for tacit knowledge transfer (Chapter 7) 
• Case studies for extending the RKI Cycle and mapping KM methods and tools 
across the product lifecycle (Chapter 8) 
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These outputs were disseminated in many fora through a variety of methods (e.g., 
papers, presentations, direct dialogue, formal/informal interviews, etc.) with sector 
stakeholders through an equally diverse set of channels (e.g., industry groups, advisory 
boards and committees, etc.), as illustrated in Figure 10-2. 
 
 
Figure 10-2 – Methods and channels of study dissemination 
 
This approach has resulted in a high level of interaction with sector stakeholders on 
most every facet of this research study, allowing immediate outcomes and impacts of 
the study to be observed.  Perhaps as a consequence of this approach, the research 
study and associated outputs have generated noteworthy media attention in recent 
months.  The first example is from the EU-based GMP Verlag Peither AG, who publishes 
GMP news for the industry and featured the researcher’s 2021 PDA Annual Meeting 
presentation (Lipa, 2021a) in a feature titled Innovations in Pharmaceutical 
Manufacturing (Peither, 2021).  This GMP Newsletter article featured only 4 of the 38 
presentations given at the conference.  The second and perhaps more significant media 
attention was that from International Pharmaceutical Quality (IPQ), entitled Regulators 
Are Exploring with Industry How to Strengthen Quality Risk Management Practices, with 
Revision of ICH Q9 a Key Focal Point (IPQ, 2021).  One part of this article was entitled 
Industry / Academia Research on QRM/KM Relationship which featured several key 
outputs from this research study, including the RKI Cycle and KTE Framework.   
 
• Total papers (as lead author):  10
• Peer-reviewed journal articles:  6
• Additional papers (case studies & survey reports): 4
• Works as a co-author:  3
• Conference presentations:  6
• Book Chapter:  2
• Panelist:  7
• Poster Session:  1
• Podcast & Webinar*:  2
• Industry Guidance: 2
• Guest lectures (Columbia + TU Dublin):  2
• Advisory Board invitation:  PDA Regulatory Affairs & 
Quality Advisory Board:  1








• PIC/S QRM Expert Circle Coordinating 
Committee
• Technological University Dublin
• Columbia University
• Interviews (regulatory authorities, industry 
leaders & SMEs)
• TU Dublin PRST
Channels of research dissemination
(with whom research was disseminated)Methods of research dissemination
*Webinar is scheduled for 20-May-2021
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To demonstrate the significant outcomes and impacts, the researcher grouped them 
into five major themes, recognising the themes are not mutually exclusive and some 
overlap exists.  Furthermore, any given output may affect more than one theme.  These 
five themes are as follows: 
1. A framework to address the untapped synergy between QRM and KM 
2. Inaugural industry guidance on KM from a premier industry association 
3. A comprehensive framework and toolkit for knowledge transfer during 
technology transfer, inclusive of tacit knowledge 
4. A mechanism for data analytics to grow knowledge and reduce risk 
5. Impact across the entire PQS 
 
The outputs of the research grouped under these themes are discussed in the following 
sections of this thesis, with associated outcomes and impacts, as applicable and known.   
 
10.1 Theme 1:  A framework to address the untapped synergy between QRM 
and KM 
Arguably the most exciting outcome of this research study is the progress on the 
relationship between QRM and KM, perhaps already of seminal importance given the 
preliminary response from stakeholders across the pharmaceutical sector.  This focus 
on the QRM-KM intersection marked novel research for the industry in moving beyond 
the concepts presented in ICH Q10 to look more holistically across the regulatory 
guidance landscape at the relationship between knowledge and risk, and knowledge 
management and risk management.  A key finding as explored in Chapter 5 was that 
there is near universal agreement that QRM and KM are highly interdependent yet 
there was broad agreement that they are only partially connected at best.  This suggests 
there is an important gap to be filled to show how QRM and KM co-enable the PQS and 
lead to the best possible risk reduction for patients.  In response to this, an output of 
this research is a framework, the RKI Cycle (Figure 5-6), which illustrates the relationship 
between risk and knowledge and demonstrates how QRM and KM are connected.  As 
detailed in Chapter 8, outcomes of this framework are presented as examples and case 
studies which illustrate the broad applicability and importance of the RKI Cycle across 
the product lifecycle, and to the four elements of the PQS (e.g., change management, 
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etc.) proposed in ICH Q10 (ICH, 2008).  The RKI Cycle was published in a peer-reviewed 
journal and was considered to be a significant contribution and of enough importance 
to potential stakeholders, that a regulator successfully petitioned the journal to allow 
open access to the paper to ensure broad global reach and dissemination.  It was further 
made available openly with permission from the peer-reviewed journal through the TU 
Dublin Level3 journal (Lipa, O’Donnell and Greene, 2020b). 
 
This framework has been greeted with great interest and support across the 
pharmaceutical sector.  One example of this is found in the results of a survey (Lipa, 
O’Donnell and Greene, 2021) to industry and regulators33, summarised in the following 
points: 
 
• When asked if the RKI Cycle was helpful as a means of depicting the relationship 
between QRM and KM 84% agreed the framework was helpful, and only 9% 
disagreed. 
 
• When asked “Would you support deploying such a framework within your 
organisation, in pursuit of better integration of QRM and KM?”, 92% of industry 
respondents answered Yes, while 0% answered No (8% answered Not sure). 
 
• When regulators were asked “Can you envisage companies deploying this 
framework within their organisations?” 83% of regulators answered Yes, while 
0% answered No (17% answered Not sure). 
 
• When asked to identify and rank benefits (impacts) of improved QRM-KM 
integration, there was acknowledgement that many important benefits could 
follow.  Table 10-1 lists the top five potential benefits of improved QRM-KM 
integration identified by each industry and regulator participants.  The top two 
ranked items (in bold) were aligned across both sets of participants.   
 
 
33 The ‘regulator’ responses cited in the survey report represent the opinions of six members of the 
PIC/S QRM Expert Circle Coordinating Committee as of 21-February-2021, and do not represent the full 
view of the Coordinating Committee nor of the wider PIC/S organisation. 
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Table 10-1 – Top ranked potential benefits (impacts) of RKI Cycle 
Rank 
Top 5 Benefits (impacts) identified by 
industry participants 
Top 5 Benefits (impacts) identified by 
regulator participants 
1 
Better risk-based decisions –where 
decisions are informed by risk and 
knowledge 
Better risk-based decisions –where 
decisions are informed by risk and 
knowledge 
2 
More data/knowledge-driven risk 
assessments 
More data/knowledge-driven risk 
assessments 
3 
Increased ability to leverage off of prior 
knowledge 
Improved PQS effectiveness –where an 
integrated approach to risk and 
knowledge supports decision making, 
validation, change management, out-
sourcing, etc. 
4 
Improved control strategies –which 
better reflect risk and knowledge 
Improved protection and value for 
patients –reduced risks of defects, drug 
shortages, etc. 
5 
Improved PQS effectiveness –where an 
integrated approach to risk and 
knowledge supports decision making, 
validation, change management, out-
sourcing, etc. 
A better ability to deal with advances in 
manufacturing which utilise big-data, 
automation, artificial intelligence, etc. 
 
• When asked about improvement opportunities of the RKI Cycle, the main 
suggestion was the interest in more detail through examples, case studies, etc.  
 
• Open-ended feedback was solicited and was generally supportive, in alignment 
with the preceding highlights.  Illustrative open-ended comments include: 
o It is a simple and very useful graphic of the inverse relationship between 
risk and knowledge. 
o This Infinity loop is intuitive, easy to comprehend, and logical. 
o It visually clarifies the interdependency of both QRM and RM. 
o The linkage is [quite] clear to me. Knowledge informing risk and risk 
informing knowledge as a continuous process makes great sense. 
o KM is not well in practice today as compare to QRM could be a reason for 
just partial integration. 
o It explains very clearly how they are related and need to stay connected 
through long lifecycle in a constant state of learning and inertia. 
o Great work that will catalyse new thinking in this important area.  
 
Perhaps the most important impact will be the opportunity the RKI Cycle presents to 
improve QRM-KM integration.  While the effort to apply the RKI Cycle has commenced 
and is discussed in Chapter 8, the researcher recommends additional stakeholder 
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guidance be developed to support implementation and move more quickly towards 
patients fully reaping the benefits of this important output. 
 
In addition to the results of the survey, evidence of the RKI Cycle’s immediate influence 
on industry stakeholders can be seen through interactions by the researcher with 
multiple industry associations as follows: 
 
• The RKI Cycle is one of many outputs of this thesis featured in the ISPE Good 
Practice Guide for Knowledge Management in the Pharmaceutical Industry (ISPE, 
2021b) as described in section 10.2.  Furthermore, the RKI Cycle is featured as 
an element of the ISPE Guide cover artwork, which underscores the importance 
as viewed by industry KM SMEs authoring the ISPE Guide. 
 
• The researcher presented several elements of this research study at the 2021 
PDA Annual Meeting (Lipa, 2021a).   This sparked significant interest from PDA, 
including a request to re-broadcast the recorded presentation to other 
geographic regions.  Most notably, the PDA Regulatory Affairs and Quality 
Advisory Board (RAQAB) requested the researcher to attend the April 2021 
board meeting to brief the board on the research and propose how PDA might 
advance the topic of KM for their membership.  The researcher obliged, and 
provided a briefing (Lipa, 2021b).  The main outcome of the PDA RAQAB meeting 
was that the board better understood KM and its criticality to QRM, and as a 
direct result of this briefing, PDA RAQAB is currently in the process of proposing 
a Task Force to develop a ‘long range plan’ for KM, of which the researcher has 
already been invited to participate (and possibly lead).  A key deliverable of such 
a Task Force is likely to include a Technical Report on Knowledge Management 
(i.e., an additional industry guidance document).   
 
• The RKI Cycle has also been cited by the recently published Pharmaceutical 
Manufacturing Technology Centre (PMTC) Guide to Data Analytics for 
Pharmaceutical Manufacturing (PMTC, 2020), given its relevance to translating 
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information from data analytics into knowledge and applying this knowledge to 
reduce risk. 
 
A final point of relevance for the RKI Cycle was made by Dr. Edward Hoffman, retired 
Chief Knowledge Officer from NASA.  Dr. Hoffman participated in the Confirmation 
Examination for the researcher in November 2020.  During the discussion following the 
confirmation exam, Dr. Hoffman provided supportive feedback for this model and 
acknowledgement of the underlying challenges in connecting risk management and 
knowledge management based on his experiences at NASA.  Dr. Hoffman remarked: 
 
I love the model – I love the connection between risk and knowledge.  I’ve always 
seen it.  It’s essential.  For 20 years I’ve been stunned by the lack of connection 
between QRM and knowledge, and partly is that there are so many silos in 
organisations. 
 
These insights by Dr. Hoffman were important as they verified the fundamental 
underlying assumption of the importance of connecting risk and knowledge, and 
furthermore that Dr. Hoffman had witnessed similar challenges in another highly 
technical and complex industry.   
 
The strong interest, supportive feedback, and potential for significant impact of the RKI 
Cycle appears evident through these early reactions across the sector stakeholders, 
even though the RKI Cycle was published barely six months prior to the submission of 
this thesis.  The researcher is delighted with this response and the dialogue it has 
created within the sector.  Future work is planned and will be discussed in Chapter 12.   
 
10.2 Theme 2:  Inaugural pharmaceutical industry guidance on KM from a 
premier industry association 
Perhaps the most visible, tangible, and immediate outcome of this research is the 
inclusion of significant elements of it in an upcoming pharmaceutical industry guidance 
document on knowledge management from a premier industry association, ISPE.  ISPE 
‘is the world’s largest not-for-profit association serving its members by leading 
scientific, technical, and regulatory advancement through the entire pharmaceutical 
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lifecycle’ (ISPE, 2021a).  ISPE has over 18,000 members in 90 countries (ISPE, 2021c) and 
produces industry guidance documents as characterised by the ISPE website (ISPE, 
2021d):   
 
Produced by pharmaceutical manufacturing industry professionals, ISPE 
Guidance Documents provide the practical, "real world" information you need to 
help your company build on current best practices to meet and exceed regulatory 
standards…Reflecting current regulatory expectations and best practices, Good 
Practice Guides (GPGs) help to narrow interpretation of regulatory standards for 
improved compliance and quality, efficiency, and cost reductions. They typically 
focus on the “how”. 
 
These guidance documents are created through a robust process including authorship 
by a team of SMEs, industry review and feedback, and internal ISPE processes for quality 
control.  This new guidance document, ISPE Good Practice Guide, Knowledge 
Management in the Pharmaceutical Industry, was published in May 2021 (ISPE, 2021b).  
As mentioned in Chapter 4 (section 4.1,) the researcher was a member of the team of 
SME authors of this ISPE Guide on KM, comprised of 10 industry SMEs on knowledge 
management.   
 
While the overall guide itself was not a direct output of this research, this research study 
significantly informed and shaped the ISPE Guide and was instrumental in addressing 
industry feedback.  In particular, the Knowledge Management Process Model, an output 
of this research introduced in Chapter 4 of this thesis (Figure 4-2), plays a central role in 
the ISPE Guide and is featured as a standalone chapter in the Guide (Chapter 4).  
Consistent with the intent of the ISPE Guide, this Knowledge Management Process 
Model provides a previously missing ‘how’ to facilitate understanding and application 
of KM.  In all, a total of seven outputs from this research study are featured in the ISPE 
Guide, as listed in Table 10-2. 
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Table 10-2 – Thesis outputs used by ISPE Good Practice Guide:  Knowledge Management 
ISPE Guide 
Reference Reference to output from this thesis 
Figure 2.3 
Section 2.1.3 Figure 5-5 – Decreasing risk though increasing applied knowledge over time 
Figure 4.1 
Section 4.1 Figure 4-2 – Knowledge Management Process Model 
Figure 5.4 
Section 5.2.2 




Table 8-1 – Stage-appropriate KM methods & tools across the product 
lifecycle 
Figure 11.1 
Appendix 5 Figure 5-6 – The Risk-Knowledge Infinity Cycle applied to ICH Q10 
Figure 14.1 
Appendix 8 Figure 7-1 – The KT
E Framework on a page * 
Figure 14.2 
Appendix 8 Figure 7-2 – Technology Transfer Batch Execution Review 
*A simplified version was used in the ISPE Guide, this version is available in the PDA article (Lipa, Greene 
and Calnan, 2021) 
 
Throughout the development of the Guide, it was not the researcher’s intention to self-
advocate or ‘market’ use of these outputs.  Rather, as some on the ISPE SME author 
team were aware of the ongoing research effort and research progress was being 
regularly published, these inclusions were typically a ‘pull’ from the ISPE SME author 
team members and were subsequently vetted through the full ISPE SME author team 
and industry review processes34.  During the review process, 258 comments were 
received from 27 pharmaceutical industry and health authority representatives and 
addressed by the SME author team.   
  
These outputs used by the ISPE Guide cover a broad scope from this thesis, lending 
further credibility and visible endorsement of this research study.  The publishing of the 
ISPE Guide will immediately make these outputs broadly visible and available to the 
industry where its impact will become apparent over time. 
 
 
34 ISPE Guides go through a robust guidance document process involving pharmaceutical industry 
professionals. The Guides are authored by pharmaceutical industry representatives and subject matter 
experts (SMEs).  Once authored, Guides are reviewed and approved by pharmaceutical industry 
representatives in the same subject matter but not the group who authored the Guide. (ISPE, 2021d) 
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10.3 Theme 3:  The first comprehensive framework and toolkit for knowledge 
transfer during technology transfer, inclusive of tacit knowledge 
This research study started with an initial focus on improving knowledge transfer during 
technology transfer, in particular of tacit knowledge transfer, and one of the first 
outputs of the research was a framework for enhanced knowledge transfer, the KTE 
Framework.  The research study started with the characterisation of the current state 
of knowledge transfer during technology transfer.  The results of this assessment, 
published in a peer-reviewed paper (Lipa, Kane and Greene, 2019), verified that there 
is little guidance for knowledge transfer overall, and almost none for tacit knowledge 
(inclusive of ‘know-how’), leading to explicit knowledge transfer being only marginally 
effective, and tacit knowledge as being somewhat ineffective.  This paper subsequently 
received recognition as the IVT 2020 Author of the Year Award (IVT Network, 2020), a 
testament to the interest in and relevance of the topic. 
 
The subsequent development of the KTE Framework (Figure 7-1), as detailed in Chapter 
7, led to several meaningful interactions with stakeholders, including feedback sessions 
with several pharmaceutical companies and a presentation at the 2020 PDA Europe 
Quality & Regulations Conference (Lipa, 2020a) where the research insights on 
technology transfer and knowledge transfer were shared.  This presentation was well 
received and triggered a request by the PDA SME team authoring a revision to PDA 
Technical Report No. 65, Technology Transfer (PDA, 2014b) to solicit input for the PDA 
Technical Report from the researcher on knowledge transfer.  The revision of this PDA 
Technical Report was being planned in 2019 and was a subject of the researcher’s 
critique during the literature review, as detailed in Chapter 2 (section 2.3.2).  The 
researcher used this opportunity to influence the revision to the PDA Technical Report, 
providing several comments for consideration, with a focus on improving knowledge 
transfer and the recognition of tacit knowledge.  This PDA Technical Report is still in 
revision as of the date of this thesis, so the extent to which these comments are 
incorporated is not yet known.   
 
Also related to knowledge transfer and of great interest to the researcher is the subtopic 
of tacit knowledge transfer.  To this end another output of the study was the design and 
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deployment by the researcher of new KM practices to focus on tacit knowledge transfer 
as discussed in Chapter 7 (section 7.2) of this thesis. The results – captured as a case 
study (Lipa, Kane and Greene, 2020) – are promising as they are shown to drive 
proactive interventions and a significant reduction in deviations in the quality system 
for the company involved in the case study.  The impact of this was an immediate and 
direct reduction of risk and improvement in right-first-time qualification batch 
execution.  This in turn benefited patients as this vaccine product was designated a 
breakthrough therapy35 by the FDA, and successful on-time qualification meant patients 
would have access to an important new therapy more quickly.  Furthermore, there were 
benefits to the company in the form of meeting cost and schedule commitments (as 
well as avoiding reputational risk if delays were encountered).  
 
Lastly, a late-breaking development for this research study is an unsolicited case study 
of KTE Framework application.  Upon reading the peer-reviewed article in the PDA 
Journal of Science and Technology in which the KTE Framework was published (Lipa, 
Greene and Calnan, 2021), a team from a Singapore manufacturing facility who had 
previously been a receiving unit in a technology transfer created a matrix36 based on 
their challenging experience with a technology transfer as shown in Figure 10-3.   
 
 
35 Breakthrough Therapy designation is a process designed to expedite the development and review of 
drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the 
drug may demonstrate substantial improvement over available therapy on a clinically significant 
endpoint(s). (https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-
priority-review/breakthrough-therapy)  
36 The matrix in the figure has been anonymised to blind the identity of the organisation and the 
associated product. 
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Figure 10-3 – A gap assessment against the KTE Framework (case study) 
 
The green boxes in Figure 10-3 (‘Gap Category’ as per included legend) depict the 
knowledge transfer challenges identified by the researcher (e.g., knowledge leakage, as 
detailed in Chapter 6, section 6.2.1).  The blue boxes in Figure 10-3 (‘Principles’ as per 
included legend ) depict the high-level requirements identified by the researcher (e.g., 
KT is guided by an intentional and robust plan, as detailed in Chapter 6, section 6.2.2).  
Figure 10-4 highlights these linkages (in green and blue boxes respectively), mapped 
back to the detailed requirements for a knowledge transfer framework as defined in 
Chapter 6 (section 6.2.2), Figure 6-3. 
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Figure 10-4 – Mapping of KTE Framework case study to knowledge transfer framework 
requirements 
 
The Singapore manufacturing site contacted the researcher directly, as the researcher 
was the corresponding author with contact details listed on the published paper.  As the 
KTE Framework was published only two months prior to this contact, this is clear 
evidence of the research having an immediate, direct, and global impact on how people 
view knowledge transfer during technology transfer.  This is especially true as this case 
study identified clear issues which demonstrate the need for why the framework was 
created.  The team in Singapore indicated to the researcher that they plan to develop a 
knowledge management playbook for technology transfer based on the KTE Toolkit, 
aligned with the researcher’s intended use.  
 
As these examples demonstrate, the KTE Framework and associated KTE Toolkit as 
outputs from this research study have already demonstrated tangible outcomes and 
impact, including:  
 
• Increased awareness of the current issues with knowledge transfer and its 
effectiveness, including looking at technology transfer through a knowledge 
transfer lens 
• Improvements in quality and right-first-time outcomes through new tacit 























































(1) Narrow Focus on the “golden 
batch” 
(2) Knowledge transfer is heavily 
biased toward documents, while 
tacit knowledge is not 
methodically transferred 
(3) Knowledge leakage as valuable 
experience and learnings not 
captured, recognized or 
considered relevant 
(5) Knowledge leakage through 
loss of staff experience 
(4) Knowledge leakage due to lack 
of structured and standardized 
knowledge management 
approaches 
(6) Context of the technology 
transfer causing obstructed 
knowledge flow 
Challenges
more specific problem statements
Ineffective Knowledge Transfer 
during Technology Transfer 
(both explicit and tacit 
knowledge)
Problem Statement
Knowledge exists (it was created to begin with)
Knowledge leakage is minimized through systematic 
knowledge capture
Knowledge is identified (a ‘known known’)
A holistic plan for knowledge transfer
Change recognized as a risk & learning opportunity
Plan to capture / grow knowledge
Knowledge leakage minimized through standard KM 
approaches
Standard KM processes followed
Standard KM processes are effective
Barriers / obstruction to knowledge flow recognized
KM processes ‘in the flow’ of work
Organizational pressure / motivations recognized
Capability & Competency of Receiving Unit known
Mindsets & behaviors for managing knowledge
Tacit knowledge is recognized as important
Knowledge leakage is minimized through retention of 
critical knowledge
Detailed Requirements for a Knowledge Transfer Framework
(I) Knowledge Transfer is guided by 
an intentional and robust plan
(IV) Tacit knowledge is uncovered 
and transferred during technology 
transfer
(II) Knowledge Transfer is best 
enabled by a culture that values 
knowledge as an asset
(III) Standardized approaches for KM 
are established both for explicit and 
for tacit knowledge
(V) Knowledge transfer is measured 
and results in an action plan to 
address gaps and opportunities
High Level Requirements
Drivers for effective Knowledge Transfer
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• Influence on an additional industry guidance document (PDA Technical Report 
No. 65, Technology Transfer (PDA, 2014b)) 
 
10.4 Theme 4:  A mechanism for data analytics to grow knowledge and reduce 
risk 
Preliminary research into the link between data analytics and KM marks another area 
of novelty in this research study.   As described in Chapter 8 (section 8.3), the RKI Cycle 
can act as a mechanism to connect data analytics to risk reduction.  Currently the topic 
of linking data analytics (a topic receiving significant attention recently due to the focus 
on digital transformations in industry (CIO, 2018)), to KM and to QRM has not been well 
defined.   
 
The PMTC Guide to Data Analytics for Pharmaceutical Manufacturing (PMTC, 2020) 
states: 
 
data & analytics are central to informing quality systems … Data and data 
analytics are drivers for knowledge and knowledge generation, and can support 
KM and QRM systems, which should better inform risk management activities.  
 
The description for Figure 6.1 from the PMTC Guide (PMTC, 2020) (Item A in Figure 10-5) 
includes:  
 
[Figure 6.1] highlights the quality systems and regulatory guidelines that enable 
a state of control to be maintained during the product manufacturing lifecycle … 
the figure shows data and data analytics as central to informing these quality 
systems, which can provide even greater opportunity to ensure the safety of the 
public health and patients. 
 
The researcher, during his presentation at the launch of the PMTC Guide launch (Lipa, 
2020b), demonstrated how the RKI Cycle can provide the missing mechanism for the 
‘how’ to connect data and data analytics to KM and QRM to achieve these outcomes 
(Item B in Figure 10-5).  
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Figure 10-5 – RKI Cycle as a mechanism for data analytics to inform KM and QRM 
 
These concepts were well received and have initiated dialogue with PMTC for future 
cross-discipline research and connectivity.  This is an important topic for future research 
as will be presented in Chapter 12, which can also help further clarify the relationships 
between data, information, and knowledge.   
 
10.5 Theme 5:  Impact across the entire Pharmaceutical Quality System 
Another major outcome of this research study is the potential for broad application 
across the PQS, ‘top to bottom’ (i.e., across all PQS enablers and elements) and ‘end to 
end’ (i.e., across all PQS lifecycle stages).  Although this study started with a focus on 
technology transfer, it has reshaped the understanding of KM as a PQS enabler, engaged 
the practice of QRM to truly co-enable the PQS, proven the impact of improved 
knowledge management and knowledge transfer to the lifecycle stage of technology 
transfer, and has been mapped to demonstrate how many of these outcomes can 
extend to impact the entire product lifecycle.  Figure 10-6 captures the essence of this 
concept, where KM and QRM are interconnected to each other, directly to the PQS 
elements and applicable across the product lifecycle. 
 
?
RKI Cycle as a mechanism for 
data analytics to 
generate knowledge and 
enable risk reduction
A:  Figure 6.1 from PMTC Guide
B:  Alternate view proposed by researcher
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Figure 10-6 – A re-framed and united PQS foundation 
This holds exciting promise for the reach and significance of the RKI Cycle, warranting 
further research and further development of support materials (e.g., a training and 
application package).  
 
10.6 Summary of research study outputs, outcomes, and impacts 
Table 10-3 provides a summary of the five research impact themes with associated 
mapping of outputs, outcomes, and impacts, as defined in Figure 10-1 at the start of 
this chapter.  Note that several of the outputs (e.g., RKI Cycle) apply to more than one 
impact theme, as these outputs are not mutually exclusive to any single outcome or 
impact. 
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Table 10-3 – Mapping impact themes to outputs, outcomes, and impacts 
Impact Theme Outputs | Products of research Outcomes | Awareness and use of outputs Impacts | Consequences of people using outputs (*planned / future) 
1:  A framework to 
address the untapped 
synergy between QRM 
and KM 
• Various publications & presentations 
• Report:  QRM-KM current state 
integration 
• Framework:  RKI Cycle 
• Recognition within pharma sector that QRM & KM 
should be well connected but are not in practice 
• RKI Cycle verified beneficial, made publicly available 
• ISPE Good Practice Guide: Knowledge Management 
• PMTC Guide to Data Analytics for Pharmaceutical 
Manufacturing  
• PDA RAQAB evaluating a Task Force for KM 
• Media coverage by IPQ and GMP Verlag Peither AG 
• Better risk-based decisions* 
• Improved control strategies* 
• Improved PQS effectiveness* 
• Improved protection and value for patients 
(e.g., reduced risks of defects, drug shortages)*  
• A better ability to deal with advances in 
manufacturing which utilise big-data, 
automation, artificial intelligence, etc.* 
2:  Inaugural industry 
guidance on KM from a 
premier industry 
association 
• Various publications & presentations 
• Model:  Knowledge Management 
Process Model 
• Framework:  RKI Cycle 
• Framework:  KTE Framework 
• Case study:  Tacit knowledge transfer 
• ISPE Good Practice Guide: Knowledge Management • Better risk-based decisions, leading to improved 
patient value and safety* 
• Operational outcomes for organisations 
managing knowledge as an asset (cost savings, 
time savings, reduced risk, improved right-first-
time execution, more competent workforce)* 
3:  The first 
comprehensive 
framework and toolkit 
for knowledge transfer 
during technology 
transfer, inclusive of 
tacit knowledge 
• Various publications & presentations 
• Current state assessment:  Technology 
transfer KT effectiveness 
• Framework:  KTE Framework 
• Toolkit:  KTE Toolkit 
• Processes:  Tacit knowledge transfer 
• Case Study:  Tacit knowledge transfer 
• Increased recognition of poor knowledge transfer 
• ISPE Good Practice Guide: Knowledge Management 
• Case study:  Tacit knowledge transfer 
• Case study:  KTE Framework gap assessment 
• Further consideration of KM for PDA Technical 
Report No. 65, Technology Transfer 
• Media coverage:  IVT Author of the Year Award 
• Improved outcomes of technology transfer, 
including reduction of risk and fewer quality 
defects 
• Knowledge available during commercial 
manufacturing to support KM and QRM (e.g., 
better risk-based decisions and operational 
outcomes)* 
4:  A mechanism for 
data analytics to grow 
knowledge & reduce 
risk 
• Various publications & presentations 
• Framework:  RKI Cycle 
• Recognition as an area of future study with PMTC, 
with post-graduate research opportunities being 
explored 
• To be determined, but ultimately reducing risk 
through ensuring data analytics-driven insights 
are recognised as knowledge and made 
available through KM 
5:  Impact across the 
entire Pharmaceutical 
Quality System 
• Various publications & presentations 
• Framework:  RKI Cycle 
• Recognition of the broad applicability and centrality 
of the RKI Cycle to the PQS and opportunities to 
further develop RKI Cycle application packages 
• To be determined, but ultimately scaling impacts 
above across lifecycle for greater impact 
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There are likely additional outcomes and impacts to emerge from this research study, 
perhaps including: 
 
• Further application of the RKI Cycle, both across the lifecycle but also to other 
types of risk beyond quality risk, as the underlying relationship between 
knowledge and risk is not unique to quality.   The concepts of the RKI Cycle are 
broadly applicable to other types of risk, such as technical risk, supply chain risk, 
and financial risk.  
• The creation of additional KM frameworks for other stages of the product 
lifecycle, based on the principles defined in the KTE Framework. 
• The global pharmaceutical supply chain may be reshaped in the wake of the 
COVID-19 pandemic, in response to ‘re-shoring’ efforts driven by supply chain 
security concerns. This in turn could lead to a tidal wave of technology transfers, 
for which the KTE Framework could see accelerated uptake and relevance. 
• Subsequent refinement of the concept of knowledge culture for the 
pharmaceutical industry. 
• A notable approach to this research study is the systems thinking37 applied by 
the researcher, including focus on previously unstudied intersections between 
these related but distinct disciplines of KM, QRM, quality culture, and data 
analytics.  As such, this research study has also reached a diverse audience given 
the nature of this research and identified many opportunities for future 
research, as will be explored in Chapter 12. 
 
The researcher believes this research study has broad reach, as it has the potential to 
affect many in the pharmaceutical sector in how to manage knowledge to reduce risk 
and improve operational performance.  The research study outcomes are arguably 
significant since they have the opportunity to have a favourable impact on patient 
protection, as well as the already proven impact to increase quality and right-first-time 
 
37 Systems thinking as defined by Arnold and Wade is “a set of synergistic analytic skills used to improve 
the capability of identifying and understanding systems, predicting their behaviours, and devising 
modifications to them in order to produce desired effects.” (Arnold and Wade, 2015) 
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execution during technology transfer.  Furthermore, the researcher believes this study 
has ‘planted many seeds to germinate’ which will grow over the months and years 
ahead and deliver yet unknown outcomes and impacts.   
 
The following chapter presents a conclusion to this research study and includes a 
summary of the primary outputs mapped back to the relevant areas of the PQS to which 
they relate.  
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Chapter 11:  Conclusions to this Research Study  
 
The purpose of this chapter is to draw final conclusions for this research study.   
 
As stated in Chapter 1 (section 1.1), the overarching goal of this research study was to 
provide tangible benefit to the patient by improving PQS effectiveness through 
meaningful advancement of KM as a PQS enabler.  Stated simply, improving KM will 
improve the PQS effectiveness and corresponding product quality, and in turn providing 
important benefits to patients.   
 
On reflection of the research activities and outputs described in this thesis and as a 
means to summarise the research progression, the researcher created Figure 11-1 to 
illustrate the research study context as the starting point of this research and a 
roadmap of this research study.  The study roadmap illustrates the cascading 
requirements for the dual PQS enablers of QRM and KM.  Furthermore, the study 
roadmap includes the starting point for several levels of KM and its connectivity to QRM 
(FROM: … with red text) and defines what is now possible (TO: …) as a result of the 
contributions of this study.   
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Figure 11-1 – A roadmap of this research study 
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The introduction of ICH Q10 positions an effective PQS as a means to enhance the 
quality and availability of medicines in the interest of public health: 
 
ICH Q10 demonstrates industry and regulatory authorities’ support of an 
effective pharmaceutical quality system to enhance the quality and availability 
of medicines around the world in the interest of public health. Implementation 
of ICH Q10 throughout the product lifecycle should facilitate innovation and 
continual improvement and strengthen the link between pharmaceutical 
development and manufacturing activities.  
 
As introduced in Chapter 1 (section 1.6) and explored throughout this research study, 
these research outputs have the opportunity to impact several areas of the PQS as first 
presented in Figure 1-6: 
1. KM as an enabler to the PQS, via a Knowledge Management Process Model  
2. KM with QRM as dual enablers to the PQS, via the RKI Cycle 
3. Technology Transfer as a stage in the product lifecycle via the KTE Framework 
4. The end-to-end product lifecycle, via broad application of the RKI Cycle 
 
Figure 11-2 was created by the researcher to illustrate where primary research study 
outputs map to the various areas of the PQS.   
 
 
Figure 11-2 – Mapping of selected research study outputs to the PQS 
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The impact of each of these research outputs to the PQS is summarised as follows: 
1. The new Knowledge Management Process Model, as presented in Chapter 4 and 
designed based on the QRM Process Model from ICH Q9, can broadly impact 
how KM is understood as an enabler to the PQS, through a more pragmatic, 
structured, and sequential breakdown of the KM process.  This new Knowledge 
Management Process Model addresses the definition KM provided by ICH Q10, 
and goes further to include the concepts of tacit knowledge, the connection of 
KM to business processes, and enablers to successful KM (e.g., standardised 
processes and sponsorship).  Through a better understanding of the mechanics 
of KM, the industry can better utilise KM to enable all facets of the PQS and 
beyond for operational effectiveness, employee engagement, and more.   
 
2. The Risk-Knowledge Infinity Cycle, or RKI Cycle, a novel framework to connect 
QRM and KM as presented in Chapter 5, can (and has already started to) define 
the understanding of the relationship between risk and knowledge, the 
relationship between risk management and knowledge management, and the 
importance of linking the two.  Linking these two disciplines offers the promise 
of improving fundamental PQS outcomes, including better risk-based decision 
making, more data and knowledge driven risk assessments, better use of prior 
knowledge and improved protection and value for patients, to name a few.  This 
framework links QRM and KM and has a resulting impact on every facet of the 
PQS. 
 
3. The KTE Framework and KTE Toolkit to enhance knowledge transfer effectiveness 
(Chapter 7) are specifically designed as a knowledge management approach for 
the lifecycle stage of technology transfer and have proven their effectiveness to 
technology transfer.  The underlying principles to this framework and toolkit 
have the potential to be rapidly scaled across the product lifecycle.  
 
4. The RKI Cycle has broad applicability across the end-to-end product lifecycle, as 
explored in Chapter 8, as well as the potential to be a uniting mechanism for 
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QRM, KM, and data analytics, ensuring the best possible risk-based decisions are 
made across the product lifecycle, whether for product development, 
technology transfer, change management, or any other element (or lifecycle 
stage) of the PQS.  
 
The preliminary outcomes and impact of each one of these research outputs are 
described in detail in Chapter 10 of this research study through a set of themes intended 
to convey tangible and meaningful advancements.  Collectively, these outcomes make 
a substantial contribution to the PQS, with significant impact and broad reach.   
 
As introduced in Chapter 1, the aim of this research study was to benefit the patient by 
improving the effectiveness of the PQS (Figure 1-1).  In reflecting on this goal, with the 
study outputs and their impact to PQS effectiveness well characterised, the researcher 
created Figure 11-3 (based on Figure 1-1 and Figure 11-2) as a means to ‘close the loop’ 
back to the patient by illustrating how these outputs lead to patient benefits.   
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the impact of 
the RKI Cycle 
Unlocking knowledge to benefit the patient
Connecting KM and QRM to strengthen 
science and risk-based decision making
Will allow the industry to…
• Improved risk-based decision making
• Acceleration of product development 
• More robust processes
• Solving problems at root cause
• Right-first time and on-time technology transfer
• and more…
And will benefit the patient through
• Increased product quality (e.g., reduced variability)
• Accelerated availability of new therapies
• Fewer drug shortages
• and more…
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Indeed, an opportunity to unlock knowledge is presented through the outputs and 
outcomes of this study with many promising and important benefits. 
 
While this research study started with a focus on improving knowledge transfer for 
technology transfer (i.e., element 3 in Figure 11-2), this study has led the researcher on 
an exciting, educational, and thought-provoking journey which expanded the horizons 
of the researcher’s knowledge, experience, perspectives, and influence.  The 
opportunity to apply systems thinking and explore the intersections between the 
disciplines of QRM and KM in particular, as well as that of KM and data analytics, has 
been an enlightening opportunity.  Doing such an exploration both across the 
pharmaceutical sector and on a global scale has made the experience all the more 
enriching for the researcher.  This research study has allowed the researcher to reflect 
and engage with other stakeholders he would not normally have a reason to and to test 
new ideas.  Furthermore, while the researcher has been a long time KM professional in 
industry, this research study allowed the researcher to shed the constraints of the views 
and association of a single company and explore perspectives and engage with 
audiences from across the sector.   
 
An unavoidable reality that emerged during the course of this study was the global 
COVID-19 pandemic and the undeniable impact it had and will have on our society and 
the pharmaceutical sector.  While COVID-19 impacts are still emerging, the impact of 
travel restrictions and market demand has already prompted changes to the industry 
(e.g., at least a temporary shift specifically in how technology transfers are done 
leveraging smart glasses and other technologies).  In light of all of this, one must ponder: 
 
• How effective is knowledge transfer in such scenarios?   
• Employees are also being onboarded remotely, perhaps without even meeting 
their peer groups in person.  How will relationships and trust develop?   
• Will there be a surge of technology transfers to ‘re-shore’ production within a 
country’s home borders, to reduce supply chain risk and complexity, and reduce 
dependence of a nation’s drug supply on other nations? 
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• How can the learnings about rapid product development and technology 
transfer be applied to accelerate access (and hopefully reduce cost) to future 
therapies, and what role can KM play? 
 
It is anticipated that more of these scenarios will unfold over time.  While this 
development did not change the course of the research study, it is quite possible that 
the COVID-19 pandemic may expedite the adoption of these outputs.   
 
The researcher is gratified by the response to this study and all those who contributed, 
in ways big and small.  The early results are promising, with the potential to drive a 
paradigm shift on how people think about knowledge management and its 
indispensable role in an effective PQS, and how knowledge management can be applied 
for meaningful and sustained benefits beyond the PQS.   
 
The researcher hopes this study will have a significant and lasting impact on the 
pharmaceutical sector, through the outputs delivered and outcomes already in motion 
as a result of this study, and others to follow inspired by this study.  This is especially 
relevant considering society is arguably facing a time of rapid and unprecedented 
change, already facing the complexity and need for speed with ATMPs, disrupted by the 
COVID-19 pandemic, and now confronting geopolitical forces which may well realign 
supply chains, and make accelerated development and new technologies the ‘new 
normal.’  Never before has it been more important to integrate knowledge and risk.  
Many exciting opportunities lie ahead, and the most important stakeholders of the 
industry’s success – the patients, who are not abstract and nameless entities but who 
are family members, friends, and colleagues – are waiting. 
 
The next and final chapter in this research study, Opportunities for Future Research, will 
present a variety of topics to further examine to further extend the impacts of this 
research study.     
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Chapter 12:  Opportunities for Future Research 
 
The purpose of this chapter is to identify areas for future research.  Although the 
researcher believes this study can help the sector take a step change forward in the 
adoption of KM and its connectivity with QRM, this study also explored many new 
aspects of KM and its interdependency with other disciplines.  As such, many exciting 
research opportunities were identified, including the opportunity to directly advance 
the outputs from this study (e.g., through application guides or software applications) 
and to further explore many important interdependencies and adjacencies (e.g., data 
analytics).  The following sections identify several exciting opportunities for further 
study.   
 
12.1 Extension of the Risk-Knowledge Infinity Cycle Framework 
One recommendation for future research efforts is to supplement the work done in this 
study with supporting materials to extend and accelerate the impact of the RKI Cycle 
across the product lifecycle and to other elements within the PQS.  These concepts 
were briefly explored as part of this study, but further work is warranted to better 
position the RKI Cycle for expansion.  As part of this effort, supporting materials such as 
an application or deployment guide with associated training to enable a team to quickly 
understand, apply, and benefit from the RKI Cycle will be needed.  Additional case 
studies, both prospective (i.e., how the RKI Cycle can provide benefit) and retrospective 
(i.e., how the RKI Cycle could have provided benefit) can also assist in communicating 
and refining the framework.  Other cases of how the framework can be applied should 
also be explored, such as to inform a learning curriculum.  Furthermore, exploring 
commonality with other industries (e.g., aerospace, as identified during the 
confirmation exam feedback), is an opportunity to further extend the reach of the 
framework beyond the pharmaceutical industry.   
 
12.2 Integrated knowledge management frameworks across the product 
lifecycle 
A feature of this study was the focus on KM for the technology transfer stage of the 
product lifecycle.  This study established a KM framework to standardise knowledge 
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management during technology transfer, the Knowledge Transfer Enhancement (KTE) 
Framework.  The researcher believes the underlying basis of a PDCA cycle as used for 
the KTE Framework as a closed-loop continual improvement process should be a 
suitable basis from which to build a KM framework for the other three stages of the 
product lifecycle (product development, commercial manufacturing, and product 
discontinuation).  Furthermore, a majority of the tools in the KTE Toolkit will also be 
portable across stages.  Additional areas of focus could include: 
• Further definition of practices specified in the KTE Toolkit (i.e., as identified in 
Table 7-1). 
• A training package to support use of the KTE Framework and KTE Toolkit . 
• A maturity model for knowledge transfer (including a gap assessment so 
companies can assess their current processes and quickly identify areas of 
improvement). 
• Simplification of the KTE Framework and KTE Toolkit as warranted based on initial 
use and feedback. 
• Exploration of the Information-space (“I-space”) model defined by Boisot (I-
Space Institute, 2008) for mapping strategic knowledge.  This model has been 
used to further define and prioritize mission-critical knowledge for complex 
industries, as described by Kennedy-Reid and Ihrig (Kennedy-Reid and Ihrig, 
2013) and Ihrig and MacMillan (Macmillan and Ihrig, 2015), and could potentially 
be applied for each stage of the product lifecycle. 
 
12.3 The link between knowledge management and data analytics 
As introduced in Chapter 8, the link between KM and data analytics is an area of novel 
research that will better link data and data analytics more systematically into the PQS.  
The researcher sometimes describes this opportunity as the ‘vertical integration’ of the 
data-information-knowledge pyramid (Figure 8-5).  Given the industry focus on digital 
transformation (CIO, 2018), more data will become available, and the RKI Cycle and 
effective KM practices will be instrumental in how that data is surfaced as knowledge 
through data analytics, as illustrated in Figure 12-1.   
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Figure 12-1 – The opportunity to feed KM from data and data analytics 
 
12.4 KM competency building 
It is likely KM could further benchmark the QRM journey towards effectiveness to seek 
other areas for development of guidance and supporting materials.  One of these areas 
is that of KM competency building, through an associated KM competency model to 
define target competency levels, related training assets, and delivery thereof.  This work 
could also define best practices for KM roles.   
 
12.5 Additional opportunities 
There are other, more focused topics of interest to the researcher that are not covered 
in detail as part of this research study which could benefit from further study, as follows: 
 
• An expansion on knowledge culture, based on the work in this thesis. 
• Further exploration and modelling of knowledge leakage, as characterised by 
the researcher in Chapter 6 (section 6.2.1). 
• The concept of ‘democratisation of knowledge,’ and how to determine what 
knowledge is required on a role-specific basis, and how this knowledge can be 
‘democratised’ to enable maximum efficiency and effective decision making. 
• Topics introduced (or at least accelerated) by the COVID-19 pandemic, including: 
o Virtual technology transfers and critical success factors, considering the 













































































































































© Lipa & O’Donnell 2020




  168 
during this study in Chapter 6 and Chapter 7 (e.g., is remote support for 
a technology transfer using smart glasses as effective as a person in plant 
supporting the transfer?). 
o How the outputs of this research study could be positioned to enhance 
the potential wave of ‘re-shoring’ technology transfers, if such a need 
emerges, to increase speed, reduce cost, and help ensure sustained 
supply.  
• Examining the feasibility and defining associated requirements for applications 
(e.g., checklists or gap assessments) or other software to accelerate the reach 
and impact of the RKI Cycle or KTE Framework and KTE Toolkit would be an area 
of valuable research, given the focus on digital.  Such software applications 
would also support the standardisation, consistent use, and portability of the 
frameworks and supporting elements.  
• Further explore the relevance and application of work by Teece et al. (Teece, 
Pisano and Shuen, 1997) on dynamic capabilities and strategic management, 
specifically that of dynamic knowledge based on increasing complexity (e.g., 
ATMPs) and accelerating rate of change for the industry (e.g., COVID-triggered 
acceleration of new therapies, merger and acquisition activity, etc.). 
 
At the time of this thesis submission, work is underway to evaluate opportunities for 
further research on a variety of these topics.  An immediate research project is being 
proposed in which the researcher will act as supervisor to a full time Ph.D. student, 
which will include (at a minimum) further exploration and development of the link 
between KM and the RKI Cycle to data analytics in partnership with PMTC.  This proposal 
will also include an opportunity to follow up with NASA on the potential impact of the 
RKI Cycle for aerospace, as well as further exploration of how the RKI Cycle can support 
the sharing of lessons and risk-based decision making.  
 
This research study has opened the door to many exciting opportunities, and the 
researcher is excited for the story to continue to unfold through these proposed next 
steps.   
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Appendix 1 – Researcher’s Prior Experience 
 
The researcher’s formative experience in knowledge management prior to commencement of this research study, presented in chronological 
order of events.  
 
Experience / Activity / Event Affiliation / 
Audience 
Location Description 
FDA-Conformia-PhRMA Pharmaceutical Development / Risk Management Industry Workshop (12-
13 Sep 2007) (FDA-Conformia CRADA, 2007) FDA & Industry Washington, DC 
Member of MSD 
contingent  
MSD Knowledge Management Strategy Kickoff Workshop (3Q 2007) MSD internal n/a Facilitator 
FDA-Conformia-PhRMA Summit - Pharmaceutical Development / Risk Management (20-21 Feb 
2008) (FDA-Conformia CRADA, 2008) FDA & Industry Washington, DC 
Member of MSD 
contingent  
MSD KM Strategy Project initiated via Lean Six Sigma Black Belt Methodology (DMADV) (2008) MSD internal n/a LSS Black Belt Certification 
MSD Small Molecule Commercialisation KM Strategy 1.0 (2009) MSD internal n/a Project Leader and Lead Author 
Lean Six Sigma Black Belt Certification for development of KM Strategy (2009) MSD internal n/a Black Belt Certification 
Knowledge Management:  Some Ways Industry is Addressing This.  In ISPE Washington 2010 
Conference - FDA-ISPE Collaboration:  Pharmaceutical Quality System. (Lipa, 2011a) ISPE Washington, DC Speaker & Panellist 
Knowledge Management:  An Iterative Process.  In 2011 ISPE/PDA/FDA/EMA Pharmaceutical 
Quality Systems (ICH Q10) Conference (Lipa, 2011a) 
ISPE, PDA, FDA, 
EMA Arlington, VA Speaker & Panellist 
Knowledge Management:  An Iterative Process.  In 2011 ISPE/PDA/FDA/EMA Pharmaceutical 
Quality Systems (ICH Q10) Conference (Lipa, 2011b) 
ISPE, PDA, FDA, 
EMA 
Brussels, 
Belgium Speaker & Panellist 
KM Case Study:  Combining Social Computing and Organizational Development Efforts into a 
Virtual Technical Network (VTN).  In APQC 2012 KM Conference. (Guenard, Bruno and Lipa, 2012) APQC Houston, TX Speaker & Panellist 
Knowledge Management:  An Iterative Process.  In 2012 PDA/FDA/JPMA/PMDA Pharmaceutical 
Quality Systems (ICH Q10) Conference  (Lipa, 2012) 
PDA, FDA, 
JPMA, PMDA Tokyo, Japan Speaker & Panellist 
Enabling a New Way of Working through Inclusion and Social Media:  A Case Study.  OD 
Practitioner, 45(4), 9-16. (Fall 2013) (Guenard et al., 2013) 
OD 
Practitioner n/a Publication - Author 
Knowledge Management:  An Iterative Process.  In 2013 ISPE/FDA Pharmaceutical Quality System 
(ICH Q10) Conference. (Lipa, 2013) ISPE / FDA Beijing, China Speaker & Panellist 
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Experience / Activity / Event Affiliation / 
Audience 
Location Description 
A Practical Approach to Managing Knowledge – A Case Study of the Evolution of KM at Merck. 
Pharmaceutical Engineering, 33(6). (2013) (Lipa et al., 2013) 
Pharmaceutical 
Engineering n/a Author 
Manufacturing Leadership Council 2014 Manufacturing Leadership Award (Workplace Leadership 
Category) for MMD's Virtual Technical Network (VTN). (Frost & Sullivan, 2014) MSD internal n/a Award recipient 
The Know-How and Know-Why:  An Interview with Merck. ISPE Pharmaceutical Engineering 
Supplement - Knowledge Management E-Journal, 33(6), 20-24. (2014) (Calnan, 2014b) 
Pharmaceutical 
Engineering n/a SME Interviewee 
A Practical Approach to Managing Knowledge - Making Knowledge Flow in Merck's Manufacturing 
Division. In APQC 2014 KM Conference  (Thien and Lipa, 2014) APQC Houston, TX Speaker & Panellist 
Knowledge You Need to Know.  In ISPEAK - The Official Blog of ISPE. (2014) (Lipa, 2014a) ISPE n/a Author 
A Practical Approach to Managing Knowledge.  In 2014 ISPE-FDA CGMP Conference.  ISPE, FDA Baltimore, MD Speaker & Panellist 
A Practical Approach to Managing Knowledge – A Case Study at Merck. In 2014 BioProcess 
International Conference. (Lipa, 2014b) 
BioProcess 
International Boston, MA Speaker & Panellist 
A Practical Approach to Managing Knowledge:  Making Knowledge Flow in Merck’s Manufacturing 
Division.  In NASA Knowledge 2020 Conference, NASA Kennedy Space Centre. (2014) (Lipa and 
Guenard, 2014) 
NASA Cape Canaveral, FL Speaker & Panellist 
2014 PDA Knowledge Management Workshop - Enabler for ICH Q8 - Q11, QRM and Continued 
Process Verification - Raising the Awareness (PDA, 2014a) PDA Bethesda, MD 
Planning Committee & 
Breakout Moderator 
A Practical Approach to Managing Knowledge in Merck’s Manufacturing Division. In KM Dublin 
2015.  (Lipa, 2015) 
Regulatory 
Science Ireland Dublin, Ireland Speaker 
KM Dublin 2015 Symposium on Knowledge Management - From Discovery to Patient Regulatory Science Ireland Dublin, Ireland Breakout Moderator 
A Practical Approach to Managing Knowledge…2.0.  In NASA Knowledge 2020 Conference, NASA 
Johnson Space Centre. (2015) (Lipa and Bruno, 2015) NASA Houston, TX Speaker & Panellist 
The Role of KM in Merck's Journey to World Class Supply.  In APQC 2015 KM Conference. 
(Morrissey and Lipa, 2015) APQC Houston, TX Speaker & Panellist 
Kane, P., Lipa, M., & Hubert, C. (2015). Pharmaceutical Industry KM Focus Group Summary – 
APQC 2015. In APQC KM Conference 2015. (Kane, Lipa and Hubert, 2015) 
APQC (pharma 
focus group) Houston, TX Facilitator 
Steering Committee Member - 2017 APQC Knowledge Management Conference APQC Houston, TX Steering Committee Member 
Helping the World Be Well:  Knowledge Management in MMD.  Guest lecture for Information & 
Knowledge Strategy MS Program, Columbia University, New York. (2016) (Lipa, 2016) 
Columbia 
University New York, NY 
Guest Lecturer (Columbia 
University MS Program) 
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Experience / Activity / Event Affiliation / 
Audience 
Location Description 
Steering Committee Member - 2018 APQC Knowledge Management Conference APQC Houston, TX Steering Committee Member 
A Vision for Prior Knowledge – and How to Manage Knowledge as an Asset. In CASSS CMC 
Regulatory Forum. (2018) (Lipa, 2018a) CASSS Washington DC Speaker & Panellist 
Contributing book editor:  A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical 
Industry. (N. Calnan, P. Kane, M. Lipa, & J. Menezes, Eds.). CRC Press. (2018) (Calnan et al., 
2018) 
Book Editor n/a Contributing Editor 
Yegneswaran, P., Thien, M., & Lipa, M.  Why Knowledge Management is Good Business, A 
Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical Industry (3-17), CRC Press. 
(2018) (Yegneswaran, Thien and Lipa, 2017) 
Book Chapter 
Author n/a Author 
Kane, P. & Lipa, M.  The House of Knowledge Excellence - A Framework for Success.  In A Lifecycle 
Approach to Knowledge Excellence in the Biopharmaceutical Industry (181-224), CRC Press. (2018) 
(Kane and Lipa, 2018) 
Book Chapter 
Author n/a Author 
Lipa, M. & Schuttig, J.  KM Evolution at Merck & Co., Inc.:  Managing Knowledge in Merck 
Manufacturing Division.  In A Lifecycle Approach to Knowledge Excellence in the 
Biopharmaceutical Industry (243-260), CRC Press. (2018) (Lipa and Schuttig, 2018) 
Book Chapter 
Author n/a Author 
Steering Committee Member - 2019 APQC Knowledge Management Conference APQC Houston, TX Steering Committee Member 
Building Learning and Continuous Improvement into Everyday Work:  The Quest to Learn Lessons 
in Merck Manufacturing.  In APQC 2018 KM Conference. (Lipa and Schuttig, 2018) APQC Houston, TX Speaker & Panellist 
World Bank KM Forum - Working Smarter Together - Private Sector Panel World Bank Washington, DC Panellist 
Evolution of Merck Strategy for Managing Knowledge.  Guest lecture for Information & Knowledge 
Strategy MS Program, Columbia University, New York. (2018)  (Lipa, 2018b) 
Columbia 
University New York, NY 
Guest Lecturer (Columbia 
University MS Program) 
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Appendix 2 – Details of Research Study Activities 
 
This appendix provides details of all of the main study outputs including publications, 
conference presentations, panel discussions and other interactions to solicit feedback 
and disseminate this research to stakeholders across the sector. The figure below from 
Chapter 1 (Figure 1-5) provides a mapping of each activity onto the research timeline, 
and the table following provides the corresponding details for each activity numbered 








Research Activity / Output Affiliation / Audience Location Description 
1 Lipa, M. J. (2019) Capture and Reuse of Critical 
Knowledge in an Evolving Workforce: A Model 
for Technology Transfer.  In 2019 PDA Annual 
Meeting.   




2 Lipa, M. J. & Kane, P. E. (2019) Knowledge 
Management Research in the 
Biopharmaceutical Sector.  In An Audience with 
Regulators, Academia and Industry:  The Role 
of Effective QRM & KM in Product Realisation 








3 APQC Advanced Benchmarking (invitation only 








4 Lipa, M. J., Kane, P. E. & Greene, A. (2019) 
Effective Knowledge Transfer During 
Biopharmaceutical Technology Transfer: How 
Well Do We Do It? Institute of Validation 
Technology (IVT), 25 (4).  















Phase 1:  Problem Definition Phase 2:  KM Framework (KTE) & KTE Toolkit
Phase 3:  QRM-KM Framework



























X Conference / 
Presentation
















Research Activity / Output Affiliation / Audience Location Description 
*Award recipient, Journal of Validation 
Technology 2020 Author of the Year* 
5 Lipa, M. J., Kane, P. E., & Greene, A. (2019)  
Effective Knowledge Transfer during 
Biopharmaceutical Technology Transfer – How 
well do we do it?  KENX Commissioning, 





6 Lipa, M. J. (2020)  Knowledge Management: 
Development of pragmatic industry guidance to 
benefit our patients & organizations.  In ISPE 
2019 Annual Meeting & Expo.  




7 Guenard, R. et al. (2020) A Test Case in CMC 
Business Processes from Late-Stage 
Development to Commercial Manufacturing.  
BioPhorum Operations Group (paper and tool)  
BioPhorum n/a Co-Author, 
Knowledge 
Map SME & 
facilitator 
8 Kane, P. E. and Lipa, M. J. (2020) Advancing 
Knowledge Management (KM) as an ICH Q10 
Enabler in the Biopharmaceutical Industry, 
Dublin:  TU Dublin Academic Press  
TU Dublin n/a Co-Author 
9 Lipa, M. J. (2020) Knowledge Management as a 
Pharmaceutical Quality System Enabler: How 
Enhanced Knowledge Transfer can help close 
the Q10 to Q12 Gap.  In 2020 PDA Europe  
PDA Virtual Speaker & 
Panellist 
10 Lipa, M. J., Greene, A., & Calnan, N. (2020)  
Knowledge Management as a Pharmaceutical 
Quality System Enabler: How Enhanced 
Knowledge Transfer can help close the Q10 to 
Q12 Gap.  PDA Journal of Pharmaceutical 
Science and Technology July 2020  (accepted) 




n/a Lead Author 
11 Kane, P. E., Lipa, M. J., Greene, A., & Calnan, N. 
(2020) Knowledge Management 
Implementation: A Survey of the 
Biopharmaceutical Industry.  In ISPE 






12 Lipa, M. J., Kane, P. E., & Greene, A. (2020) 
Knowledge Excellence in the Lab: How 
Knowledge Management Can Enhance Lab 
Performance, In Quality Control Lab – A Crucial 
Contributor to Pharmaceutical Value Creation 




n/a Lead Author 
13 Lipa, M. J. (2020) Reflections on a KM Journey.  
Guest lecture for Information & Knowledge 










14 Lipa, M. J., O'Donnell, K., & Greene, A. (2020) 
Managing Knowledge and Risk – A Literature 
Review on the Interdependency of QRM and 
KM as ICH Q10 Enablers.  Institute of Validation 
technology (IVT), 26 (4). 
IVT Network n/a Lead Author 





Research Activity / Output Affiliation / Audience Location Description 
15 Podcast - Voices in Validation - Managing 
Knowledge as an Asset in the 
Biopharmaceutical Industry (recorded 11-Sep-
2020)  
IVT Network Online Speaker 
16 Lipa, M. J., O'Donnell, K., & Greene, A. (2020) 
Knowledge as the Currency of Managing Risk: A 
Novel Framework to Unite Quality Risk 
Management and Knowledge Management.  
Institute of Validation technology (IVT), 26 (5). 
IVT Network n/a Lead Author 
17 Lipa, M. (2020) Knowledge as the Currency of 
Managing Risk: A Novel Framework to Unite 
Quality Risk Management & Knowledge 
Management.  In PMTC Guide to Data Analytics 
for Pharmaceutical Manufacturing Launch. 
PMTC Virtual Speaker & 
Panellist 
18 “Establishing a “New Normal” for Pharma 
Quality Practices” in 2020 Bio/Pharma Virtual 
Congress.   
PharmaTech Virtual Panellist 
19 Industry SME Reviewer (invited), PDA Technical 
Report No. 65, Technology Transfer 
PDA n/a Invited as 
industry SME 
20 Lipa, M, Kane, P., Greene, A. (2020) Simple 
Practices to Facilitate the Flow of Valuable 
Tacit Knowledge during Biopharmaceutical 
Technology Transfer: A Case Study, Level3, vol. 
15, no. 2. 
TU Dublin n/a Lead Author 
21 Lipa, M, Kane, P., Greene, A. (2021) Mapping 
KM Methods and Tools across the 
Pharmaceutical Product Lifecycle, Level3, vol. 
15, no. 2. 
TU Dublin n/a Lead Author 
22 Lipa, M. J. (2021) “Holding On to What You 
Know: Improving Knowledge Transfer to 
Reduce Risk and Benefit Patients,” in 2021 PDA 
Annual Meeting. 
PDA Virtual Speaker & 
Panellist 
23 Lipa, M., O'Donnell, K., & Greene, A. (2021) A 
Survey Report on the Current State of Quality 
Risk Management (QRM) and Knowledge 
Management (KM) Integration, Level3, vol. 15, 
no. 3 
TU Dublin n/a Lead Author 
24 Lipa, M. J., (2021) Knowledge Management, on 
invitation to the PDA Regulatory Affairs and 
Quality Advisory Board (15-Apr-2021) 
PDA Virtual Invited 
industry SME 
25 ISPE (2021b) ISPE Good Practice Guide: 
Knowledge Management in the 
Pharmaceutical Industry. Tampa, FL: ISPE. 
ISPE n/a SME on 
Authoring 
Team  
26 Lipa, M. J. et al. (2021) “Exploring the Risk-
Knowledge Infinity Cycle (RKI Cycle) Across the 
Product Lifecycle,” ISPE Webinar. (Note:  This 
paper has been accepted by ISPE but not yet 
published.  It will first be presented at a 
webinar scheduled on 20-May-2021.) 
ISPE n/a Lead Author 
 
